Cancer therapy targeting cancer stem cells
Compounds targeting signaling pathways force cancer stem cells to differentiate, solving the problem that existing treatment methods are difficult to eliminate cancer stem cells, and achieving effective treatment for a variety of cancers, including colon cancer, gastric cancer, prostate cancer, etc.
Patent Information
- Application Number
- CN201980039988.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2019-03-07
- Filing Date
- 2019-05-03
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2039-05-03
AI Technical Summary
Existing cancer treatments are difficult to target and eliminate dangerous cells in tumors - cancer stem cells, leading to drug resistance and persistent cancer spread.
A compound that targets signaling pathways, which forces cancer stem cells to differentiate, thereby inhibiting metastasis and tumor growth, is developed the same pathways used by embryonic stem cells during differentiation and development and is only present in embryonic stem cells rather than healthy in adult organizations.
These compounds can not only reduce tumor volume and prolong life, but also prevent metastasis and recurrence. They are more effective than traditional treatment methods and are widely used in many types of cancers such as colon cancer, gastric cancer, prostate cancer, testicular cancer, etc. potential.
Smart Images

Figure CN112312899B_ABST
Abstract
Description
[0001] Related applications
[0002] This application claims priority under 35 U.S.C. § 119(e) to U.S. Provisional Applications USSN 62 / 667,412, filed May 4, 2018, and USSN 62 / 815,251, filed March 7, 2019, the disclosures of each of which are incorporated herein by reference. Background Art
[0003] Cancer is ubiquitous and, despite medical advances, remains the leading cause of death worldwide. In 2017, an estimated 1.7 million new cases of cancer were diagnosed and 600,000 people died from the disease. 1 Cancer is the second leading cause of death worldwide, accounting for nearly one in six deaths. Over the next 20 years, the number of new cases is expected to increase by approximately 70%. The economic impact of cancer is substantial and growing. In 2010, the total annual economic cost of cancer was estimated to be approximately US$1.16 trillion. 2
[0004] Cancer is a general term for a broad range of diseases that can affect any part of the body. Other terms used are malignant tumor and neoplasm. Cancer is caused by the transformation of normal cells into tumor cells in a multistage process, typically progressing from a precancerous lesion to a malignant tumor. A defining characteristic of cancer is the rapid development of abnormal cells that grow beyond their usual boundaries and can then invade adjacent parts of the body and spread to other organs, a process known as metastasis. Metastasis is the leading cause of cancer death. The most common causes of cancer death are lung cancer, liver cancer, colorectal cancer, stomach cancer, and breast cancer.
[0005] Despite some progress in treating subsets of cancer types, the average cancer mortality rate remains extremely high, with little improvement overall in the ongoing cancer crisis. Almost all modern cancer treatments, including chemotherapy, targeted therapies, and immunotherapy, focus on eliminating tumors without targeting the most dangerous cells within a tumor: cancer stem cells. Cancer stem cells are responsible for the spread of cancer cells throughout the body, tumor growth, cancer resistance to chemotherapy, and tumor recurrence after treatment or surgical removal. 3,4 Because current treatments do not target the cancer stem cell population, they often lead to the emergence of drug-resistant tumors and continued cancer spread. Summary of the Invention
[0006] The discovery of cancer stem cells provides an opportunity to merge the fields of oncology and embryonic stem cell biology. 5,6By targeting what makes cancer so dangerous—the embryonic properties of cancer stem cells that underlie its growth, spread, and drug resistance—the development of effective and non-toxic treatments could be achieved through a strategy known as cancer suppressor therapy. A therapy that could both reduce tumor size and destroy cancer stem cells would revolutionize cancer treatment. 7
[0007] This article describes compounds that force cancer stem cells to differentiate and inhibit signaling pathways required for metastasis—the same pathways used by embryonic stem cells during differentiation and development. 8,9 These properties can be safely targeted because they are present only in embryonic stem cells and not in healthy adult tissue.
[0008] These compounds will be more effective than traditional cancer treatments in reducing tumor growth, extending lifespan, and preventing metastasis and recurrence. Moreover, because reactivation of embryonic properties is a property shared by a wide range of tumors, cancer-suppressing therapies are expected to be effective against many different types of cancer, including colon, stomach, prostate, testicular, and breast cancers.
[0009] Disclosed herein are compounds, methods, compositions, uses and kits that allow for the treatment of proliferative diseases, benign neoplasms and cancer.
[0010] In one aspect, the compounds of the present disclosure have formula (0):
[0011]
[0012] or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, cocrystal, tautomer, stereoisomer, isotopically labeled derivative or prodrug thereof, wherein the variables described in formula (0) are as described herein. In another aspect, the present disclosure provides a method for treating cancer, comprising administering to a subject a therapeutically effective amount of a compound of formula (0), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, cocrystal, tautomer, stereoisomer, isotopically labeled derivative or prodrug thereof, wherein the variables described in formula (0) are as described herein.
[0013] In one aspect, the compounds of the present disclosure have the formula (0'):
[0014]
[0015] or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, cocrystal, tautomer, stereoisomer, isotopically labeled derivative or prodrug thereof, wherein the variables described in formula (O') are as described herein. In another aspect, the present disclosure provides a method for treating cancer, comprising administering to a subject a therapeutically effective amount of a compound of formula (O'), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, cocrystal, tautomer, stereoisomer, isotopically labeled derivative or prodrug thereof, wherein the variables described in formula (O') are as described herein.
[0016] In one aspect, the compounds of the present disclosure have formula (I):
[0017]
[0018] or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, cocrystal, tautomer, stereoisomer, isotopically labeled derivative or prodrug thereof, wherein the variables described in Formula (I) are as described herein. In another aspect, the present disclosure provides a method for treating cancer, comprising administering to a subject a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, cocrystal, tautomer, stereoisomer, isotopically labeled derivative or prodrug thereof, wherein the variables described in Formula (I) are as described herein.
[0019] In certain embodiments, the cancer comprises cancer stem cells. In certain embodiments, the cancer involves or is associated with cancer stem cells. In certain embodiments, the cancer is colorectal cancer, gastric cancer, gastrointestinal stromal tumor, ovarian cancer, lung cancer, breast cancer, pancreatic cancer, testicular cancer, or prostate cancer. In certain embodiments, the cancer is liver cancer or endometrial cancer. In certain embodiments, the cancer is leukemia. In certain embodiments, the cancer is lymphoma. In certain embodiments, the cancer is multiple myeloma. In certain embodiments, the subject is in need of regenerative medicine or therapy.
[0020] In yet another aspect, the present disclosure provides a method comprising contacting a cell with an effective amount of formula (0) or (0′), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, cocrystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof.
[0021] In yet another aspect, the present disclosure provides methods and uses comprising contacting a cell with an effective amount of Formula (I) or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, cocrystal, tautomer, stereoisomer, isotopically labeled derivative or prodrug thereof.
[0022] In certain embodiments, the compound of formula (I) is of formula (IA):
[0023] In certain embodiments, Formula (I) is Formula (IB), wherein: where R 7 In certain embodiments, Formula (I) is Formula (IC), wherein:
[0024] in In certain embodiments, Formula (I) is Formula (IC), wherein:
[0025] Among them is imidazolyl, oxazolyl, azetidinyl, -C≡C- or In certain embodiments, Formula (I) is Formula (ID), wherein:
[0026] where R 7 is a substituted or unsubstituted 3- to 7-membered monocyclic heterocyclic group or a substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl group.
[0027] In some embodiments, the present disclosure provides a composition comprising a compound of formula (0) or (0′), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, cocrystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof; and optionally a pharmaceutically acceptable excipient. In certain embodiments, the composition is a pharmaceutical composition. In certain embodiments, the composition further comprises an additional pharmaceutical agent.
[0028] In some embodiments, the present disclosure provides a composition comprising a compound of formula (I), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, cocrystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof; and optionally a pharmaceutically acceptable excipient. In certain embodiments, the composition is a pharmaceutical composition. In certain embodiments, the composition further comprises another pharmaceutical agent.
[0029] In certain embodiments, the present disclosure provides a kit comprising a compound of formula (0) or (0′), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, cocrystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof; or a composition described herein; and instructions for using the compound, pharmaceutically acceptable salt, solvate, hydrate, polymorph, cocrystal, tautomer, stereoisomer, isotopically labeled derivative, prodrug, or pharmaceutical composition.
[0030] In a further embodiment, the present disclosure provides a kit comprising a compound of Formula (I), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, cocrystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof; or a composition described herein; and instructions for using the compound, pharmaceutically acceptable salt, solvate, hydrate, polymorph, cocrystal, tautomer, stereoisomer, isotopically labeled derivative, prodrug, or pharmaceutical composition.
[0031] The details of certain embodiments of the invention are set forth in the detailed description, as described below. Other features, objects and advantages of the invention will be apparent from the definitions, drawings, examples and claims. BRIEF DESCRIPTION OF THE DRAWINGS
[0032] Figure 1 Compound 1-1 was shown to deplete the embryonic-like gastric cell population in gastric cancer.
[0033] Figure 2 Compound I-1 was shown to reduce OCT4 expression in gastric cancer cells.
[0034] Figure 3 Compound 1-1 was shown to reduce nanog expression in gastric cancer cells.
[0035] Figure 4 The results showed that compound I-1 had no toxicity to healthy liver cells.
[0036] Figure 5 Compound I-1 was shown to inhibit the growth of gastric cancer cells.
[0037] Figure 6 The in vitro properties of Compound 1-1 (eg, solubility, microsomal stability, and plasma stability) are demonstrated.
[0038] Figure 7 The pharmacokinetics of compound 1-1 in mice are shown.
[0039] Figure 8 The mouse tolerability results of compound 1-1 are shown.
[0040] definition
[0041] For convenience, certain terms employed herein, in the specification, examples, and appended claims, are collected here.
[0042] Unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular.
[0043] The phrase "in some embodiments" is used interchangeably with the phrase "in certain embodiments."
[0044] The following definitions are of more general terms used in this application:
[0045] Unless the context clearly indicates otherwise, the singular terms "a," "an," and "the" include plural referents. Similarly, the word "or" is intended to include "and" unless the context clearly indicates otherwise.
[0046] Except in the examples, or where otherwise indicated, all numbers used herein expressing amounts of ingredients or reaction conditions are to be understood as modified in all instances by the term "about." "About" and "approximately" generally mean an acceptable degree of error for the amount measured, given the nature or precision of the measurements. Exemplary degrees of error are within 20 percent (%), typically within 10%, or more typically within 5%, 4%, 3%, 2%, or 1% of a given value or range of values.
[0047] The definitions of specific functional groups and chemical terms are described in more detail below. Chemical elements are identified according to the CAS version of the Periodic Table of the Elements on the inside cover of Handbook of Chemistry and Physics, 75th edition, and specific functional groups are generally defined as described therein. In addition, the general principles of organic chemistry as well as specific functional moieties and reactivity are described in Organic Chemistry, Thomas Sorrell, University Science Books, Sausalito, 1999; Smith and March, March's Advanced Organic Chemistry, 5th edition, John Wiley & Sons, New York, 2001; Larock, Comprehensive Organic Transformations, VCH Publishers, New York, 1989; and Carruthers, Some Modern Methods of Organic Synthesis, 3rd edition, Cambridge University Press, Cambridge, 1987.
[0048] The compounds described herein may include one or more asymmetric centers and may therefore exist in various stereoisomeric forms, such as enantiomers and / or diastereomers. For example, the compounds described herein may be in the form of a single enantiomer, diastereomer, or geometric isomer, or may be in the form of a mixture of stereoisomers, including racemic mixtures and mixtures enriched in one or more stereoisomers. Isomers may be separated from the mixture by methods known to those skilled in the art, including chiral high pressure liquid chromatography (HPLC) and the formation and crystallization of chiral salts; or preferred isomers may be prepared by asymmetric synthesis. See, e.g., Jacques et al., Enantiomers, Racemates and Resolutions (Wiley Interscience, New York, 1981); Wilen et al., Tetrahedron 33:2725 (1977); Eliel, EL Stereochemistry of Carbon Compounds (McGraw-Hill, NY, 1962); and Wilen, SH Tables of Resolving Agents and Optical Resolutions, p. 268 (EL Eliel, ed., Univ. of Notre Dame Press, Notre Dame, IN 1972). The present disclosure additionally encompasses compounds as individual isomers substantially free of other isomers, as well as alternatively, mixtures of various isomers.
[0049] In the formula, is a single bond, wherein the stereochemistry of the moiety directly attached thereto is unspecified, is absent or is a single bond, and or Is a single bond or a double bond.
[0050] Unless otherwise provided, the formulae described herein include compounds that do not include isotopically enriched atoms as well as compounds that include isotopically enriched atoms. Compounds that include isotopically enriched atoms are useful as analytical tools and / or probes, for example, in biological assays.
[0051] Term " aliphatic " includes saturation and unsaturation, non-aromatic, straight chain (that is, non-branched), side chain, non-cyclic and cyclic (that is, carbocycle) hydrocarbon.In some embodiments, aliphatic group is optionally replaced by one or more functional groups (for example, halogen, such as fluorine).As will be understood by those of ordinary skill in the art, " aliphatic " is intended to include alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl and cycloalkynyl moiety in this article.
[0052] When a range of values ("range") is listed, it is intended to encompass every value and subrange within the range. Unless otherwise provided, a range includes the values at both ends of the range. For example, "an integer between 1 and 4" means 1, 2, 3, and 4. For example, "C 1-6 "Alkyl" is intended to encompass C1, C2, C3, C4, C5, C6, C 1-6 、C 1-5 、C 1-4 、C 1-3 、C 1-2 、C 2-6 、C 2-5 、C 2-4 、C 2-3 、C 3-6 、C 3-5 、C 3-4 、C 4-6 、C 4-5 and C 5-6 alkyl.
[0053] "Alkyl" refers to a straight-chain or branched saturated hydrocarbon group having 1 to 20 carbon atoms ("C 1-20 In some embodiments, an alkyl group has 1 to 12 carbon atoms ("C 1-12 In some embodiments, an alkyl group has 1 to 10 carbon atoms ("C 1-10 In some embodiments, an alkyl group has 1 to 9 carbon atoms ("C 1-9 In some embodiments, an alkyl group has 1 to 8 carbon atoms ("C 1-8 In some embodiments, an alkyl group has 1 to 7 carbon atoms ("C 1-7 In some embodiments, an alkyl group has 1 to 6 carbon atoms ("C 1-6 In some embodiments, an alkyl group has 1 to 5 carbon atoms ("C 1-5 In some embodiments, an alkyl group has 1 to 4 carbon atoms ("C 1-4 In some embodiments, an alkyl group has 1 to 3 carbon atoms ("C 1-3 In some embodiments, an alkyl group has 1 to 2 carbon atoms ("C 1-2 In some embodiments, an alkyl group has 1 carbon atom ("C1 alkyl"). In some embodiments, an alkyl group has 2 to 6 carbon atoms ("C 2-6 C 1-6Examples of alkyl groups include methyl (C1), ethyl (C2), n-propyl (C3), isopropyl (C3), n-butyl (C4), tert-butyl (C4), sec-butyl (C4), isobutyl (C4, n-pentyl (C5), 3-pentyl (C5), pentyl (C5), neopentyl (C5), 3-methyl-2-butyl (C5), tert-pentyl (C5), and n-hexyl (C6). Additional examples of alkyl groups include n-heptyl (C7), n-octyl (C8), and the like. Unless otherwise specified, each example of alkyl is independently optionally substituted, e.g., unsubstituted (“unsubstituted alkyl”) or substituted with one or more substituents (“substituted alkyl”). In certain embodiments, alkyl groups are unsubstituted C 1-12 Alkyl (e.g., -CH3(Me), unsubstituted ethyl (Et), unsubstituted propyl (Pr, e.g., unsubstituted n-propyl (n-Pr), unsubstituted isopropyl (i-Pr)), unsubstituted butyl (Bu, e.g., unsubstituted n-butyl (n-Bu), unsubstituted tert-butyl (tert-Bu or t-Bu), unsubstituted sec-butyl (sec-Bu or s-Bu), unsubstituted isobutyl (i-Bu)). In certain embodiments, alkyl is substituted C 1-12 Alkyl (such as substituted C 1-6 Alkyl, for example, -CH2F, -CHF2, -CF3, -CH2CH2F, -CH2CHF2, -CH2CF3 or benzyl (Bn). The point of attachment of the alkyl group can be a single bond (for example, in -CH3), a double bond (for example, in =CH2), or a triple bond (for example, in ≡CH). The moieties =CH2 and ≡CH are also alkyl groups.
[0054] In some embodiments, the alkyl group is substituted with one or more halogens. A "perhaloalkyl" is a substituted alkyl group as defined herein in which all hydrogen atoms are independently replaced with halogens (e.g., fluorine, bromine, chlorine, or iodine). In some embodiments, the alkyl moiety has 1 to 8 carbon atoms ("C 1-8 In some embodiments, the alkyl moiety has 1 to 6 carbon atoms ("C 1-6 In some embodiments, the alkyl moiety has 1 to 4 carbon atoms ("C 1-4 In some embodiments, the alkyl moiety has 1 to 3 carbon atoms ("C 1-3 In some embodiments, the alkyl moiety has 1 to 2 carbon atoms ("C 1-2In some embodiments, all hydrogen atoms are replaced by fluorine. In some embodiments, all hydrogen atoms are replaced by chlorine. Examples of perhaloalkyl groups include -CF3, -CF2CF3, -CF2CF2CF3, -CCl3, -CFCl2, -CF2Cl, and the like.
[0055] "Alkenyl" refers to a straight or branched chain hydrocarbon group ("C 2-20 In some embodiments, an alkenyl group has 2 to 10 carbon atoms ("C 2-10 In some embodiments, an alkenyl group has 2 to 9 carbon atoms ("C 2-9 In some embodiments, an alkenyl group has 2 to 8 carbon atoms ("C 2-8 In some embodiments, an alkenyl group has 2 to 7 carbon atoms ("C 2-7 In some embodiments, an alkenyl group has 2 to 6 carbon atoms ("C 2-6 In some embodiments, an alkenyl group has 2 to 5 carbon atoms ("C 2-5 In some embodiments, an alkenyl group has 2 to 4 carbon atoms ("C 2-4 In some embodiments, an alkenyl group has 2 to 3 carbon atoms ("C 2-3 In some embodiments, an alkenyl group has 2 carbon atoms ("C2 alkenyl"). The one or more carbon-carbon double bonds can be internal (such as in 2-butenyl) or terminal (such as in 1-butenyl). C 2-4 Examples of alkenyl groups include ethenyl (C2), 1-propenyl (C3), 2-propenyl (C3), 1-butenyl (C4), 2-butenyl (C4), butadienyl (C4), and the like. 2-6 Examples of the alkenyl group include the aforementioned C 2-4 In some embodiments, alkenyl is an unsubstituted C 1-4, C 1-6, C 1-8, C 1-9, C 2-10, C 3-11, C 3-12, C 3-13, C 3-14, C 3-16, C 3-17, C 3-18, C 3-19, C 4-20, C 5-31, C 4-32, C 4-33, C 4-34, C 4-35, C 4-36, C 4-37, C 4-38, C 4-39, C 5-40, C 5-50, C 5-60, C 5-70, C 5-80, C 5-90, C 5-100, C 5-110, C 5-120, C 5-130, C 5-140, C 5-150, C 5-160, C 5-170, C 5-180, C 5-1 2-10 In certain embodiments, alkenyl is a substituted C 2-10 In alkenyl, a C=C double bond whose stereochemistry is not specified (e.g., -CH=CHCH3, ) can be in the (E)- or (Z)-configuration.
[0056] "Alkynyl" refers to a straight or branched chain hydrocarbon radical ("C 2-20 In some embodiments, an alkynyl group has 2 to 10 carbon atoms ("C 2-10 In some embodiments, an alkynyl group has 2 to 9 carbon atoms ("C 2-9 In some embodiments, an alkynyl group has 2 to 8 carbon atoms ("C 2-8 In some embodiments, an alkynyl group has 2 to 7 carbon atoms ("C 2-7 In some embodiments, an alkynyl group has 2 to 6 carbon atoms ("C 2-6 In some embodiments, an alkynyl group has 2 to 5 carbon atoms ("C 2-5 In some embodiments, an alkynyl group has 2 to 4 carbon atoms ("C 2-4 In some embodiments, an alkynyl group has 2 to 3 carbon atoms ("C 2-3 In some embodiments, an alkynyl group has 2 carbon atoms (a "C2 alkynyl"). The one or more carbon-carbon triple bonds can be internal (such as in 2-butynyl) or terminal (such as in 1-butynyl). C 2-4 Examples of alkynyl groups include ethynyl (C2), 1-propynyl (C3), 2-propynyl (C3), 1-butynyl (C4), 2-butynyl (C4), and the like. 2-6 Examples of alkenyl groups include the above-mentioned C 2-4 Alkynyl and pentynyl (C5), hexynyl (C6), etc. Other examples of alkynyl include heptynyl (C7), octynyl (C8), etc. Unless otherwise specified, each instance of alkynyl is independently optionally substituted, e.g., unsubstituted (an “unsubstituted alkynyl”) or substituted with one or more substituents (a “substituted alkynyl”). In certain embodiments, alkynyl is an unsubstituted C 2-10 In certain embodiments, the alkynyl group is a substituted C 2-10 Alkynyl.
[0057] "Carbocyclyl" or "carbocyclic" refers to a non-aromatic ring system having 3 to 13 ring carbon atoms ("C 3-13 In some embodiments, a carbocyclyl group has 3 to 8 ring carbon atoms ("C 3-8 In some embodiments, a carbocyclyl group has 3 to 7 ring carbon atoms ("C 3-7In some embodiments, a carbocyclyl group has 3 to 6 ring carbon atoms ("C 3-6 In some embodiments, a carbocyclyl group has 5 to 10 ring carbon atoms ("C 5-10 Carbocyclyl”). Exemplary C 3-6 Carbocyclic groups include cyclopropyl (C3), cyclopropenyl (C3), cyclobutyl (C4), cyclobutenyl (C4), cyclopentyl (C5), cyclopentenyl (C5), cyclohexyl (C6), cyclohexenyl (C6), cyclohexadienyl (C6), and the like. 3-8 Carbocyclic groups include the aforementioned C 3-6 Carbocyclic groups and cycloheptyl (C7), cycloheptenyl (C7), cycloheptadienyl (C7), cycloheptatrienyl (C7), cyclooctyl (C8), cyclooctenyl (C8), bicyclo [2.2.1] heptyl (C7), bicyclo [2.2.2] octyl (C8), etc. Exemplary C 3-10 Carbocyclic groups include the aforementioned C 3-8 Carbocyclic groups and cyclononyl (C9), cyclononenyl (C9), cyclodecyl (C 10 ), cyclodecenyl (C 10 ), octahydro-1H-indenyl (C9), decahydronaphthyl (C 10 ), spiro[4.5]decyl (C 10 ) and the like. As shown in the foregoing examples, in certain embodiments, a carbocyclyl is monocyclic ("monocyclic carbocyclyl") or contains a fused, bridged, or spirocyclic ring system, such as a bicyclic ring system ("bicyclic carbocyclyl"). A carbocyclyl can be saturated, and a saturated carbocyclyl is referred to as a "cycloalkyl". In some embodiments, a carbocyclyl is a monocyclic saturated carbocyclyl ("Cycloalkyl") having 3 to 10 ring carbon atoms. 3-10 In some embodiments, a cycloalkyl group has 3 to 8 ring carbon atoms ("C 3-8 In some embodiments, a cycloalkyl group has 3 to 6 ring carbon atoms ("C 3-6 In some embodiments, a cycloalkyl group has 5 to 6 ring carbon atoms ("C 5-6 In some embodiments, a cycloalkyl group has 5 to 10 ring carbon atoms ("C 5-10 Cycloalkyl”). C 5-6 Examples of cycloalkyl groups include cyclopentyl (C5) and cyclohexyl (C5). 3-6 Examples of the cycloalkyl group include the aforementioned C 5-6 Cycloalkyl as well as cyclopropyl (C3) and cyclobutyl (C4). 3-8 Examples of the cycloalkyl group include the aforementioned C 3-6Cycloalkyl and cycloheptyl (C7) and cyclooctyl (C8). Unless otherwise specified, each instance of a cycloalkyl group is independently unsubstituted (an “unsubstituted cycloalkyl”) or substituted (a “substituted cycloalkyl”) with one or more substituents. In certain embodiments, a cycloalkyl group is an unsubstituted C 3-10 In certain embodiments, a cycloalkyl group is a substituted C 3-10 Cycloalkyl. Carbocyclyl can be partially unsaturated. Carbocyclyl can include zero, one or more (e.g., two, three or four, where valence permits) C=C double bonds in all rings of a non-aromatic or heteroaromatic carbocyclic system. Carbocyclyls that include one or more (e.g., two or three, where valence permits) C=C double bonds in a carbocyclic ring are referred to as "cycloalkenyls." Carbocyclyls that include one or more (e.g., two or three, where valence permits) C≡C triple bonds in a carbocyclic ring are referred to as "cycloalkynyls." Carbocyclyls include aryls. "Carbocyclyl" also includes ring systems in which a carbocyclyl ring as defined above is fused to one or more aryl or heteroaryl groups, wherein the point of attachment is on the carbocyclyl ring, and in this case, the number of carbons continues to represent the number of carbons in the carbocyclic ring system. Unless otherwise stated, each instance of a carbocyclyl is independently optionally substituted, e.g., unsubstituted ("unsubstituted carbocyclyl") or substituted ("substituted carbocyclyl") with one or more substituents. In certain embodiments, a carbocyclyl group is an unsubstituted C 3-10 In certain embodiments, a carbocyclyl group is a substituted C 3-10 Carbocyclyl. In certain embodiments, the carbocyclyl is substituted or unsubstituted, 3 to 7 members, and monocyclic. In certain embodiments, the carbocyclyl is substituted or unsubstituted, 5 to 13 members, and bicyclic.
[0058] In some embodiments, a "carbocyclyl" is a monocyclic saturated carbocyclyl ("C 3-10 In some embodiments, a cycloalkyl group has 3 to 8 ring carbon atoms ("C 3-8 In some embodiments, a cycloalkyl group has 3 to 6 ring carbon atoms ("C 3-6 In some embodiments, a cycloalkyl group has 5 to 6 ring carbon atoms ("C 5-6 In some embodiments, a cycloalkyl group has 5 to 10 ring carbon atoms ("C 5-10 Cycloalkyl”). C 5-6 Examples of cycloalkyl groups include cyclopentyl (C5) and cyclohexyl (C5). 3-6 Examples of the cycloalkyl group include the aforementioned C 5-6 Cycloalkyl as well as cyclopropyl (C3) and cyclobutyl (C4). 3-8Examples of the cycloalkyl group include the aforementioned C 3-6 Cycloalkyl and cycloheptyl (C7) and cyclooctyl (C8). Unless otherwise specified, each instance of cycloalkyl is independently unsubstituted (an “unsubstituted cycloalkyl”) or substituted (a “substituted cycloalkyl”) with one or more substituents. In certain embodiments, cycloalkyl is an unsubstituted C 3-10 In certain embodiments, the cycloalkyl group is a substituted C 3-10 Cycloalkyl.
[0059] "Heterocyclyl" or "heterocyclic" refers to a radical of a 3- to 13-membered non-aromatic ring system having ring carbon atoms and 1 to 4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur ("3-10 membered heterocyclyl"). In heterocyclyl groups containing one or more nitrogen atoms, the point of attachment may be a carbon or nitrogen atom, where valence permits. A heterocyclyl group may be monocyclic ("monocyclic heterocyclyl") or a fused, bridged, or spirocyclic ring system, such as a bicyclic ring system ("bicyclic heterocyclyl"). A heterocyclyl group may be saturated or partially unsaturated. A heterocyclyl group may include zero, one or more (e.g., two, three, or four, where valence permits) double bonds in all rings of a non-aromatic or heteroaromatic heterocyclyl ring system. Partially unsaturated heterocyclyl groups include heteroaryls. Heterocyclyl bicyclic ring systems may include one or more heteroatoms in one or both rings. "Heterocyclyl" also includes ring systems in which the heterocyclyl ring as defined above is fused to one or more carbocyclyl groups, wherein the point of attachment is on the carbocyclyl or heterocyclyl ring; or includes ring systems in which the heterocyclyl ring as defined above is fused to one or more aryl or heteroaryl groups, wherein the point of attachment is on the heterocyclyl ring, and in such cases, the number of ring members continues to represent the number of ring members in the heterocyclyl ring system. Unless otherwise indicated, each instance of heterocyclyl is independently optionally substituted, for example, unsubstituted ("unsubstituted heterocyclyl") or substituted ("substituted heterocyclyl") with one or more substituents. In certain embodiments, heterocyclyl is an unsubstituted 3-10 membered heterocyclyl. In certain embodiments, heterocyclyl is a substituted 3-10 membered heterocyclyl. In certain embodiments, heterocyclyl is substituted or unsubstituted, 3 to 7 members, and monocyclic. In certain embodiments, heterocyclyl is substituted or unsubstituted, 5 to 13 members, and bicyclic.
[0060] In some embodiments, a heterocyclyl group is a 5-10 membered non-aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5-10 membered heterocyclyl”). In some embodiments, a heterocyclyl group is a 5-8 membered non-aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5-8 membered heterocyclyl”). In some embodiments, a heterocyclyl group is a 5-6 membered non-aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5-6 membered heterocyclyl”). In some embodiments, a 5-6 membered heterocyclyl group has 1-3 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, a 5-6 membered heterocyclyl group has 1-2 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, a 5-6 membered heterocyclyl group has one ring heteroatom selected from nitrogen, oxygen, and sulfur.
[0061] Exemplary 3-membered heterocyclic groups containing one heteroatom include aziridinyl, oxiranyl, or thiothianyl. Exemplary 4-membered heterocyclic groups containing one heteroatom include azetidinyl, oxetanyl, and thietanyl. Exemplary 5-membered heterocyclic groups containing one heteroatom include tetrahydrofuranyl, dihydrofuranyl, tetrahydrophenylthio, dihydrophenylthio, pyrrolidinyl, dihydropyrrolyl, and pyrrolyl-2,5-dione. Exemplary 5-membered heterocyclic groups containing two heteroatoms include dioxolanyl, oxasulfanyl, disulfanyl, and oxazolidin-2-one. Exemplary 5-membered heterocyclic groups containing three heteroatoms include triazolinyl, oxadiazolinyl, and thiadiazolinyl. Exemplary 6-membered heterocyclic groups containing one heteroatom include piperidinyl, tetrahydropyranyl, dihydropyridinyl, and thianyl. Exemplary 6-membered heterocyclic groups containing two heteroatoms include piperazinyl, morpholinyl, dithianyl, and dioxanyl. Exemplary 6-membered heterocyclic radicals containing two heteroatoms include triazinyl. Exemplary 7-membered heterocyclic radicals containing one heteroatom include azepanyl, oxepanyl and thiepanyl. Exemplary 8-membered heterocyclic radicals containing one heteroatom include azocyclooctanyl, oxepanyl and thiepanyl. Exemplary 5-membered heterocyclic radicals (also referred to as 5,6-bicyclic heterocycles in this article) fused to a C6 aryl ring include indolinyl, isoindolinyl, dihydrobenzofuranyl, dihydrobenzothienyl, benzoxazolinone, etc. Exemplary 6-membered heterocyclic radicals (also referred to as 6,6-bicyclic heterocycles in this article) fused to an aryl ring include tetrahydroquinolinyl, tetrahydroisoquinolinyl, etc.
[0062] "Aryl" refers to a group having 6-14 ring carbon atoms and zero heteroatoms provided in the aromatic ring system, a monocyclic or polycyclic (e.g., bicyclic or tricyclic) 4n+2 aromatic ring system (e.g., having 6, 10, or 14 pi electrons in common in the ring array) ("C 6-14In some embodiments, an aryl group has six ring carbon atoms ("C6 aryl"; e.g., phenyl). In some embodiments, an aryl group has ten ring carbon atoms ("C 10 "Aryl"; for example, naphthyl, such as 1-naphthyl and 2-naphthyl). In some embodiments, an aryl group has fourteen ring carbon atoms ("C 14 "Aryl"; e.g., anthracenyl). "Aryl" also includes ring systems in which an aryl ring, as defined above, is fused to one or more carbocyclyl or heterocyclyl groups, wherein the radical or point of attachment is on the aryl ring, and in such cases, the number of carbon atoms continues to refer to the number of carbon atoms in the aryl ring system. Unless otherwise indicated, each instance of an aryl group is independently optionally substituted, e.g., unsubstituted (an "unsubstituted aryl") or substituted with one or more substituents (a "substituted aryl"). In certain embodiments, an aryl group is an unsubstituted C 6-14 In certain embodiments, aryl is a substituted C 6-14 Aryl.
[0063] "Heteroaryl" refers to a radical of a 5-10 membered monocyclic or bicyclic -4n+2 aromatic ring system (e.g., having 6 or -10 pi electrons in common in the array of rings) having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur ("5-10 membered heteroaryl"). In heteroaryl groups containing one or more nitrogen atoms, the point of attachment can be a carbon or nitrogen atom, where valence permits. Heteroaryl bicyclic ring systems may include one or more heteroatoms in one or both rings. "Heteroaryl" includes ring systems in which a heteroaryl ring as defined above is fused to one or more carbocyclyl or heterocyclyl groups, wherein the point of attachment is on the heteroaryl ring, and in such cases, the number of ring members continues to represent the number of ring members in the heteroaryl ring system. "Heteroaryl" also includes ring systems in which a heteroaryl ring, as defined above, is fused to one or more aryl groups, wherein the point of attachment is on either the aryl or heteroaryl ring, and in such cases, the number of ring members refers to the number of ring members in the fused (aryl / heteroaryl) ring system. For bicyclic heteroaryls, in which one ring contains no heteroatoms (e.g., indolyl, quinolinyl, carbazolyl, etc.), the point of attachment can be on either ring, e.g., the ring with the heteroatom (e.g., 2-indolyl) or the ring without the heteroatom (e.g., 5-indolyl).
[0064] In some embodiments, heteroaryl is a 5-10 membered aromatic ring system having ring carbon atoms provided in the aromatic ring system and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5-10 membered heteroaryl”). In some embodiments, heteroaryl is a 5-8 membered aromatic ring system having ring carbon atoms provided in the aromatic ring system and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5-8 membered heteroaryl”). In some embodiments, heteroaryl is a 5-6 membered aromatic ring system having ring carbon atoms provided in the aromatic ring system and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5-6 membered heteroaryl”). In some embodiments, 5-6 membered heteroaryl has 1-3 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, 5-6 membered heteroaryl has 1-2 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, the 5-6 membered heteroaryl group has one ring heteroatom selected from nitrogen, oxygen, and sulfur. Unless otherwise specified, each instance of a heteroaryl group is independently optionally substituted, e.g., unsubstituted ("unsubstituted heteroaryl") or substituted ("substituted heteroaryl") with one or more substituents. In certain embodiments, a heteroaryl group is an unsubstituted 5-14 membered heteroaryl group. In certain embodiments, a heteroaryl group is a substituted 5-14 membered heteroaryl group.
[0065] Exemplary 5-membered heteroaryl groups containing one heteroatom include pyrrolyl, furyl, and thiophenyl. Exemplary 5-membered heteroaryl groups containing two heteroatoms include imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, and isothiazolyl. Exemplary 5-membered heteroaryl groups containing three heteroatoms include triazolyl, oxadiazolyl, and thiadiazolyl. Exemplary 5-membered heteroaryl groups containing four heteroatoms include tetrazolyl. Exemplary 6-membered heteroaryl groups containing one heteroatom include pyridyl. Exemplary 6-membered heteroaryl groups containing two heteroatoms include pyridazinyl, pyrimidinyl, and pyrazinyl. Exemplary 6-membered heteroaryl groups containing three or four heteroatoms include triazinyl and tetrazinyl, respectively. Exemplary 7-membered heteroaryl groups containing one heteroatom include aza Oxalic acid thia Exemplary 5,6-bicyclic heteroaryl groups include indolyl, isoindolyl, indazolyl, benzotriazolyl, benzothiophenyl, isobenzothiophenyl, benzofuranyl, benzisofuranyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzoxadiazolyl, benzothiazolyl, benzisothiazolyl, benzothiadiazolyl, indolizinyl, and purinyl. Exemplary 6,6-bicyclic heteroaryl groups include naphthyridinyl, pteridinyl, quinolinyl, isoquinolinyl, cinnolinyl, quinoxalinyl, phthalazinyl, and quinazolinyl.
[0066] "Partially unsaturated" refers to a group that includes at least one double or triple bond. The term "partially unsaturated" is intended to encompass rings with multiple sites of unsaturation and is not intended to include aromatic groups (e.g., aryl or heteroaryl) as defined herein. Likewise, "saturated" refers to a group that does not contain double or triple bonds, i.e., contains all single bonds.
[0067] In some embodiments, aliphatic, alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl groups as defined herein are optionally substituted (e.g., "substituted" or "unsubstituted" alkyl, "substituted" or "unsubstituted" alkenyl, "substituted" or "unsubstituted" alkynyl, "substituted" or "unsubstituted" carbocyclyl, "substituted" or "unsubstituted" heterocyclyl, "substituted" or "unsubstituted" aryl, or "substituted" or "unsubstituted" heteroaryl). In general, the term "substituted," whether or not preceded by "optionally," means that at least one hydrogen present on a group (e.g., a carbon or nitrogen atom) is replaced with an available substituent, such as a substituent that, upon substitution, results in a stable compound, such as a compound that does not spontaneously undergo transformation, such as by rearrangement, cyclization, elimination, or other reaction. Unless otherwise indicated, a "substituted" group has a substituent at one or more substitutable positions of the group, and when more than one position in any given structure is substituted, the substituent is the same or different at each position. Unless otherwise provided, the substituent on the polycyclic ring can be on any substitutable position of any monocyclic ring of the polycyclic ring. It is envisaged that the term "substituted" includes substitutions with all available substituents of an organic compound (any substituents described herein that cause the formation of stable compounds). The present disclosure contemplates any and all such combinations to obtain stable compounds. For the purposes of this disclosure, heteroatoms such as nitrogen may have hydrogen substituents and / or any suitable substituents as described herein that satisfy the valence of the heteroatoms and cause the formation of a stable portion.
[0068] Exemplary carbon atom substituents include halogen, -CN, -NO2, -N3, -SO2H, -SO3H, -OH, -OR aa 、-ON(R bb )2、-N(R bb )2、-N(R bb )3 + X - 、-N(OR cc )R bb 、-SH、-SR aa 、-SSR cc 、-C(=O)R aa 、-CO2H、-CHO、-C(OR cc )2, -CO2Raa 、-OC(=O)R aa 、-OCO2R aa 、-C(=O)N(R bb )2、-OC(=O)N(R bb )2、-NR bb C(=O)R aa 、-NR bb CO2R aa 、--NR bb C(=O)N(R bb )2、-C(=NR bb )R aa 、-C(=NR bb )OR aa 、-OC(=NR bb )R aa 、-OC(=NR bb )OR aa 、-C(=NR bb )N(R bb )2、-OC(=NR bb )N(R bb )2、-NR bb C(=NR bb )N(R bb )2、-C(=O)NR bb SO2R aa 、-NR bb SO2R aa 、-SO2N(R bb )2、-SO2R aa 、-SO2OR aa 、-OSO2R aa 、-S(=O)R aa 、-OS(=O)R aa 、-Si(R aa )3、-OSi(R aa )3-C(=S)N(R bb )2、-C(=O)SR aa 、-C(=S)SR aa 、-SC(=S)SR aa 、-SC(=O)SR aa 、-OC(=O)SR aa 、-SC(=O)OR aa 、-SC(=O)R aa 、-P(=O)(R aa )2、-P(=O)(OR cc )2、-OP(=O)(R aa )2、-OP(=O)(ORcc )2、-P(=O)(N(R bb )2)2、-OP(=O)(N(R bb )2)2、-NR bb P(=O)(R aa )2、-NR bb p(=O)(OR cc )2、-NR bb P(=O)(N(R bb )2)2、-P(R cc )2、-P(OR cc )2、-P(R cc )3 + X - 、-P(OR cc )3 + X - 、-P(R cc )4、-P(OR cc )4、-OP(R cc )2、-OP(R cc )3 + X - 、-OP(OR cc )2、-OP(OR cc )3 + X - 、-OP(R cc )4、-OP(OR cc )4、-B(R aa )2、-B(OR cc )2, -BR aa (OR cc ), C 1-10 Alkyl, C 1-10 Perhalogenated alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, hetero C 1-10 Alkyl, hetero C 2-10 Alkenyl, hetero C 2-10 Alkynyl, C 3-10 Carbocyclic group, 3-14 membered heterocyclic group, C 6-14 Aryl and 5-14 membered heteroaryl, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl and heteroaryl is independently replaced by 0, 1, 2, 3, 4 or 5 R dd Group substitution; wherein X - is the counterion;
[0069] Or the two geminal hydrogen atoms on the carbon atom are replaced by groups =O, =S, =NN(R bb )2, =NNR bb C(=O)Raa 、=NNR bb C(=O)OR aa 、=NNR bb S(=O)2R aa 、=NR bb or = NOR cc Replacement;
[0070] R aa Each instance of is independently selected from C 1-10 Alkyl, C 1-10 Perhalogenated alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, hetero C 1-10 Alkyl, hetero C 2-10 Alkenyl, hetero C 2-10 Alkynyl, C 3-10 Carbocyclic group, 3-14 membered heterocyclic group, C 6-14 Aryl and 5-14 membered heteroaryl, or two R aa The groups are connected to form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl and heteroaryl group is independently replaced by 0, 1, 2, 3, 4 or 5 R dd group substitution;
[0071] R bb Each instance of is independently selected from hydrogen, -OH, -OR aa 、-N(R cc )2, -CN, -C(=O)R aa 、-C(=O)N(R cc )2, -CO2R aa 、-SO2R aa 、-C(=NR cc )OR aa 、-C(=NR cc )N(R cc )2、-SO2N(R cc )2, -SO2R cc 、-SO2OR cc 、-SOR aa 、-C(=S)N(R cc )2, -C(=O)SR cc 、-C(=S)SR cc 、-P(=O)(R aa )2、-P(=O)(OR cc )2、-P(=O)(N(R cc )2)2、C 1-10 Alkyl, C 1-10 Perhalogenated alkyl, C 2-10Alkenyl, C 2-10 Alkynyl, hetero C 1-10 Alkyl, hetero C 2-10 Alkenyl, hetero C 2-10 Alkynyl, C 3-10 Carbocyclic group, 3-14 membered heterocyclic group, C 6-14 Aryl and 5-14 membered heteroaryl, or two R bb The groups are connected to form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl and heteroaryl group is independently replaced by 0, 1, 2, 3, 4 or 5 R dd Group substitution; wherein X - is the counterion;
[0072] R cc Each instance of is independently selected from hydrogen, C 1-10 Alkyl, C 1-10 Perhalogenated alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, hetero C 1-10 Alkyl, hetero C 2-10 Alkenyl, hetero C 2-10 Alkynyl, C 3-10 Carbocyclic group, 3-14 membered heterocyclic group, C 6-14 Aryl and 5-14 membered heteroaryl, or two R cc The groups are connected to form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl and heteroaryl group is independently replaced by 0, 1, 2, 3, 4 or 5 R dd group substitution;
[0073] R dd Each instance of is independently selected from halogen, -CN, -NO2, -N3, -SO2H, -SO3H, -OH, -OR ee 、-ON(R ff )2、-N(R ff )2、-N(R ff )3 + X - 、-N(OR ee )R ff 、-SH、-SR ee 、-SSR ee 、-C(=O)R ee 、-CO2H、-CO2R ee 、-OC(=O)R ee 、-OCO2R ee 、-C(=O)N(R ff )2、-OC(=O)N(Rff )2、-NR ff C(=O)R ee 、-NR ff CO2R ee 、-NR ff C(=O)N(R ff )2、-C(=NR ff )OR ee 、-OC(=NR ff )R ee 、-OC(=NR ff )OR ee 、-C(=NR ff )N(R ff )2、-OC(=NR ff )N(R ff )2、-NR ff C(=NR ff )N(R ff )2、-NR ff SO2R ee 、-SO2N(R ff )2, -SO2R ee 、-SO2OR ee 、-OSO2R ee 、-S(=O)R ee 、-Si(R ee )3、-OSi(R ee )3、-C(=S)N(R ff )2, -C(=O)SR ee 、-C(=S)SR ee 、-SC(=S)SR ee 、-P(=O)(OR ee )2、-P(=O)(R ee )2、-OP(=O)(R ee )2、-OP(=O)(OR ee )2、C 1-6 Alkyl, C 1-6 Perhalogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, hetero C 1-6 Alkyl, hetero C 2-6 Alkenyl, hetero C 2-6 Alkynyl, C 3-10 Carbocyclic group, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl and heteroaryl are independently replaced by 0, 1, 2, 3, 4 or 5 R gg Group substitution, or two geminal Rdd Substituents may be linked to form =O or =S; where X - is the counterion;
[0074] R ee Each instance of is independently selected from C 1-6 Alkyl, C 1-6 Perhalogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, hetero C 1-6 Alkyl, hetero C 2-6 Alkenyl, hetero C 2-6 Alkynyl, C 3-10 Carbocyclic group, C 6-10 aryl, 3-10 membered heterocyclyl and 3-10 membered heteroaryl, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl and heteroaryl is independently replaced by 0, 1, 2, 3, 4 or 5 R gg group substitution;
[0075] R ff Each instance of is independently selected from hydrogen, C 1-6 Alkyl, C 1-6 Perhalogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, hetero C 1-6 Alkyl, hetero C 2-6 Alkenyl, hetero C 2-6 Alkynyl, C 3-10 Carbocyclic group, 3-10 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, or two R ff The groups are connected to form a 3-10 membered heterocyclyl or 5-10 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl and heteroaryl group is independently replaced by 0, 1, 2, 3, 4 or 5 R gg group substitution; and
[0076] R gg Each instance of is independently halogen, -CN, -NO2, -N3, -SO2H, -SO3H, -OH, -OC 1-6 Alkyl, -ON(C 1-6 Alkyl)2, -N(C 1-6 Alkyl)2, -N(C 1-6 Alkyl)3 + X - 、-NH(C 1-6 Alkyl)2 + X - 、-NH2(C 1-6 alkyl) + X - 、-NH3+ X - 、-N(OC 1-6 Alkyl)(C 1-6 Alkyl), -N(OH)(C 1-6 Alkyl), -NH(OH), -SH, -SC 1-6 Alkyl, -SS(C 1-6 alkyl), -C(=O)(C 1-6 alkyl), -CO2H, -CO2(C 1-6 alkyl), -OC(=O)(C 1-6 Alkyl), -OCO2(C 1-6 alkyl), -C(=O)NH2, -C(=O)N(C 1-6 alkyl)2, -OC(=O)NH(C 1-6 alkyl), -NHC(=O)(C 1-6 Alkyl), -N(C 1-6 alkyl)C(=O)(C 1-6 Alkyl), -NHCO2(C 1-6 alkyl), -NHC(=O)N(C 1-6 Alkyl)2, -NHC(=O)NH(C 1-6 alkyl), -NHC(=O)NH2, -C(=NH)O(C 1-6 alkyl), -OC(=NH)(C 1-6 alkyl), -OC(=NH)OC 1-6 Alkyl, -C(=NH)N(C 1-6 Alkyl)2, -C(=NH)NH(C 1-6 alkyl), -C(=NH)NH2, -OC(=NH)N(C 1-6 Alkyl)2, -OC(NH)NH(C 1-6 alkyl), -OC(NH)NH2, -NHC(NH)N(C 1-6 Alkyl)2, -NHC(=NH)NH2, -NHSO2(C 1-6 Alkyl), -SO2N(C 1-6 Alkyl)2, -SO2NH(C 1-6 alkyl), -SO2NH2, -SO2C 1-6 Alkyl, -SO2OC 1-6 Alkyl, -OSO2C 1-6 Alkyl, -SOC 1-6 Alkyl, -Si(C 1-6 alkyl)3, -OSi(C 1-6 alkyl)3-C(=S)N(C 1-6 alkyl)2、C(=S)NH(C 1-6alkyl), C(=S)NH2, -C(=O)S(C 1-6 alkyl), -C(=S)SC 1-6 Alkyl, -SC(=S)SC 1-6 Alkyl, -P(=O)(OC 1-6 alkyl)2, -P(=O)(C 1-6 alkyl)2, -OP(=O)(C 1-6 alkyl)2, -OP(=O)(OC 1-6 Alkyl)2, C 1-6 Alkyl, C 1-6 Perhalogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, hetero C 1-6 Alkyl, hetero C 2-6 Alkenyl, hetero C 2-6 Alkynyl, C 3-10 Carbocyclic group, C 6-10 Aryl, 3-10 membered heterocyclyl, 5-10 membered heteroaryl; or two geminal R gg Substituents may be linked to form =O or =S; where X - It is a counter ion.
[0077] In certain embodiments, carbon atom substituents are independently halogen, substituted (eg, substituted with one or more halogens), or unsubstituted C 1-6 Alkyl, -OR aa 、-SR aa 、-N(R bb )2, -CN, -SCN, -NO2, -C(=O)R aa 、-CO2R aa 、-C(=O)N(R bb )2, -OC(=O)R aa 、-OCO2R aa 、-OC(=O)N(R bb )2、-NR bb C(=O)R aa 、-NR bb CO2R aa or -NR bb C(=O)N(R bb ) 2. In certain embodiments, the carbon atom substituents are independently halogen, substituted (eg, substituted with one or more halogens), or unsubstituted C 1-6 Alkyl, -OR aa 、-SR aa 、-N(R bb )2, -CN, -SCN, -NO2, -C(=O)R aa 、-CO2R aa、-C(=O)N(R bb )2, -OC(=O)R aa 、-OCO2R aa 、-OC(=O)N(R bb )2、-NR bb C(=O)R aa 、-NR bb CO2R aa or -NR bb C(=O)N(R bb )2, where R aa is hydrogen, substituted (eg, substituted with one or more halogens) or unsubstituted C 1-6 alkyl, an oxygen protecting group attached to an oxygen atom, or a sulfur protecting group attached to a sulfur atom (e.g., acetamidomethyl, t-Bu, 3-nitro-2-pyridinesulfinyl, 2-pyridine-sulfinyl, or trityl); each Rbb is independently hydrogen, substituted (e.g., substituted with one or more halogens), or unsubstituted C 1-6 In certain embodiments, the carbon atom substituents are independently halogen, substituted (e.g., substituted with one or more halogens), or unsubstituted C 1-6 Alkyl, -OR aa 、-SR aa 、-N(R bb ) 2, -CN, -SCN or -NO 2. In certain embodiments, the carbon atom substituents are independently halogen, substituted (e.g., substituted with one or more halogen moieties) or unsubstituted C 1-6 Alkyl, -OR aa 、-SR aa 、-N(R bb )2, -CN, -SCN or -NO2, where R aa is hydrogen, substituted (eg, substituted with one or more halogens) or unsubstituted C 1-6 alkyl, an oxygen protecting group attached to an oxygen atom, or a sulfur protecting group attached to a sulfur atom (e.g., acetamidomethyl, t-Bu, 3-nitro-2-pyridinesulfinyl, 2-pyridine-sulfinyl, or trityl); and each R bb are independently hydrogen, substituted (eg, substituted with one or more halogens) or unsubstituted C 1-6 Alkyl or nitrogen protecting group.
[0078] A "counterion" or "anionic counterion" is a negatively charged group associated with a positively charged group to maintain electronic neutrality. Anionic counterions can be monovalent (i.e., include one formal negative charge). Anionic counterions can also be multivalent (i.e., include more than one formal negative charge), such as divalent or trivalent. Exemplary counterions include halides (e.g., F - 、Cl - Br - , I - )、NO3 - 、ClO4 - OH - 、H2PO4 - 、HCO3 - 、HSO4 - , sulfonate ions (e.g., methanesulfonate, trifluoromethanesulfonate, p-toluenesulfonate, benzenesulfonate, 10-camphorsulfonate, naphthalene-2-sulfonate, naphthalene-1-sulfonic acid-5-sulfonate, ethane-1-sulfonic acid-2-sulfonate, etc.), carboxylate ions (e.g., acetate, propionate, benzoate, glycerate, lactate, tartrate, glycolate, gluconate, etc.), BF4 - PF4 - PF6 - 、AsF6 - 、SbF6 - 、B[3,5-(CF3)2C6H3]4] - 、B(C6F5)4 - , BPh4 - 、Al(OC(CF3)3)4 - and carborane anions (e.g., CB 11 H 12 - or (HCB 11 Me5Br6) - ). Exemplary multivalent counterions include CO3 2- 、HPO4 2- PO4 3- 、B4O7 2- 、SO4 2- 、S2O3 2- , carboxylate anions (e.g., tartrate, citrate, fumarate, maleate, malate, malonate, gluconate, succinate, glutarate, adipate, pimelate, suberate, azelaic acid, sebacate, salicylate, phthalate, aspartate, glutamate, etc.) and carborane.
[0079] "Halo" or "halogen" refers to fluorine (fluoro, -F), chlorine (chloro, -Cl), bromine (bromo, -Br), or iodine (iodo, -I).
[0080] The nitrogen atoms may be substituted or unsubstituted, where valence permits, and include primary, secondary, tertiary, and quaternary nitrogen atoms. Exemplary nitrogen atom substituents include hydrogen, -OH, -OR aa 、-N(R cc )2, -CN, -C(=O)R aa 、-C(=O)N(R cc )2, -CO2R aa 、-SO2R aa 、-C(=NR bb )R aa 、-C(=NR cc )OR aa 、-C(=NR cc )N(R cc )2、-SO2N(R cc )2, -SO2R cc 、-SO2OR cc 、-SOR aa 、-C(=S)N(R cc )2, -C(=O)SR cc 、-C(=S)SR cc 、-P(=O)(OR cc )2、-P(=O)(R aa )2、-P(=O)(N(R cc )2)2、C 1-10 Alkyl, C 1-10 Perhalogenated alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, hetero C 1-10 Alkyl, hetero C 2-10 Alkenyl, hetero C 2-10 Alkynyl, C 3-10 Carbocyclic group, 3-14 membered heterocyclic group, C 6-14 Aryl and 5-14 membered heteroaryl, or two R groups connected to the N atom cc The groups are connected to form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl and heteroaryl group is independently replaced by 0, 1, 2, 3, 4 or 5 R dd group substituted, and wherein R aa 、R bb 、R cc and R dd As defined above.
[0081] In certain embodiments, nitrogen atom substituents are independently substituted (eg, with one or more halogens) or unsubstituted C 1-6 Alkyl, -C(=O)Raa 、-CO2R aa 、-C(=O)N(R bb ) 2 or a nitrogen protecting group. In certain embodiments, the nitrogen atom substituents are independently substituted (e.g., substituted with one or more halogens) or unsubstituted C 1-6 Alkyl, -C(=O)R aa 、-CO2R aa 、-C(=O)N(R bb )2 or a nitrogen protecting group, wherein R aa is hydrogen, substituted (eg, by one or more halogens) or unsubstituted C 1-6 alkyl, or an oxygen protecting group when attached to an oxygen atom; and each R bb are independently hydrogen, substituted (eg, substituted with one or more halogens) or unsubstituted C 1-6 In certain embodiments, the nitrogen atom substituents are independently substituted (e.g., substituted with one or more halogens) or unsubstituted C 1-6 Alkyl or nitrogen protecting group.
[0082] In certain embodiments, the substituent present on the nitrogen atom is a nitrogen protecting group (also known as an amino protecting group). Nitrogen protecting groups include -OH, -OR aa 、-N(R cc )2, -C(=O)R aa 、-C(=O)N(R cc )2, -CO2R aa 、-SO2R aa 、-C(=NR cc )R aa 、-C(=NR cc )OR aa 、-C(=NR cc )N(R cc )2、-SO2N(R cc )2, -SO2R cc 、-SO2OR cc 、-SOR aa 、-C(=S)N(R cc )2, -C(=O)SR cc 、-C(=S)SR cc 、C 1-10 Alkyl (e.g., aralkyl, heteroaralkyl), C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-10 Carbocyclic group, 3-14 membered heterocyclic group, C 6-14Aryl and 5-14 membered heteroaryl, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aralkyl, aryl and heteroaryl is independently replaced by 0, 1, 2, 3, 4 or 5 R dd substituted with a group, and wherein R aa 、R bb 、R cc and R dd As defined herein. Nitrogen protecting groups are well known in the art and include those described in detail in Protecting Groups in Organic Synthesis, TW Greene and PGM Wuts, 3rd ed., John Wiley & Sons, 1999, incorporated herein by reference.
[0083] Amide nitrogen protecting groups (e.g., -C(=O)R aa ) include formamide, acetamide, chloroacetamide, trichloroacetamide, trifluoroacetamide, phenylacetamide, 3-phenylpropionamide, picolinamide, 3-pyridylformamide, N-benzoylphenylalanyl derivatives, benzamide, p-phenylbenzamide, o-nitrophenylacetamide, o-nitrophenoxyacetamide, acetoacetamide, (N'-dithiobenzyloxyamido)acetamide, 3-(p-hydroxyphenyl)propionamide, 3-(o-nitrophenyl)propionamide, 2-methyl-2-(o-nitrophenoxy)propionamide, 2-methyl-2-(o-phenylazophenoxy)propionamide, 4-chlorobutanamide, 3-methyl-3-nitrobutanamide, o-nitrocinnamamide, N-acetylmethionine, o-nitrobenzamide, and o-(benzoyloxymethyl)benzamide.
[0084] Carbamate nitrogen protecting groups (e.g., -C(=O)OR aa) include methyl carbamate, ethyl carbamate, 9-fluorenylmethylcarbamate (Fmoc), 9-(2-sulfo)fluorenylmethylcarbamate, 9-(2,7-dibromo)fluorenylmethylcarbamate, 2,7-di-tert-butyl-[9-(10,10-dioxo-10,10,10,10-tetrahydrothioxanthenyl)]methylcarbamate (DBD-Tmoc), 4-methoxyphenacylcarbamate (Phenoc), 2,2,2-trichloroethylcarbamate (Troc), 2-trimethylsilylethylcarbamate (Teoc), 2-phenylethylcarbamate (hZ), 1-(1-adamantyl)-1-methylethylcarbamate (Adpo c), 1,1-dimethyl-2-haloethylcarbamate, 1,1-dimethyl-2,2-dibromoethylcarbamate (DB-t-BOC), 1,1-dimethyl-2,2,2-trichloroethylcarbamate (TCBOC), 1-methyl-1-(4-diphenyl)ethylcarbamate (Bpoc), 1-(3,5-di-tert-butylphenyl)-1-methylethylcarbamate (t-Bumeoc), 2-(2′- and 4′-pyridyl)ethylcarbamate (Pyoc), 2-(N,N-dicyclohexylcarboxamido)ethylcarbamate, tert-butyl carbamate (BOC), 1-adamantylcarbamate (Adoc), vinylcarbamate (Voc ), allylcarbamate (Alloc), 1-isopropylallylcarbamate (Ipaoc), cinnamylcarbamate (Coc), 4-nitrocinnamylcarbamate (Noc), 8-quinolinylcarbamate, N-hydroxypiperidinylcarbamate, alkyldithiocarbamate, benzylcarbamate (Cbz), p-methoxybenzylcarbamate (Moz), p-nitrobenzylcarbamate, p-bromobenzylcarbamate, p-chlorobenzylcarbamate, 2,4-dichlorobenzylcarbamate, 4-methylsulfinylbenzylcarbamate (Msz), 9-anthrylmethylcarbamate, diphenylmethylcarbamate, 2-methylthioethylcarbamate, 2-methylsulfonylethylcarbamate carbamate, 2-(p-toluenesulfonyl)ethylcarbamate, [2-(1,3-dithianyl)]methylcarbamate (Dmoc), 4-methylthiophenylcarbamate (Mtpc), 2,4-dimethylthiophenylcarbamate (Bmpc), 2-phosphonoethylcarbamate (Peoc), 2-triphenylphosphonoisopropylcarbamate (Ppoc), 1,1-dimethyl-2-cyanoethylcarbamate, m-chloro-p-acyloxybenzylcarbamate, p-(dihydroxyboryl)benzylcarbamate, 5-benzisoxazolylmethylcarbamate, 2-(trifluoromethyl)-6-chromonylmethylcarbamate (Tcroc), m-nitrophenylcarbamate, 3,5-dimethoxybenzylcarbamate, o-nitrobenzylcarbamate, 3,4-dimethoxy-6-nitrobenzylcarbamate, phenyl(o-nitrophenyl)methylcarbamate, tert-amylcarbamate, S-benzylthiocarbamate, p-cyanobenzylcarbamate, cyclobutylcarbamate, cyclohexylcarbamate, cyclopentylcarbamate, cyclopropylmethylcarbamate, p-decyloxybenzylcarbamate, 2,2-dimethoxyacylvinylcarbamate, o-(N,N-dimethylcarboxamido)benzylcarbamate, 1,1-dimethyl-3-(N,N-dimethylcarboxamido)propylcarbamate, 1,1-dimethylpropynylcarbamate, di(2-pyridyl)methylcarbamate, 2-furylmethylcarbamate, 2-iodoethyl carbamate, isobornyl carbamate, isobutyl carbamate, isonicotinoyl carbamate, p-(p'-methoxyphenylazo)benzyl carbamate, 1-methylcyclobutyl carbamate, 1-methylcyclohexyl carbamate, 1-methyl-1-cyclopropylmethyl carbamate, 1-methyl-1-(3,5-dimethoxyphenyl)ethyl carbamate, 1-methyl-1-(p-phenylazophenyl)ethyl carbamate, 1-methyl-1-phenylethyl carbamate, 1-methyl-1-(4-pyridyl)ethyl carbamate, phenyl carbamate, p-(phenylazo)benzyl carbamate, 2,4,6-tri-tert-butylphenyl carbamate, 4-(trimethylammonium)benzyl carbamate and 2,4,6-trimethylbenzyl carbamate.
[0085] Sulfonamide nitrogen protecting group (e.g. -S(=O)2R aa ) include p-toluenesulfonamide (Ts), benzenesulfonamide, 2,3,6,-trimethyl-4-methoxybenzenesulfonamide (Mtr), 2,4,6-trimethoxybenzenesulfonamide (Mtb), 2,6-dimethyl-4-methoxybenzenesulfonamide (Pme), 2,3,5,6-tetramethyl-4-methoxybenzenesulfonamide (Mte), 4-methoxybenzenesulfonamide (Mbs), 2,4,6-trimethylbenzenesulfonamide (Mts), 2,6-dimethoxy-4-methylbenzenesulfonamide (iMds), 2,2,5,7,8-pentamethylchroman-6-sulfonamide (Pmc), methanesulfonamide (Ms), β-trimethylsilylethanesulfonamide (SES), 9-anthracenesulfonamide, 4-(4',8'-dimethoxynaphthylmethyl)benzenesulfonamide (DNMBS), benzylsulfonamide, trifluoromethylsulfonamide and phenacylmethylsulfonamide.
[0086] Other nitrogen protecting groups include phenothiazinyl-(10)-acyl derivatives, N'-toluenesulfonylaminoacyl derivatives, N'-phenylaminosulfonyl derivatives, N-benzoylphenylalanyl derivatives, N-acetylmethionine derivatives, 4,5-diphenyl-3-oxazolin-2-one, N-phthalimide, N-dithiosuccinimide (Dts), N-2,3-diphenylmaleimide, N-2,5-dimethylpyrrole, N-1,1,4,4-tetramethyldisilazide adduct (STABASE), 5-substituted 1,3-dimethyl-1,3,5-triazacyclohexan-2-one, 5-substituted 1,3-dibenzyl-1,3,5-triazacyclohexan-2-one, 1-substituted 3,5-dinitro-4-pyridone, N-methylamine, N-allylamine, N-[2-(trimethylsilyl)ethoxy]methylamine (SEM), N-3-acetoxypropylamine, N-(1-isopropyl-4-nitro-2-oxo-3-pyrrolin-3-yl)amine, quaternary ammonium salts, N-benzylamine, N-di(4-methoxyphenyl)methylamine, N-5-dibenzosuberylamine, N-triphenylmethylamine (Tr), N-[(4-methoxyphenyl)diphenylmethyl]amine (MMTr), N-9-phenylfluorenamine (PhF), N-2,7 -Dichloro-9-fluorenylmethyleneamine, N-ferrocenylmethylamino (Fcm), N-2-pyridylamino N'-oxide, N-1,1-dimethylthiomethyleneamine, N-benzylideneamine, N-p-methoxybenzylideneamine, N-diphenylmethyleneamine, N-[(2-pyridyl)mesityl]methyleneamine, N-(N',N'-dimethylaminomethylene)amine, N,N'-isopropylidenediamine, N-p-nitrobenzylideneamine, N-salicylideneamine, N-5-chlorosalicylideneamine, N-(5-chloro-2-hydroxyphenyl)phenylmethyleneamine, N-cyclohexyleneamine, N-(5,5-dimethyl-3-oxo-1-cyclohexenyl)amine , N-borane derivatives, N-diphenylboronic acid derivatives, N-[phenyl(pentaacylchromium or tungsten)acyl]amine, N-copper chelates, N-zinc chelates, N-nitramines, N-nitrosamines, amine N-oxides, diphenylphosphoramide (Dpp), dimethylphosphoramide (Mpt), diphenylphosphoramide (Ppt), dialkylphosphoramidates, dibenzylphosphoramidate, diphenylphosphoramidate, benzenesulfenamide, o-nitrobenzenesulfenamide (Nps), 2,4-dinitrobenzenesulfenamide, pentachlorobenzenesulfenamide, 2-nitro-4-methoxybenzenesulfenamide, triphenylmethylsulfenamide, and 3-nitropyridinesulfenamide (Npys).
[0087] In certain embodiments, the nitrogen protecting group is Bn, Boc, Cbz, Fmoc, trifluoroacetyl, trityl, acetyl, or Ts.
[0088] In certain embodiments, oxygen atom substituents are independently substituted (eg, with one or more halogens) or unsubstituted C 1-6 Alkyl, -C(=O)R aa 、-CO2R aa 、-C(=O)N(R bb ) 2 or oxygen protecting groups. In certain embodiments, nitrogen atom substituents are independently substituted (eg, substituted with one or more halogens) or unsubstituted C 1-6 Alkyl, -C(=O)R aa 、-CO2R aa 、-C(=O)N(R bb )2 or oxygen protecting group, wherein R aa is hydrogen, substituted (eg, by one or more halogens) or unsubstituted C 1-6 alkyl, or an oxygen protecting group when attached to an oxygen atom; and each R bb are independently hydrogen, substituted (eg, substituted with one or more halogens) or unsubstituted C 1-6 In certain embodiments, the oxygen atom substituents are independently substituted (eg, substituted with one or more halogens) or unsubstituted C 1-6 Alkyl or oxygen protecting groups.
[0089] In certain embodiments, the substituent present on the oxygen atom is an oxygen protecting group (also referred to herein as a "hydroxy protecting group"). Oxygen protecting groups include -R aa 、-N(R bb )2, -C(=O)SR aa 、-C(=O)R aa 、-CO2R aa 、-C(=O)N(R bb )2、-C(=NR bb )R aa 、-C(=NR bb )OR aa 、-C(=NR bb )N(R bb )2、-S(=O)R aa 、-SO2R aa 、-Si(R aa )3、-P(R cc )2、-P(R cc )3 + X - 、-P(OR cc )2、-P(OR cc )3 + X - 、-P(=O)(R aa)2、-P(=O)(OR cc )2 and -P(=O)(N(R bb )2)2, where X - 、R aa 、R bb and R cc As defined herein. Oxygen protecting groups are well known in the art and include those described in detail in Protecting Groups in Organic Synthesis, TW Greene and PGM Wuts, 3rd edition, John Wiley & Sons, 1999, incorporated herein by reference.
[0090] Exemplary oxygen protecting groups include methyl, methoxymethyl (MOM), methylthiomethyl (MTM), tert-butylthiomethyl, (phenyldimethylsilyl)methoxymethyl (SMOM), benzyloxymethyl (BOM), p-methoxybenzyloxymethyl (PMBM), (4-methoxyphenoxy)methyl (p-AOM), guaiacolmethyl (GUM), tert-butoxymethyl, 4-pentenyloxymethyl (POM), silyloxymethyl, 2-methoxyethoxymethyl (MEM), 2,2,2-trichloroethoxymethyl, bis(2-chloroethoxy)methyl, 2-(trimethylsilyl)ethoxymethyl (SEMOR), tetrahydropyranyl (THP), 3-bromo Tetrahydropyranyl, tetrahydrothiopyranyl, 1-methoxycyclohexyl, 4-methoxytetrahydropyranyl (MTHP), 4-methoxytetrahydrothiopyranyl, 4-methoxytetrahydrothiopyranyl S,S-dioxide, 1-[(2-chloro-4-methyl)phenyl]-4-methoxypiperidin-4-yl (CTMP), 1,4-dioxan-2-yl, tetrahydrofuranyl, tetrahydrothiofuranyl, 2,3,3a,4,5,6,7,7a-octahydro-7,8,8-trimethyl-4,7-methanobenzofuran-2-yl, 1-ethoxyethyl, 1-(2-chloroethoxy)ethyl, 1-methyl-1-methoxyethyl, 1-methyl-1-benzyloxyethyl, 1-methyl-1 -benzyloxy-2-fluoroethyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 2-(phenylhydrogen selenyl)ethyl, tert-butyl, allyl, p-chlorophenyl, p-methoxyphenyl, 2,4-dinitrophenyl, benzyl (Bn), p-methoxybenzyl, 3,4-dimethoxybenzyl, o-nitrobenzyl, p-nitrobenzyl, p-halobenzyl, 2,6-dichlorobenzyl, p-cyanobenzyl, p-phenylbenzyl, 2-picolyl, 4-picolyl, 3-methyl-2-picolyl N-oxide, diphenylmethyl, p,p'-dinitrodiphenylmethyl, 5-dibenzosuberyl, triphenylmethyl, α-naphthyldiphenylmethyl, p-methoxyphenyldiphenyl methyl, di(p-methoxyphenyl)phenylmethyl, tri(p-methoxyphenyl)methyl, 4-(4'-bromophenacyloxyphenyl)diphenylmethyl, 4,4',4"-tris(4,5-dichlorophthalimidophenyl)methyl, 4,4',4"-tris(levulinyloxyphenyl)methyl, 4,4',4"-tris(benzoyloxyphenyl)methyl, 3-(imidazol-1-yl)bis(4',4"-dimethoxyphenyl)methyl, 1,1-bis(4-methoxyphenyl)-1'-pyrenylmethyl, 9-anthryl, 9-(9-phenyl)xanthenyl, 9-(9-phenyl-10-oxo)anthryl, 1,3-benzodisulfan-2-yl, benzisothiazolyl S,S-dioxide, trimethylsilyl (TMS), triethylsilyl (TES), triisopropylsilyl (TIPS), dimethylisopropylsilyl (IPDMS), diethylisopropylsilyl (DEIPS), dimethylhexylsilyl, tert-butyldimethylsilyl (TBDMS), tert-butyldiphenylsilyl (TBDPS), tritylsilyl, tri-p-xylylsilyl, triphenylsilyl, diphenylmethylsilyl (DPMS), tert-butylmethoxyphenylsilyl (TBMPS), formates, benzoylformates, acetates, chloroacetates, dichloroacetates, trichloroacetates, trifluoroacetates, methyl oxyacetate, triphenylmethoxyacetate, phenoxyacetate, p-chlorophenoxyacetate, 3-phenylpropionate, 4-oxopentanoate (levulinic acid ester), 4,4-(ethylenedithio)pentanoate (levulinic acid dithioacetal), pivalate, adamantanoate, crotonate, 4-methoxycrotonate, benzoate, p-phenylbenzoate, 2,4,6-trimethylbenzoate (trimethylbenzoate), methyl alkyl carbonate, 9-fluorenylmethyl carbonate (Fmoc), ethyl alkyl carbonate, 2,2,2-trichloroethyl alkyl carbonate (Troc), 2-(trimethylsilyl)ethyl carbonate (TMSEC), 2-(phenylsulfonyl)ethyl carbonate (Ps ec), 2-(triphenylphosphonium)ethyl carbonate (Peoc), isobutyl alkyl carbonate, vinyl alkyl carbonate, allyl alkyl carbonate, p-nitrophenyl alkyl carbonate, benzyl alkyl carbonate, p-methoxybenzyl alkyl carbonate, 3,4-dimethoxybenzyl alkyl carbonate, o-nitrobenzyl alkyl carbonate, p-nitrobenzyl alkyl carbonate, S-benzyl alkyl thiocarbonate, 4-ethoxy-1-naphthyl carbonate, methyl dithiocarbonate, 2-iodobenzoate, 4-azidobutyrate, 4-nitro-4-methylvalerate, o-(dibromomethyl)benzoate, 2-formylbenzenesulfonate, 2-(methylthiomethoxy)ethyl, 4-(methylthiomethoxy)butyrate, 2-( methylthiomethoxymethyl)benzoate, 2,6-dichloro-4-methylphenoxyacetate, 2,6-dichloro-4-(1,1,3,3-tetramethylbutyl)phenoxyacetate, 2,4-bis(1,1-dimethylpropyl)phenoxyacetate, chlorodiphenylacetate, isobutyrate, monosuccinate, (E)-2-methyl-2-butenoate, o-(methoxyacyl)benzoate, α-naphthoate, nitrate, alkyl N,N,N',N'-tetramethylphosphoramide, N-phenylcarbamic acid alkyl ester, borate, dimethylphosphinothioate, 2,4-dinitrophenylsulfenic acid alkyl ester, sulfate, methanesulfonate (mesylate), phenylmethylsulfonate and toluenesulfonate (Ts).
[0091] In certain embodiments, the oxygen protecting group is silyl, TBDPS, TBDMS, TIPS, TES, TMS, MOM, THP, t-Bu, Bn, allyl, acetyl, pivaloyl, or benzoyl.
[0092] In certain embodiments, the sulfur atom substituents are independently substituted (eg, with one or more halogens) or unsubstituted C 1-6 Alkyl, -C(=O)R aa 、-CO2R aa 、-C(=O)N(R bb ) 2 or a sulfur protecting group. In certain embodiments, the sulfur atom substituent is independently substituted (e.g., substituted with one or more halogens) or unsubstituted C 1-6 Alkyl, -C(=O)R aa 、-CO2R aa 、-C(=O)N(R bb )2 or a sulfur protecting group, wherein R aa is hydrogen, substituted (eg, by one or more halogens) or unsubstituted C 1-6 alkyl, or an oxygen protecting group when attached to an oxygen atom; and each R bb are independently hydrogen, substituted (eg, substituted with one or more halogens) or unsubstituted C 1-6 In certain embodiments, the sulfur atom substituents are independently substituted (e.g., substituted with one or more halogens) or unsubstituted C 1-6 Alkyl or sulfur protecting group.
[0093] In certain embodiments, the substituent present on the sulfur atom is a sulfur protecting group (also known as a "thiol protecting group"). Sulfur protecting groups include -R aa 、-N(R bb )2, -C(=O)SR aa 、-C(=O)R aa 、-CO2R aa 、-C(=O)N(R bb )2、-C(=NR bb )R aa 、-C(=NR bb )OR aa 、-C(=NR bb )N(R bb )2、-S(=O)R aa 、-SO2R aa 、-Si(R aa )3、-P(R cc )2、-P(R cc )3 + X- 、-P(OR cc )2、-P(OR cc )3 + X - 、-P(=O)(R aa )2、-P(=O)(OR cc )2 and -P(=O)(N(R bb )2)2, where R aa 、R bb , and R cc As defined herein. Sulfur protecting groups are well known in the art and include those described in detail in Protecting Groups in Organic Synthesis, TW Greene and PGM Wuts, 3rd Edition, John Wiley & Sons, 1999, which is incorporated herein by reference. In certain embodiments, the sulfur protecting group is acetamidomethyl, t-Bu, 3-nitro-2-pyridinesulfinyl, 2-pyridine-sulfinyl, or trityl.
[0094] The "molecular weight" of -R (where -R is any monovalent moiety) is calculated by subtracting the atomic weight of the hydrogen atoms from the molecular weight of the molecule RH. The "molecular weight" of -L- (where -L- is any divalent moiety) is calculated by subtracting the combined atomic weight of the two hydrogen atoms from the molecular weight of the molecule HLH.
[0095] In certain embodiments, the molecular weight of the substituent is less than 200, less than 150, less than 100, less than 50 or less than 25g / mol. In certain embodiments, the substituent is composed of carbon, hydrogen, fluorine, chlorine, bromine, iodine, oxygen, sulphur, nitrogen and / or silicon atoms. In certain embodiments, the substituent is composed of carbon, hydrogen, fluorine, chlorine, bromine and / or iodine atoms. In certain embodiments, the substituent is composed of carbon, hydrogen and / or fluorine atoms. In certain embodiments, the substituent does not include one or more, two or more or three or more hydrogen bond donors. In certain embodiments, the substituent does not include one or more, two or more or three or more hydrogen bond acceptors.
[0096] Appending the suffix "alkene" to a group indicates that the group is a multivalent (e.g., divalent, trivalent, tetravalent, or pentavalent) moiety. In certain embodiments, appending the suffix "alkene" to a group indicates that the group is a divalent moiety.
[0097] The term "hydroxy" refers to the group -OH.
[0098] The term "thiol" or "thio" refers to the group -SH.
[0099] The term "amine" or "amino" refers to the group -NH- or -NH2.
[0100] The term "acyl" refers to a group having the following general formula: -C(=O)R X1 , -C(=O)OR X1 , -C(=O)-O-C(=O)R X1 , -C(=O)SR X1 , -C(=O)N(R X1 )2, -C(=S)R X1 , -C(=S)N(R X1 )2, and -C(=S)S(R X1 ), -C(=NR X1 )R X1 , -C(=NR X1 )OR X1 , -C(=NR X1 )SR X1 and -C(=NR X1 )N(R X1 )2, where R X1 is hydrogen; halogen; substituted or unsubstituted hydroxy; substituted or unsubstituted thiol; substituted or unsubstituted amino; substituted or unsubstituted acyl; cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic group; cyclic or acyclic, substituted or unsubstituted, branched or unbranched heteroaliphatic group; cyclic or acyclic, substituted or unsubstituted, branched or unbranched alkyl; cyclic or acyclic, substituted or unsubstituted, branched or unbranched alkenyl; substituted or unsubstituted alkynyl; substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, aliphatic oxy, heteroaliphatic oxy, alkoxy, heteroalkoxy, aryloxy, heteroaryloxy, aliphatic thioxy, heteroaliphatic thioxy, alkylthioxy, heteroalkylthioxy, arylthioxy, heteroarylthioxy, mono- or di-aliphatic amino, mono- or di-heteroaliphatic amino, mono- or di-alkylamino, mono- or di-heteroalkylamino, mono- or di-arylamino or mono- or di-heteroarylamino; or two R X1The groups together form a 5 to 6 membered heterocycle. Exemplary acyl groups include aldehydes (-CHO), carboxylic acids (-CO H), ketones, acyl halides, esters, amides, imines, carbonates, carbamates, and ureas. Acyl substituents include, but are not limited to, any substituents described herein that result in the formation of a stable moiety (e.g., aliphatic, alkyl, alkenyl, alkynyl, heteroaliphatic, heterocycle, aryl, heteroaryl, acyl, oxo, imino, thioxo, cyano, isocyano, amino, azido, nitro, hydroxyl, thiol, halogen, aliphatic amino, heteroaliphatic amino, alkylamino, heteroalkylamino, arylamino, heteroarylamino, alkylaryl, arylalkyl, aliphatic oxy, heteroaliphatic oxy, alkoxy, heteroalkoxy, aryloxy, heteroaryloxy, aliphatic sulfoxy, heteroaliphatic sulfoxy, alkylsulfoxy, heteroalkylsulfoxy, arylsulfoxy, heteroarylsulfoxy, acyloxy, etc., each of which may or may not be further substituted).
[0101] The term "salt" refers to an ionic compound produced by the neutralization reaction of an acid and a base. A salt is composed of one or more cations (positively charged ions) and one or more anions (negative ions) such that the salt is electrically neutral (having no net charge). Salts of the compounds of the present disclosure include those derived from inorganic and organic acids and bases. Examples of acid addition salts are salts formed of an amino group with inorganic acids (such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, and perchloric acid) or with organic acids (such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid, or malonic acid), or by using other methods known in the art (such as ion exchange methods). Other salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate, and the like. Salts derived from appropriate bases include alkali metal salts, alkaline earth metal salts, ammonium salts and N + (C 1-4 Representative alkali metal or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Other salts include ammonium, quaternary ammonium, and amine cations formed using counterions such as halides, hydroxides, carboxylates, sulfates, phosphates, nitrates, lower alkyl sulfonates, and aryl sulfonates.
[0102] The term "pharmaceutically acceptable salt" refers to salts that are suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic reaction, etc., and that are commensurate with a reasonable benefit / risk ratio, within the scope of reasonable medical judgment. Pharmaceutically acceptable salts are well known in the art. For example, Berge et al. describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66, 1-19, incorporated herein by reference. Pharmaceutically acceptable salts of the compounds of the present disclosure include those derived from suitable inorganic and organic acids and bases. Examples of pharmaceutically acceptable non-toxic acid addition salts are salts formed of an amino group with an inorganic acid (such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, and perchloric acid) or with an organic acid (such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid, or malonic acid), or by using other methods known in the art (such as ion exchange). Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate, and the like. Salts derived from appropriate bases include alkali metal salts, alkaline earth metal salts, ammonium salts and N + (C 1-4 Alkyl)4 - Salts. Representative alkali metal or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Other pharmaceutically acceptable salts include non-toxic ammonium, quaternary ammonium, and amine cations formed, where appropriate, using counterions such as halides, hydroxides, carboxylates, sulfates, phosphates, nitrates, lower alkyl sulfonates, and aryl sulfonates.
[0103] The term "solvent" refers to a substance that dissolves one or more solutes to produce a solution. A solvent can serve as a medium for any reaction or transformation described herein. A solvent can dissolve one or more reactants or reagents in a reaction mixture. A solvent can promote mixing of one or more reagents or reactants in a reaction mixture. A solvent can also serve to increase or decrease the rate of a reaction relative to a reaction in a different solvent. Solvents can be polar or nonpolar, protic or aprotic. Common solvents that can be used in the methods described herein include, but are not limited to, acetone, acetonitrile, benzene, benzonitrile, 1-butanol, 2-butanone, butyl acetate, tert-butyl methyl ether, carbon disulfide, carbon tetrachloride, chlorobenzene, 1-chlorobutane, chloroform, cyclohexane, cyclopentane, 1,2-dichlorobenzene, 1,2-dichloroethane, dichloromethane (DCM), N,N-dimethylacetamide, N,N-dimethylformamide (DMF), 1,3-dimethyl-3,4,5,6-tetrahydro-2-pyrimidinone (DMPU), 1,4-dioxane, 1,3-dioxane, diethyl ether, 2-ethoxyethyl ether, ethyl acetate, ethanol, ethylene glycol, dimethyl ether, heptane, n-hexane, hexane
[0014] Examples include oxadiazine, hexamethylphosphoramide (HMPA), 2-methoxyethanol, ethyl 2-methoxyacetate, methanol, 2-methylbutane, 4-methyl-2-pentanone, 2-methyl-1-propanol, 2-methyl-2-propanol, 1-methyl-2-pyrrolidone, dimethyl sulfoxide (DMSO), nitromethane, 1-octanol, pentane, 3-pentanone, 1-propanol, 2-propanol, pyridine, tetrachloroethylene, tetrahydrofuran (THF), 2-methyltetrahydrofuran, toluene, trichlorobenzene, 1,1,2-trichlorotrifluoroethane, 2,2,4-trimethylpentane, trimethylamine, triethylamine, N,N-diisopropylethylamine, diisopropylamine, water, o-xylene, and p-xylene.
[0104] The term "solvate" refers to a form of a compound or salt thereof that is associated with a solvent, typically by a solvolysis reaction. This physical association may include hydrogen bonding. Conventional solvents include water, methanol, ethanol, acetic acid, DMSO, THF, diethyl ether, and the like. The compounds described herein can be prepared, for example, in crystalline form and can be solvated. Suitable solvates include pharmaceutically acceptable solvates, and also include stoichiometric solvates and non-stoichiometric solvates. In some cases, the solvate will be capable of separation, for example when one or more solvent molecules are incorporated into the crystal lattice of the crystalline solid. "Solvate" includes both solution phase and separable solvates. Representative solvates include hydrates, ethanolates, and methanolates.
[0105] The term "hydrate" refers to a compound associated with water. Generally, the number of water molecules contained in a hydrate of a compound has a definite ratio to the number of compound molecules in the hydrate. Thus, a hydrate of a compound can be represented, for example, by the general formula R·x H2O, where R is a compound and x is a number greater than 0. A given compound can form more than one hydrate, including, for example, a monohydrate (x is 1), a lower hydrate (x is a number greater than 0 and less than 1, such as a hemihydrate (R·0.5 H2O)), and a polyhydrate (x is a number greater than 1, such as a dihydrate (R·2 H2O) and a hexahydrate (R·6 H2O)).
[0106] The term "polymorph" refers to a crystalline form of a compound (or its salt, hydrate or solvate). All polymorphs have the same elemental composition. Different crystalline forms typically have different X-ray diffraction patterns, infrared spectra, melting points, densities, hardnesses, crystal shapes, optical and electrical properties, stability and solubility. Recrystallization solvents, crystallization rates, storage temperatures and other factors may lead to one crystalline form being dominant. Various polymorphs of a compound can be prepared by crystallization under different conditions.
[0107] The term "co-crystal" refers to a crystal structure comprising at least two different components (e.g., a compound of formula (I) and an acid), wherein each component is independently an atom, ion, or molecule. In certain embodiments, none of the components are solvents. In certain embodiments, at least one component is a solvent. Co-crystals of a compound of formula (I) and an acid are distinct from salts formed from a compound of formula (I) and an acid. Co-crystals can be used to improve the properties of a compound of formula (I) (e.g., solubility, stability, and ease of formulation).
[0108] In addition, the term "co-crystal" refers to a crystal structure comprising at least two different components (e.g., a compound of formula (0) and an acid), wherein each component is independently an atom, ion, or molecule. In certain embodiments, none of the components are solvents. In certain embodiments, at least one component is a solvent. A co-crystal of a compound of formula (0) or (0') with an acid is different from a salt formed by a compound of formula (0) or (0') with an acid. Co-crystals can be used to improve the properties of a compound of formula (0) or (0') (e.g., solubility, stability, and ease of formulation).
[0109] The term "tautomer" or "tautomeric" refers to two or more interconvertible compounds resulting from at least one formal migration of a hydrogen atom and at least one change in valence (e.g., a single bond to a double bond, a triple bond to a single bond, or vice versa). The exact ratio of tautomers depends on several factors, including temperature, solvent, and pH. Tautomerization (i.e., a reaction providing a tautomeric pair) can be catalyzed by acid or base. Exemplary tautomerizations include keto-to-enol, amide-to-imide, lactam-to-lactim, enamine-to-imine, and enamine-to-(different enamine) tautomerizations.
[0110] It should also be understood that compounds with the same molecular formula but different bonding properties or sequences of their atoms or the arrangement of their atoms in space are referred to as "isomers". Isomers whose atoms are arranged differently in space are referred to as "stereoisomers". In certain embodiments, if a phenyl group comprises two substituents each bonded to adjacent carbons, the compound may be referred to as an ortho isomer. In certain embodiments, if a phenyl group comprises two substituents each bonded to a carbon separated by a ring carbon, the compound may be referred to as a meta isomer. In certain embodiments, if a phenyl group comprises two substituents each bonded to a carbon separated by two ring carbons, the compound may be referred to as a para isomer.
[0111] Stereoisomers that are not mirror images of one another are termed "diastereomers," while stereoisomers that are non-superimposable mirror images of one another are termed "enantiomers." When a compound has an asymmetric center, for example, it is bonded to four different groups, then a pair of enantiomers is possible. Enantiomers are characterized by the absolute configuration of their asymmetric center and are described by the R- and S-sequencing rules of Cahn and Prelog, or by the way that the molecules rotate the plane of polarized light and are designated as right- or left-handed (i.e., (+) or (-)-isomers, respectively). Chiral compounds can exist as either individual enantiomers or as mixtures thereof. A mixture containing equal proportions of enantiomers is termed a "racemic mixture."
[0112] As used herein, the term "agent" refers to a molecule, group of molecules, complex, or substance administered to an organism for diagnostic, therapeutic, preventive medical, or veterinary purposes. In certain embodiments, the agent is a pharmaceutical agent (e.g., a therapeutic agent, a diagnostic agent, or a prophylactic agent). In certain embodiments, the compositions disclosed herein comprise one or more agents, such as a first therapeutic agent (e.g., at least one (including, for example, at least two, at least three). In some embodiments, the composition may further comprise a second therapeutic agent, a targeting moiety, a diagnostic moiety as described herein.
[0113] As used herein, the term "therapeutic agent" includes agents that are capable of providing a local or systemic biological, physiological, or therapeutic effect in a biological system to which they are administered. For example, therapeutic agents can be used to control tumor growth, control infection or inflammation, act as an analgesic, promote anti-cell attachment, and enhance bone growth, among other effects. Other suitable therapeutic agents may include antiviral agents, hormones, antibodies, or therapeutic proteins. Other therapeutic agents include prodrugs, which are agents that are not biologically active when administered but are converted to a biologically active agent by metabolism or some other mechanism after administration to a subject.
[0114] Pharmaceutical agents (e.g., therapeutic agents) can include a variety of different compounds, including chemical compounds and mixtures of chemical compounds (e.g., small organic or inorganic molecules), such as pharmaceutical compounds (e.g., compounds approved by the U.S. Food and Drug Administration for human or veterinary use as specified in the Code of Federal Regulations (CFR); targeting agents; isotopically labeled compounds; agents suitable for bioprocessing; carbohydrates; saccharins; monosaccharides; oligosaccharides; polysaccharides; biomacromolecules (e.g., peptides, proteins, and peptide analogs and derivatives); peptide mimetics; antibodies and antigen-binding fragments thereof; nucleic acids (e.g., DNA or RNA); nucleotides; nucleosides; oligonucleotides; antisense oligonucleotides; polynucleotides; nucleic acid analogs and derivatives; nucleoproteins; mucins; lipoproteins; synthetic polypeptides or proteins; small molecules linked to proteins; glycoproteins; steroids; lipids; hormones; vitamins; vaccines; immunizing agents; extracts made from biological materials such as bacteria, plants, fungi, or animal cells; animal tissues; naturally occurring or synthetic compositions; and any combination thereof.
[0115] In some embodiments, the agent is in the form of a prodrug. The term "prodrug" refers to a compound that becomes active, for example, by solvolysis, reduction, oxidation, or under physiological conditions to provide a pharmaceutically active compound in vivo. The prodrug may include a derivative of the pharmaceutically active compound, for example, an ester formed by the reaction of the acid or anhydride or mixed anhydride portion of the prodrug moiety with the hydroxyl portion of the pharmaceutically active compound, or an amide prepared by the reaction of the acid or anhydride or mixed anhydride portion of the prodrug moiety with a substituted or unsubstituted amine of the pharmaceutically active compound. Simple aliphatic or aromatic esters, amides, and anhydrides derived from acidic groups may comprise prodrugs. In some embodiments, the compositions described herein incorporate a therapeutic agent or a prodrug thereof. In some embodiments, the compositions described herein incorporate more than one therapeutic agent or prodrug.
[0116] In some embodiments, the pharmaceutical agent (e.g., therapeutic agent) is a small molecule. As used herein, the term "small molecule" may refer to a "natural product-like" compound. However, the term "small molecule" is not limited to a "natural product-like" compound. Rather, a typical feature of a small molecule is that it comprises several carbon-carbon bonds and has a molecular weight of less than 5000 daltons (5 kDa), preferably less than 3 kDa, more preferably less than 2 kDa, and most preferably less than 1 kDa. In some cases, the molecular weight of the preferred small molecule is equal to or less than 700 daltons.
[0117] Exemplary agents (e.g., therapeutic agents) in the composition include, but are not limited to, those found in Harrison's Principles of Internal Medicine, 13th ed., T.R. Harrison et al., eds. McGraw-Hill NY, NY; Physicians' Desk Reference, 50th ed., 1997, Oradell New Jersey, Medical Economics Co.; Pharmacological Basis of Therapeutics, 8th ed., Goodman and Gilman, 1990; U.S. Pharmacopeia, The National Formulary, USP XII NF XVII, 1990; the latest edition of Goodman and Oilman's The Pharmacological Basis of Therapeutics; and the latest edition of The Merck Index, the entire contents of which are incorporated herein by reference.
[0118] In some embodiments, exemplary therapeutic agents in the composition include, but are not limited to, one or more of the therapeutic agents listed in paragraph 1 of US Patent No. 9,381,253, which is incorporated herein by reference.
[0119] In other embodiments, exemplary therapeutic agents in the composition include, but are not limited to, one or more therapeutic agents listed in WO 2013 / 169739, including, for example, antihypertensives and / or collagen modifiers ("AHCMs") disclosed in paragraphs 40-49, 283, 286-295; microenvironment modulators disclosed in paragraphs 113-121 of WO 2013 / 169739, incorporated herein by reference. In some embodiments, the composition comprising the AHCM and / or microenvironment modulator causes one or more of the following in a subject: reduced solid stress (e.g., growth-induced solid stress in a tumor); reduced tumor fibrosis; reduced interstitial hypertension or interstitial fluid pressure (IFP); increased interstitial tumor transport; increased tumor or vascular perfusion; increased blood vessel diameter and / or enlargement of compressed or collapsed blood vessels; reduced or depleted one or more of: cancer cells or stromal cells (e.g., tumor-associated fibroblasts or immune cells); reduced extracellular matrix components (such as fibers (e.g., collagen, and / or polysaccharides (e.g., glycosaminoglycans such as hyaluronic acid or hyaluronic acid); reducing the level or production of collagen or procollagen; reducing the level or production of hyaluronic acid; increasing tumor oxygenation; reducing tumor hypoxia; reducing tumor acidosis; enabling immune cell infiltration; reducing immunosuppression; increasing anti-tumor immunity; reducing the production of cancer stem cells (also referred to herein as tumor-initiating cells); or enhancing the efficacy (e.g., penetration or spread) of a therapy, such as a cancer therapy (e.g., radiation, photodynamic therapy, chemotherapy, and immunotherapy), in a tumor or tumor vasculature.
[0120] Pharmaceutical agents, such as therapeutic agents, include the classes and specific examples disclosed herein. It is not intended that the classes be limited by the specific examples. One of ordinary skill in the art will also recognize many other compounds that fall within this class and are suitable for use according to the present disclosure.
[0121] Examples of therapeutic agents include, but are not limited to, antimicrobials, analgesics, anti-inflammatory agents, anti-irritants, coagulants, diuretics, sympathomimetics, anorexia, antacids and other gastrointestinal agents; antiparasitics, antidepressants, antihypertensives, anticholinergics, stimulants, antihormones, central and respiratory stimulants, drug antagonists, lipid regulators, uricosurics, cardiac glycosides, electrolytes, ergot and its derivatives, expectorants, hypnotics and sedatives, antidiabetics, dopaminergics, antiemetics, muscle relaxants, sympathomimetics, anticonvulsants, antihistamines, beta-blockers, laxatives, antiarrhythmics, contrast agents, radiopharmaceuticals, antiallergics, tranquilizers, vasodilators, antivirals and antitumor drugs or cell growth inhibitors or other agents with anticancer effects, or combinations thereof. Other suitable therapeutic agents include contraceptives and vitamins and micronutrients and macronutrients. Other examples include anti-infectives, such as antibiotics and antivirals; analgesics and analgesic combinations; anorexia medications; antiallergics; antiarthritics; antiasthmatics; anticonvulsants; antidepressants; antidiuretics; antidiarrheals; antihistamines; anti-inflammatory drugs; antimigraine preparations; antinausea drugs; antineoplastic drugs; antiparkinsonian drugs; antipruritic drugs; antipsychotics; antipyretics, antispasmodics; anticholinergics; sympathomimetics; xanthine derivatives; cardiovascular preparations, including calcium channel blockers and beta-receptor blockers. These include, but are not limited to, steroid blockers, such as pindolol and antiarrhythmics; antihypertensives; diuretics; vasodilators, including general coronary, peripheral, and cerebral; central nervous system stimulants; cough and cold remedies, including decongestants; hormones such as estradiol and other steroids, including corticosteroids; hypnotics; immunosuppressants; muscle relaxants; parasympathetics; psychostimulants; sedatives; and tranquilizers; and naturally derived or genetically engineered proteins, polysaccharides, glycoproteins, or lipoproteins.
[0122] The terms "composition" and "formulation" are used interchangeably.
[0123] A "subject" intended for administration is a human (i.e., a male or female of any age, e.g., a pediatric subject (e.g., an infant, child, or adolescent) or an adult subject (e.g., a young, middle-aged, or elderly person)) or a non-human animal. In certain embodiments, the non-human animal is a mammal (e.g., a primate (e.g., a cynomolgus monkey or a rhesus monkey), a commercially relevant mammal (e.g., a cow, pig, horse, sheep, goat, cat, or dog), or a bird. The non-human animal can be male or female at any stage of development. The non-human animal can be a transgenic animal or a genetically engineered animal.
[0124] The terms "administer," "administering," or "administration" refer to implanting, absorbing, ingesting, injecting, inhaling, or otherwise introducing a compound described herein or a composition thereof into or onto a subject.
[0125] The terms "treatment," "treat," and "treating" refer to reversing, alleviating, delaying the onset of, or inhibiting the progression of a disease described herein. In some embodiments, treatment may be administered after one or more signs or symptoms of a disease have developed or have been observed. In other embodiments, treatment may be administered in the absence of signs or symptoms of a disease. For example, treatment may be administered to a susceptible subject prior to the onset of symptoms (e.g., based on a history of symptoms). Treatment may also be continued after symptoms have resolved, e.g., to delay and / or prevent recurrence of the disease or disorder.
[0126] The terms "prevent," "preventing," or "prevention" refer to prophylactic treatment of a subject who does not currently have a disease or has not had a disease in the past but is at risk of developing the disease or who has had a disease in the past and does not currently have a disease but is at risk of regression of the disease. In certain embodiments, the subject has a higher risk of developing the disease or a higher risk of regression of the disease compared to the average healthy member of a population of subjects.
[0127] The terms "condition," "disease," and "disorder" are used interchangeably.
[0128] "Proliferative disease" refers to a disease caused by abnormal growth or spread due to cell proliferation (Walker, Cambridge Dictionary of Biology; Cambridge University Press: Cambridge, England, 1990). Proliferative diseases may be associated with: 1) pathological proliferation of normally quiescent cells; pathological migration of cells from their normal location (e.g., metastasis of tumor cells); 3) pathological expression of proteolytic enzymes, such as matrix metalloproteinases (e.g., collagenases, gelatinases, and elastases); or 4) pathological angiogenesis in proliferative retinopathy and tumor metastasis. Exemplary proliferative diseases include cancer (i.e., "malignancies"), benign tumors, diseases associated with angiogenesis, inflammatory diseases, and autoimmune diseases.
[0129] The terms "neoplasm" and "tumor" are used interchangeably herein and refer to an abnormal mass of tissue in which the growth of the mass exceeds and is not coordinated with the growth of normal tissue. A neoplasm or tumor can be "benign" or "malignant," depending on the following characteristics: degree of cell differentiation (including morphology and function), growth rate, local infiltration, and metastasis. "Benign neoplasms" are generally well differentiated, characterized by slower growth than malignant neoplasms and remain confined to the site of origin. In addition, benign neoplasms do not have the ability to infiltrate, invade, or metastasize to distant sites. Exemplary benign neoplasms include, but are not limited to, lipomas, chondromas, adenomas, acrochordons, senile hemangiomas, seborrheic keratosis, nevi, and sebaceous hyperplasia. In some cases, certain "benign" tumors may later give rise to malignant neoplasms, which may be due to other genetic changes in a subset of tumor neoplasm cells, and these tumors are referred to as "pre-malignant neoplasms." An exemplary pre-malignant neoplasm is a teratoma. In contrast, " malignant neoplasm " is usually poorly differentiated (dysplasia), and has characteristic rapid growth, with the progressive infiltration, invasion and destruction of surrounding tissue. In addition, malignant neoplasm usually has the ability to be transferred to distant sites. The term "metastasis (metastasis)", "metastasis" or "metastasize (metastasize)" refers to the diffusion or migration of cancer cells from primary or original tumor to another organ or tissue, and usually can be identified by "secondary tumors" or "secondary cell mass" of the tissue type with primary or original tumor rather than "secondary tumors" or "secondary cell mass" of the organ or tissue where secondary (metastasis) tumor is located. For example, the prostate cancer that has migrated to bone is referred to as metastatic prostate cancer, and includes the cancerous prostate cancer cells grown in bone tissue.
[0130] The term "cancer" refers to a class of diseases characterized by the development of abnormal cells that proliferate uncontrollably and have the ability to infiltrate and destroy normal body tissues. See, e.g., Stedman's Medical Dictionary, 25th ed.; Hensyl, ed.; Williams & Wilkins: Philadelphia, 1990. Exemplary cancers include, but are not limited to, acoustic neuroma; adenocarcinoma; adrenal gland cancer; anal cancer; angiosarcoma (e.g., lymphangiosarcoma, lymphangioendothelial cell sarcoma, angiosarcoma); appendix cancer; benign monoclonal gammopathy; bile duct cancer (e.g., cholangiocarcinoma); bladder cancer; breast cancer (e.g., breast adenocarcinoma, breast papillary carcinoma, breast cancer, medullary breast cancer); brain cancer (e.g., meningioma, glioblastoma, glioma (e.g., astrocytoma, oligodendroglioma), medulloblastoma); bronchogenic carcinoma; carcinoid tumor; cervical cancer (e.g., cervical adenocarcinoma); choriocarcinoma; chordoma; craniopharyngioma ; colorectal cancer (e.g., colon cancer, rectal cancer, colorectal adenocarcinoma); connective tissue cancer; epithelial cancer; ependymoma; endothelial sarcoma (e.g., Kaposi sarcoma, multiple idiopathic hemorrhagic sarcoma); endometrial cancer (e.g., uterine cancer, uterine sarcoma); esophageal cancer (e.g., esophageal adenocarcinoma, Barrett's gland carcinoma); Ewing's sarcoma; eye cancer (e.g., intraocular melanoma, retinoblastoma); familial hypereosinophilia; gallbladder cancer; gastric cancer (e.g., gastric adenocarcinoma); gastrointestinal stromal tumor (GIST); germ cell cancer; head and neck cancer (e.g., head and neck squamous cell carcinoma, oral cancer (e.g., oral squamous cell carcinoma) hematopoietic system cancers (e.g., leukemias such as acute lymphoblastic leukemia (ALL) (e.g., B-cell ALL, T-cell ALL), acute myeloid leukemia (AML) (e.g., B-cell AML, T-cell AML), chronic myeloid leukemia (CML) (e.g., B-cell CML, T-cell CML), and chronic lymphocytic leukemia (CLL) (e.g., B-cell CLL, T-cell CLL)); lymphomas such as Hodgkin lymphoma (HL) (e.g., B-cell HL , T-cell HL) and non-Hodgkin lymphoma (NHL) (e.g., B-cell NHL, such as diffuse large cell lymphoma (DLCL) (e.g., diffuse large B-cell lymphoma), follicular lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), mantle cell lymphoma (MCL), marginal zone B-cell lymphoma (e.g., mucosa-associated lymphoid tissue (MALT) lymphoma, nodal marginal zone B-cell lymphoma, splenic marginal zone B-cell lymphoma), primary mediastinal B-cell lymphoma, Burkitt lymphoma, lymphoplasmacytic lymphoma (i.e., macroglobulinemia), hairy cell leukemia (HCL), immunoblastic large cell lymphoma, precursor B lymphoblastic lymphoma, and primary central nervous system (CNS) lymphoma; and T-cell NHL, such as precursor T lymphoblastic lymphoma / leukemia, peripheral T-cell lymphoma (PTCL) (e.g., cutaneous T-cell lymphoma (CTCL) (e.g., mycosis fungoides, Sézary syndrome), angioimmunoblastic T-cell lymphoma, extranodal natural killer T-cell lymphoma, enteropathy-type T-cell lymphoma, subcutaneous panniculitis-like T-cell lymphoma, and anaplastic large cell lymphoma); mixtures of one or more leukemias / lymphomas as described above; and multiple myeloma (MM)), heavy chain disease (e.g., α chain disease, gamma chain disease, μ chain disease); hemangioblastoma; hypopharyngeal cancer; inflammatory myofibroblastic tumor; immune cell amyloidosis; kidney cancer (e.g., Wilms' tumor, renal cell carcinoma); liver cancer (e.g., hepatocellular carcinoma (HCC), malignant liver cancer); lung cancer (e.g., bronchogenic carcinoma, small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), lung adenocarcinoma); leiomyosarcoma (LMS); mastocytosis (e.g., systemic mastocytosis); muscle cancer; myelodysplastic syndrome (MDS); mesothelioma; myeloproliferative disorders (MPD) (e.g., polycythemia vera (PV), essential thrombocythemia (ET), myeloid metaplasia of unknown etiology (AMM), etc.) Myelofibrosis (MF), chronic idiopathic myelofibrosis, chronic myelocytic leukemia (CML), chronic neutrophilic leukemia (CNL), hypereosinophilic syndrome (HES)); neuroblastoma; neurofibromas (e.g., neurofibromatosis type 1 or type 2, schwannoma); neuroendocrine cancers (e.g., gastrointestinal pancreatic neuroendocrine tumors (GEP-NETs), carcinoid tumors); osteosarcomas (e.g., bone cancer); ovarian cancer (e.g., cystadenocarcinoma, ovarian embryonal carcinoma, ovarian adenocarcinoma); papillary adenocarcinoma; pancreatic cancer (e.g., pancreatic adenocarcinoma, intraductal papillary mucinous neoplasms (IPMNs), islet cell tumors); penile cancer (e.g., Paget's disease of the penis and scrotum); pinealoma; primitive neuroectodermal tumors (PNT); plasmacytoma; paraneoplastic syndromes; intraepithelial neoplasia; prostate cancer (e.g., prostate adenocarcinoma); rectal cancer; rhabdomyosarcoma; salivary gland cancer; skin cancer (e.g., squamous cell carcinoma (SCC), keratoacanthoma (KA), melanoma, basal cell carcinoma (BCC)); small bowel cancer (e.g., appendix cancer); soft tissue sarcomas (e.g., malignant fibrous histiocytoma (MFH), liposarcoma, malignant peripheral nerve sheath tumor (MPNST), chondrosarcoma, fibrosarcoma, myxosarcoma); sebaceous gland carcinoma; small bowel cancer; sweat gland cancer; synovioma; testicular cancer (e.g., seminoma, testicular embryonal carcinoma); thyroid cancer (e.g., papillary thyroid carcinoma, papillary thyroid carcinoma (PTC), medullary thyroid carcinoma); urethral cancer; vaginal cancer;and vulvar cancer (e.g., Paget's disease of the vulva).
[0131] Cancer cells exhibit characteristics similar to embryonic stem cells. As used herein, cancer stem cells (CSCs) are embryonic-like cancer cells with one or more embryonic characteristics. CSCs are generally considered to be problematic cancer cells due to their ability to metastasize and form tumors in other parts of the human body. As used herein, "embryonic characteristics" refer to gene and / or miRNA expression and / or biological characteristics similar to embryonic cells. Undifferentiated cancer cells with embryonic characteristics have metastatic capacity, are resistant to chemotherapy and radiotherapy, and have the ability to grow again after most tumors are removed or reduced after surgery and / or other cancer treatments.
[0132] In some embodiments, cancer stem cells are characterized by expression of genes and / or miRNAs associated with an embryonic state. In some embodiments, cancer stem cells express one or more (e.g., 1, 2, 3, 4, 5, 6, or more) genes or miRNAs associated with an embryonic state.
[0133] In some embodiments, cancer stem cells are characterized by one or more embryonic characteristics. Examples of embryonic characteristics include, but are not limited to, cell self-renewal properties, hyperproliferative activity, pluripotency, multipotency, expression of embryonic markers, lack of differentiation markers, resistance to chemotherapy, motility, and the ability to generate different cell lineages.
[0134] As used herein, the term "regenerative medicine" or "regenerative therapy" refers to promoting the regenerative capacity of cells, tissues and / or organs. Regenerative medicine includes cell and / or tissue engineering to replace, engineer or regenerate cells, tissues and / or organs; and / or restore or improve one or more biological functions of dysfunctional or damaged cells, tissues and / or organs; as well as tissue engineering and organ regeneration. As used herein, "regenerative capacity" refers to the conversion of cells such as stem cells into dividing progenitor cells and differentiated tissue-specific cells. Regenerative capacity can additionally or alternatively indicate the ability of cells, tissues and / or organs to replicate, proliferate, restore function and / or regenerate.
[0135] An "effective amount" of a composition described herein is an amount sufficient to elicit a desired biological response. The effective amount of a composition described herein can vary depending on factors such as the desired biological endpoint, the pharmacokinetics of the composition, the condition being treated, the mode of administration, and the age and health of the subject. In certain embodiments, the effective amount is a therapeutically effective amount. In certain embodiments, the effective amount is a prophylactically effective amount. In certain embodiments, the effective amount is the amount of a composition or pharmaceutical composition described herein in a single dose. In certain embodiments, the effective amount is the combined amount of a composition or pharmaceutical composition described herein in multiple doses.
[0136] A "therapeutically effective amount" of a composition described herein is an amount sufficient to provide a therapeutic benefit in the treatment of a condition or sufficient to delay or minimize one or more symptoms associated with the condition. A therapeutically effective amount of a composition refers to an amount of a therapeutic agent, alone or in combination with other therapies, that provides a therapeutic benefit in the treatment of the condition. The term "therapeutically effective amount" can include an amount that improves overall therapy; reduces or avoids symptoms, signs, or causes of a condition; and / or enhances the therapeutic efficacy of another therapeutic agent.
[0137] A "prophylactically effective amount" of a compound described herein is an amount sufficient to prevent a condition or one or more symptoms associated with a condition or to prevent its recurrence. A prophylactically effective amount of a compound refers to an amount of a therapeutic agent, alone or in combination with other agents, that provides a prophylactic benefit in preventing the condition. The term "prophylactically effective amount" can include an amount that improves overall prevention or enhances the prophylactic efficacy of another prophylactic agent.
[0138] The term "gene" refers to a nucleic acid fragment that provides a template for producing a gene product. In certain embodiments, the nucleic acid fragment includes regulatory sequences before and after the coding sequence. A "native gene" refers to a gene found in nature that has its own regulatory sequences. A "chimeric gene" or "chimeric construct" refers to any gene or construct that contains regulatory and coding sequences not found in nature, rather than a natural gene. Therefore, a chimeric gene or chimeric construct may contain regulatory sequences and coding sequences derived from different sources, or regulatory sequences and coding sequences derived from the same source but arranged in a manner different from nature. An "endogenous gene" refers to a natural gene in its natural location in the genome of an organism. An "exogenous" gene refers to a gene that is not typically found in a host organism, but is introduced into a host organism through gene transfer. An exogenous gene can include a natural gene or a chimeric gene that is inserted into a non-natural organism. A "transgenic gene" is a gene that is introduced into a genome through a transformation procedure.
[0139] The terms "nucleic acid" or "nucleic acid sequence," "nucleic acid molecule," "nucleic acid fragment," or "polynucleotide" are used interchangeably. A polynucleotide molecule is a biological polymer composed of nucleotide monomers covalently bonded in a chain. DNA (deoxyribonucleic acid) and RNA (ribonucleic acid) are examples of polynucleotides with different biological functions. DNA is composed of two polynucleotide chains, each of which is helical. In nature, RNA typically occurs as a single strand that folds back on itself. Exemplary types of RNA include double-stranded RNA (dsRNA), small interfering RNA (siRNA), short hairpin (shRNA), microRNA (miRNA), messenger RNA (mRNA), antisense RNA, transfer RNA (tRNA), small nuclear RNA (snRNA), and ribosomal RNA (rRNA).
[0140] The present disclosure is not intended to be limited in any way by the foregoing list of exemplary substituents.Additional terms may be defined in other sections of this disclosure. DETAILED DESCRIPTION
[0141] Before describing the disclosed systems, compounds, compositions, methods, uses, and kits in greater detail, it should be understood that the aspects described herein are not limited to specific embodiments, methods, apparatuses, or configurations and as such may, of course, vary. It should also be understood that the terminology used herein is for the purpose of describing particular aspects only and is not intended to be limiting unless specifically defined herein.
[0142] The compounds disclosed herein and their compositions and kits can be used for the treatment of cancer and proliferative diseases. The compounds can differentiate embryonic cancer stem cells, disrupt their proliferation and / or inhibit their ability to form new tumors. Embryonic properties, including embryonic gene expression patterns, are reactivated in a variety of different types of cancer. In certain embodiments, the cancer is colorectal cancer, gastric cancer, gastrointestinal stromal tumor, ovarian cancer, lung cancer, breast cancer, pancreatic cancer, prostate cancer, testicular cancer, or lymphoma. For example, embryonic properties have been found in cancer stem cells from solid tumors, such as colorectal cancer, gastric cancer, ovarian cancer, lung cancer, breast cancer, pancreatic cancer, and prostate cancer. 10 Embryonic properties have also been found in cancer stem cells from hematopoietic cancers such as leukemias and lymphomas. 14
[0143] Compound
[0144] In certain aspects, the present disclosure provides compounds of formula (0) and (0').
[0145] The present disclosure describes compounds of Formula (I) described herein.
[0146] In certain embodiments, the compound is of formula (0):
[0147]
[0148] or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, cocrystal, tautomer, stereoisomer, isotopically labeled derivative or prodrug thereof, wherein:
[0149] L A -N(R 2 )(L 1 R 1 ) or -C(=O)NR 1 R 2 ;
[0150] L 1 is a single bond or -C(=O)-;
[0151] When L 1 When it is a single bond, R 1 is substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 2-6 Alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted 3- to 13-membered monocyclic or bicyclic carbocyclyl, substituted or unsubstituted 3- to 13-membered monocyclic or bicyclic heterocyclyl, or substituted or unsubstituted 5- to 11-membered monocyclic or bicyclic heteroaryl;
[0152] When L 1 When it is -C(=O)-, R 1 C 1-6 Alkyl, wherein the substituent contains at least one double bond, triple bond or heteroatom; substituted or unsubstituted C 2-6 Alkenyl, substituted or unsubstituted C 2-6 Alkynyl; substituted or unsubstituted 3- to 13-membered monocyclic or bicyclic carbocyclyl; substituted or unsubstituted 3- to 13-membered monocyclic or bicyclic heterocyclyl; substituted or unsubstituted 6- to 11-membered monocyclic or bicyclic aryl; or substituted or unsubstituted 5- to 11-membered monocyclic or bicyclic heteroaryl;
[0153] R 2 is hydrogen, substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 2-6 Alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted 3- to 13-membered monocyclic or bicyclic carbocyclyl, substituted or unsubstituted 3- to 13-membered monocyclic or bicyclic heterocyclyl, substituted or unsubstituted 5- to 11-membered monocyclic or bicyclic heteroaryl, or a nitrogen protecting group;
[0154] R 3 is hydrogen, halogen, substituted or unsubstituted C 1-6 Alkyl, -OR a 、-N(R a )2 or -CN;
[0155] R a Each instance of is independently hydrogen, substituted or unsubstituted C 1-6 Alkyl, oxygen protecting group when attached to oxygen atom or nitrogen protecting group when attached to nitrogen atom;
[0156] or R 2 and R 3 are linked to their intervening atoms to form a substituted or unsubstituted 5-membered monocyclic heterocyclyl or heteroaryl;
[0157] q is 0 or 1;
[0158] Each instance of Y is independently N or CR 4 ;
[0159] R 4 Each instance of is independently hydrogen, halogen, substituted or unsubstituted C 1-6 Alkyl, -OR a 、-N(R a )2 or -CN;
[0160] is phenyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, imidazolyl, oxazolyl, thiazolyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, azetidinyl, -C≡C- or
[0161] when When it is phenyl, pyridyl, pyridazinyl, pyrimidinyl or pyrazinyl, bond b and bond c are in meta or para position relative to each other;
[0162] R 5 Each instance of is independently hydrogen, halogen, substituted or unsubstituted C 1-6 Alkyl, -OR a 、-N(R a )2 or -CN;
[0163] Where valence permits, n is 0, 1, 2, 3 or 4, wherein when n is 1, 2, 3 or 4, there is no R 5 When connected to nitrogen atoms;
[0164] L B -N(R 6 )L 2 -or-L 2 N(R 6 )-;
[0165] L 2 -C(=O)-, or -S(=O)2-;
[0166] Each R 6 are independently hydrogen, substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 2-6 Alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted 3- to 13-membered monocyclic or bicyclic carbocyclyl, substituted or unsubstituted 3- to 13-membered monocyclic or bicyclic heterocyclyl, substituted or unsubstituted 6- to 11-membered monocyclic or bicyclic aryl, substituted or unsubstituted 5- to 11-membered monocyclic or bicyclic heteroaryl, or a nitrogen protecting group;
[0167] s is 0 or 1;
[0168] R 7 is a substituted or unsubstituted 3- to 7-membered monocyclic carbocyclyl, a substituted or unsubstituted 3- to 7-membered monocyclic heterocyclyl, a substituted or unsubstituted phenyl, or a substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl; and
[0169] R 8 Each instance of is independently hydrogen, halogen, substituted or unsubstituted C 1-6 Alkyl, -OR a 、-N(R a )2 or -CN.
[0170] In certain embodiments, the compound of formula (0') has the following formula:
[0171]
[0172] or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, cocrystal, tautomer, stereoisomer, isotopically labeled derivative or prodrug thereof, wherein:
[0173] L 1 is a single bond or -C(=O)-;
[0174] When L 1 When it is a single bond, R 1 is substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 2-6 Alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted 3- to 13-membered monocyclic or bicyclic carbocyclyl, substituted or unsubstituted 3- to 13-membered monocyclic or bicyclic heterocyclyl, or substituted or unsubstituted 5- to 11-membered monocyclic or bicyclic heteroaryl;
[0175] When L 1 When it is -C(=O)-, R 1 C 1-6 Alkyl, wherein the substituent contains at least one double bond, triple bond or heteroatom; substituted or unsubstituted C 2-6 Alkenyl, substituted or unsubstituted C 2-6 Alkynyl; substituted or unsubstituted 3- to 13-membered monocyclic or bicyclic carbocyclyl; substituted or unsubstituted 3- to 13-membered monocyclic or bicyclic heterocyclyl; substituted or unsubstituted 6- to 11-membered monocyclic or bicyclic aryl; or substituted or unsubstituted 5- to 11-membered monocyclic or bicyclic heteroaryl;
[0176] R 2 is hydrogen, substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 2-6 Alkenyl, substituted or unsubstituted C 2-6alkynyl, substituted or unsubstituted 3- to 13-membered monocyclic or bicyclic carbocyclyl, substituted or unsubstituted 3- to 13-membered monocyclic or bicyclic heterocyclyl, substituted or unsubstituted 5- to 11-membered monocyclic or bicyclic heteroaryl, or a nitrogen protecting group;
[0177] R 3 is hydrogen, halogen, substituted or unsubstituted C 1-6 Alkyl, -OR a 、-N(R a )2 or -CN;
[0178] R a Each instance of is independently hydrogen, substituted or unsubstituted C 1-6 Alkyl, oxygen protecting group when attached to oxygen atom or nitrogen protecting group when attached to nitrogen atom;
[0179] or R 2 and R 3 are linked to their intervening atoms to form a substituted or unsubstituted 5-membered monocyclic heterocyclyl or heteroaryl;
[0180] q is 0 or 1;
[0181] Each instance of Y is independently N or CR 4 ;
[0182] R 4 Each instance of is independently hydrogen, halogen, substituted or unsubstituted C 1-6 Alkyl, -OR a 、-N(R a )2 or -CN;
[0183] is phenyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, imidazolyl, oxazolyl, thiazolyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, azetidinyl, -C≡C- or
[0184] when When it is phenyl, pyridyl, pyridazinyl, pyrimidinyl or pyrazinyl, bond b and bond c are in meta or para position relative to each other;
[0185] R 5 Each instance of is independently hydrogen, halogen, substituted or unsubstituted C 1-6 Alkyl, -OR a 、-N(R a )2 or -CN;
[0186] Where valence permits, n is 0, 1, 2, 3 or 4, wherein when n is 1, 2, 3 or 4, there is no R 5 When connected to nitrogen atoms;
[0187] L 2 -C(=O)-, or -S(=O)2-;
[0188] Each R 6 are independently hydrogen, substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 2-6 Alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted 3- to 13-membered monocyclic or bicyclic carbocyclyl, substituted or unsubstituted 3- to 13-membered monocyclic or bicyclic heterocyclyl, substituted or unsubstituted 6- to 11-membered monocyclic or bicyclic aryl, substituted or unsubstituted 5- to 11-membered monocyclic or bicyclic heteroaryl, or a nitrogen protecting group;
[0189] s is 0 or 1;
[0190] R 7 is a substituted or unsubstituted 3- to 7-membered monocyclic carbocyclyl, a substituted or unsubstituted 3- to 7-membered monocyclic heterocyclyl, a substituted or unsubstituted phenyl, or a substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl; and
[0191] R 8 Each instance of is independently hydrogen, halogen, substituted or unsubstituted C 1-6 Alkyl, -OR a 、-N(R a )2 or -CN.
[0192] In certain embodiments, the compound is of formula (I):
[0193]
[0194] or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, cocrystal, tautomer, stereoisomer, isotopically labeled derivative or prodrug thereof, wherein:
[0195] L 1 is a single bond or C(=O)-;
[0196] When L 1 When it is a single bond, R 1 is substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 2-6 Alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted 3- to 13-membered monocyclic or bicyclic carbocyclyl, substituted or unsubstituted 3- to 13-membered monocyclic or bicyclic heterocyclyl, or substituted or unsubstituted 5- to 11-membered monocyclic or bicyclic heteroaryl;
[0197] When L 1When it is -C(=O)-, R 1 is a substituted C containing at least one double bond, triple bond or heteroatom 1-6 Alkyl; substituted or unsubstituted C 2-6 Alkenyl, substituted or unsubstituted C 2-6 Alkynyl; substituted or unsubstituted 3- to 13-membered monocyclic or bicyclic carbocyclyl; substituted or unsubstituted 3- to 13-membered monocyclic or bicyclic heterocyclyl; substituted or unsubstituted 6- to 11-membered monocyclic or bicyclic aryl; or substituted or unsubstituted 5- to 11-membered monocyclic or bicyclic heteroaryl;
[0198] R 2 is hydrogen, substituted or unsubstituted C 1-6 an alkyl group, or a nitrogen protecting group;
[0199] R 3 is halogen, substituted or unsubstituted C 1-6 Alkyl, -OR a 、-N(R a )2, or -CN;
[0200] R a Each instance of is independently hydrogen, substituted or unsubstituted C 1-6 Alkyl, oxygen protecting group when attached to oxygen atom or nitrogen protecting group when attached to nitrogen atom;
[0201] or R 2 and R 3 are linked to their intervening atoms to form a substituted or unsubstituted 5-membered monocyclic heterocyclyl or heteroaryl;
[0202] Each instance of Y is independently N or CR 4 ;
[0203] R 4 Each instance of is independently hydrogen, halogen, substituted or unsubstituted C 1-6 Alkyl, -OR a 、-N(R a )2 or -CN;
[0204] is phenyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, imidazolyl, oxazolyl, azetidinyl, -C≡C- or
[0205] Bond b and bond c are in meta or para position relative to each other;
[0206] R 5 Each instance of is independently hydrogen, halogen, substituted or unsubstituted C 1-6 Alkyl, -OR a 、-N(R a )2 or -CN;
[0207] Where valence permits, n is 0, 1, 2, 3 or 4, wherein when n is 1, 2, 3 or 4, there is no R 5 When connected to nitrogen atoms;
[0208] L 2 is -C(=O)- or -S(=O)2-;
[0209] R 6 is hydrogen, substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 2-6 Alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted 3- to 13-membered monocyclic or bicyclic carbocyclyl, substituted or unsubstituted 3- to 13-membered monocyclic or bicyclic heterocyclyl, substituted or unsubstituted 6- to 11-membered monocyclic or bicyclic aryl, substituted or unsubstituted 5- to 11-membered monocyclic or bicyclic heteroaryl, or a nitrogen protecting group;
[0210] R 7 is a substituted or unsubstituted 3- to 7-membered monocyclic carbocyclyl, a substituted or unsubstituted 3- to 7-membered monocyclic heterocyclyl, a substituted or unsubstituted phenyl, or a substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl; and
[0211] R 8 Each instance of is independently hydrogen, halogen, substituted or unsubstituted C 1-6 Alkyl, -OR a 、-N(R a )2 or -CN.
[0212] In certain embodiments:
[0213] L 1 is a single bond or -C(=O)-;
[0214] When L 1 When it is a single bond, R 1 is substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 2-6 Alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted 3- to 13-membered monocyclic or bicyclic carbocyclyl, substituted or unsubstituted 3- to 13-membered monocyclic or bicyclic heterocyclyl, or substituted or unsubstituted 5- to 11-membered monocyclic or bicyclic heteroaryl;
[0215] When L 1 When it is -C(=O)-, R 1 is a substituted C containing at least one double bond, triple bond or heteroatom 1-6 Alkyl; substituted or unsubstituted C 2-6Alkenyl, substituted or unsubstituted C 2-6 Alkynyl; substituted or unsubstituted 3- to 13-membered monocyclic or bicyclic carbocyclyl; substituted or unsubstituted 3- to 13-membered monocyclic or bicyclic heterocyclyl; substituted or unsubstituted 6- to 11-membered monocyclic or bicyclic aryl; or substituted or unsubstituted 5- to 11-membered monocyclic or bicyclic heteroaryl;
[0216] R 2 is hydrogen, substituted or unsubstituted C 1-6 an alkyl group, or a nitrogen protecting group;
[0217] R 3 is halogen, substituted or unsubstituted C 1-6 Alkyl, -OR a 、-N(R a )2, or -CN;
[0218] R a Each instance of is independently hydrogen, substituted or unsubstituted C 1-6 Alkyl, oxygen protecting group when attached to oxygen atom or nitrogen protecting group when attached to nitrogen atom;
[0219] or R 2 and R 3 are linked to their intervening atoms to form a substituted or unsubstituted 5-membered monocyclic heterocyclyl or heteroaryl;
[0220] Each instance of Y is independently N or CR 4 ;
[0221] R 4 Each instance of is independently hydrogen, halogen, substituted or unsubstituted C 1-6 Alkyl, -OR a 、-N(R a )2 or -CN;
[0222] is phenyl, pyridyl, pyridazinyl, pyrimidinyl or pyrazinyl;
[0223] Bond b and bond c are in meta or para position relative to each other;
[0224] R 5 Each instance of is independently hydrogen, halogen, substituted or unsubstituted C 1-6 Alkyl, -OR a , -N(Ra)2 or -CN;
[0225] Where valence permits, n is 0, 1, 2, 3 or 4, wherein when n is 1, 2, 3 or 4, there is no R 5 When connected to nitrogen atoms;
[0226] L 2is -C(=O)- or -S(=O)2-;
[0227] R 6 is hydrogen, substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 2-6 Alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted 3- to 13-membered monocyclic or bicyclic carbocyclyl, substituted or unsubstituted 3- to 13-membered monocyclic or bicyclic heterocyclyl, substituted or unsubstituted 6- to 11-membered monocyclic or bicyclic aryl, substituted or unsubstituted 5- to 11-membered monocyclic or bicyclic heteroaryl, or a nitrogen protecting group;
[0228] R 7 is a substituted or unsubstituted 3- to 7-membered monocyclic carbocyclyl, a substituted or unsubstituted 3- to 7-membered monocyclic heterocyclyl, a substituted or unsubstituted phenyl, or a substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl; and
[0229] R 8 Each instance of is independently hydrogen, halogen, substituted or unsubstituted C 1-6 Alkyl, -OR a 、-N(R a )2 or -CN.
[0230] In certain embodiments, the compound is of formula (I):
[0231]
[0232] or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, cocrystal, tautomer, stereoisomer, isotopically labeled derivative or prodrug thereof, wherein:
[0233] L 1 is a single bond or -C(=O)-;
[0234] When L 1 When it is a single bond, R 1 is substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 2-6 Alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted 3- to 13-membered monocyclic or bicyclic carbocyclyl, substituted or unsubstituted 3- to 13-membered monocyclic or bicyclic heterocyclyl, or substituted or unsubstituted 5- to 11-membered monocyclic or bicyclic heteroaryl;
[0235] When L 1 When it is -C(=O)-, R 1 is a substituted C containing at least one double bond, triple bond or heteroatom 1-6 Alkyl; substituted or unsubstituted C2-6 Alkenyl, substituted or unsubstituted C 2-6 Alkynyl; substituted or unsubstituted 3- to 13-membered monocyclic or bicyclic carbocyclyl; substituted or unsubstituted 3- to 13-membered monocyclic or bicyclic heterocyclyl; substituted or unsubstituted 6- to 11-membered monocyclic or bicyclic aryl; or substituted or unsubstituted 5- to 11-membered monocyclic or bicyclic heteroaryl;
[0236] R 2 is hydrogen, substituted or unsubstituted C 1-6 an alkyl group, or a nitrogen protecting group;
[0237] R 3 is halogen, substituted or unsubstituted C 1-6 Alkyl, -OR a 、-N(R a )2, or -CN;
[0238] R a Each instance of is independently hydrogen, substituted or unsubstituted C 1-6 Alkyl, oxygen protecting group when attached to oxygen atom or nitrogen protecting group when attached to nitrogen atom;
[0239] or R 2 and R 3 are linked to their intervening atoms to form a substituted or unsubstituted 5-membered monocyclic heterocyclyl or heteroaryl;
[0240] Each instance of Y is independently N or CR 4 ;
[0241] R 4 Each instance of is independently hydrogen, halogen, substituted or unsubstituted C 1-6 Alkyl, -OR a 、-N(R a )2 or -CN;
[0242] is phenyl, pyridyl, pyridazinyl, pyrimidinyl or pyrazinyl;
[0243] Bond b and bond c are in meta or para position relative to each other;
[0244] R 5 Each instance of is independently hydrogen, halogen, substituted or unsubstituted C 1-6 Alkyl, -OR a 、-N(R a )2 or -CN;
[0245] Where valence permits, n is 0, 1, 2, 3 or 4, wherein when n is 1, 2, 3 or 4, there is no R 5 When connected to nitrogen atoms;
[0246] L 2 is -C(=O)- or -S(=O)2-;
[0247] R 6 is hydrogen, substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 2-6 Alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted 3- to 13-membered monocyclic or bicyclic carbocyclyl, substituted or unsubstituted 3- to 13-membered monocyclic or bicyclic heterocyclyl, substituted or unsubstituted 6- to 11-membered monocyclic or bicyclic aryl, substituted or unsubstituted 5- to 11-membered monocyclic or bicyclic heteroaryl, or a nitrogen protecting group;
[0248] R 7 is a substituted or unsubstituted 3- to 7-membered monocyclic carbocyclyl, a substituted or unsubstituted 3- to 7-membered monocyclic heterocyclyl, a substituted or unsubstituted phenyl, or a substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl; and
[0249] R 8 Each instance of is independently hydrogen, halogen, substituted or unsubstituted C 1-6 Alkyl, -OR a 、-N(R a )2 or -CN.
[0250] In certain embodiments, Formula (I) is Formula (IA):
[0251]
[0252] (For example, ).
[0253] In certain embodiments, Formula (I) is the following:
[0254]
[0255] (For example, ).
[0256] In certain embodiments, Formula (I) is Formula (IB):
[0257] where R 7 It is a substituted or unsubstituted 3-pyridyl group.
[0258] In certain embodiments, Formula (I) is Formula (IC):
[0259]
[0260] in is pyridyl, pyridazinyl, pyrimidinyl or pyrazinyl. In certain embodiments, Formula (I) is Formula (IC), wherein In certain embodiments, Formula (I) is Formula (IC), wherein In certain embodiments, Formula (I) is Formula (IC), wherein In certain embodiments, Formula (I) is Formula (IC), wherein for
[0261] In certain embodiments, the compound of Formula (I) has Formula (IC):
[0262]
[0263] in is thiazolyl, piperidinyl, piperazinyl, morpholinyl or thiomorpholinyl. In certain embodiments, Formula (I) is Formula (IC), wherein In certain embodiments, Formula (I) is Formula (IC), wherein is piperidinyl, piperazinyl, morpholinyl or thiomorpholinyl. In certain embodiments, Formula (I) is Formula (IC), wherein It is piperazinyl.
[0264] In certain embodiments, Formula (I) is Formula (ID):
[0265] where R 7 is a substituted or unsubstituted 3- to 7-membered monocyclic heterocyclic group or a substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl group.
[0266] In certain embodiments, Formula (I) is the following:
[0267] where R 7 is a substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl group (eg, a substituted or unsubstituted 3-pyridyl group).
[0268] In certain embodiments, Formula (I) is the following:
[0269] in:
[0270] R 1 is substituted or unsubstituted C 1-6 Alkyl (e.g., unsubstituted C 1-6 alkyl);
[0271] R2 is substituted or unsubstituted C 1-6 Alkyl (e.g., unsubstituted C 1-3 alkyl); and
[0272] R 7 is a substituted or unsubstituted pyridyl group (eg, a substituted or unsubstituted 3-pyridyl group).
[0273] In certain embodiments, Formula (I) is the following:
[0274]
[0275] (For example,
[0276] ),
[0277] where R 2 is substituted or unsubstituted C 1-6 Alkyl (eg, Me).
[0278] In certain embodiments, Formula (I) is Formula (I-1A):
[0279]
[0280] In certain embodiments, Formula (I) is Formula (I-1B):
[0281] where R 7 It is a substituted or unsubstituted 3-pyridyl group.
[0282] In certain embodiments, Formula (I) is Formula (I-1C)):
[0283]
[0284] in is pyridyl, pyridazinyl, pyrimidinyl or pyrazinyl. In certain embodiments, Formula (I) is Formula (I-1C), wherein is imidazolyl, oxazolyl, azetidinyl, -C≡C- or
[0285] In certain embodiments, Formula (I) is Formula (I-1C)):
[0286]
[0287] in is thiazolyl, piperidinyl, piperazinyl, morpholinyl or thiomorpholinyl.
[0288] In certain embodiments, Formula (I) is Formula (I-1D):
[0289] where R 7 is a substituted or unsubstituted 3- to 7-membered monocyclic heterocyclic group or a substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl group.
[0290] In certain embodiments, Formula (I) is the following:
[0291]
[0292] (For example, ).
[0293] In certain embodiments, Formula (I) is the following:
[0294]
[0295] (For example, ).
[0296] In certain embodiments, Formula (I) is the following:
[0297]
[0298] (For example, ).
[0299] In certain embodiments, Formula (I) is the following:
[0300]
[0301] (For example, ).
[0302] In certain embodiments, Formula (I) is the following:
[0303]
[0304] (For example, ).
[0305] In certain embodiments, Formula (I) is the following:
[0306]
[0307] (For example, ).
[0308] In certain embodiments, q is 0 or 1. In certain embodiments, q is 1. In certain embodiments, q is 0.
[0309] In certain embodiments, L A -C(=O)NR 1 R 2 In certain embodiments, the compound of formula (0) has the following formula: In certain embodiments, q is 0 or 1. In certain embodiments, q is 1. In certain embodiments, q is 0.
[0310] In some embodiments, L A -N(R 2 )(L 1 R 1 In certain embodiments, the compound of formula (0) has the following formula: In certain embodiments, q is 0 or 1. In certain embodiments, q is 1. In certain embodiments, q is 0. In certain embodiments, L 1 In some embodiments, the compound of formula (0) has the following formula: In certain embodiments, L 1 In certain embodiments, the compound of formula (0) has the following formula:
[0311] In certain embodiments, L 1 is a single bond. In certain embodiments, L 1 It is -C(=O)-.
[0312] In certain embodiments, L 1 is a single bond, and R 1 is substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 2-6 Alkenyl, substituted or unsubstituted C 2-6 In certain embodiments, R 1 is substituted or unsubstituted C 1-6 In certain embodiments, R 1 For unsubstituted C 1-6 In certain embodiments, R 1is an unsubstituted C1 alkyl. In certain embodiments, R 1 is an unsubstituted C2 alkyl. In certain embodiments, R 1 is an unsubstituted C3 alkyl. In certain embodiments, R 1 is an unsubstituted C4 alkyl. In certain embodiments, R 1 is an unsubstituted C5 alkyl. In certain embodiments, R 1 is an unsubstituted C6 alkyl. In certain embodiments, R 1 C 1-6 In certain embodiments, R 1 is a substituted C1 alkyl. In certain embodiments, R 1 In certain embodiments, R 1 is a substituted C3 alkyl. In certain embodiments, R 1 is a substituted C4 alkyl. In certain embodiments, R 1 is a substituted C5 alkyl. In certain embodiments, R 1 is a substituted C6 alkyl. In certain embodiments, R 1 Fluorinated C 1-6 In certain embodiments, R 1 is substituted or unsubstituted C 2-6 In certain embodiments, R 1 is substituted or unsubstituted C 2-6 In certain embodiments, R 1 is substituted or unsubstituted C 2-6 In certain embodiments, R 1 is a substituted or unsubstituted 3 to 13 membered monocyclic or bicyclic carbocyclic group. 1 is a substituted or unsubstituted 3 to 13 membered monocyclic or bicyclic heterocyclic group. 1 is a substituted or unsubstituted 5- to 11-membered monocyclic or bicyclic heteroaryl group.
[0313] In certain embodiments, L 1 is -C(=O)-; and R 1 is a substituted C containing at least one double bond, triple bond or heteroatom 1-6 Alkyl; substituted or unsubstituted C 2-6 Alkenyl, substituted or unsubstituted C 2-6substituted or unsubstituted 3 to 13 membered monocyclic or bicyclic carbocyclyl; substituted or unsubstituted 3 to 13 membered monocyclic or bicyclic heterocyclyl; substituted or unsubstituted 6 to 11 membered monocyclic or bicyclic aryl; or substituted or unsubstituted 5 to 11 membered monocyclic or bicyclic heteroaryl. In certain embodiments, R 1 is a substituted C containing at least one heteroatom 1-6 In certain embodiments, R 1 is a substituted C containing at least one double bond 1-6 In certain embodiments, R 1 is a substituted C containing at least one triple bond 1-6 alkyl.
[0314] In certain embodiments, R 2 In certain embodiments, R 2 In certain embodiments, R 2 is substituted or unsubstituted C 1-6 In certain embodiments, R 2 For unsubstituted C 1-6 In certain embodiments, R 2 In certain embodiments, R 2 is Et, Pr or Bu. In certain embodiments, R 2 Fluorinated C 1-6 In certain embodiments, R 2 A nitrogen protecting group.
[0315] In certain embodiments, R 2 is a substituted or unsubstituted 3 to 7 membered monocyclic carbocyclyl. 2 is a substituted or unsubstituted 3 to 5 membered monocyclic carbocyclyl. 2 is a substituted or unsubstituted 3 to 7 membered monocyclic heterocyclic group. 2 is a substituted or unsubstituted 3 to 5 membered monocyclic heterocyclic group. 2 is substituted or unsubstituted phenyl. In certain embodiments, R 2 is a substituted or unsubstituted 5- to 6-membered monocyclic heteroaryl group.
[0316] In some embodiments, R 3 is hydrogen, halogen, substituted or unsubstituted C 1-6 Alkyl, -OR a 、-N(R a )2 or -CN. In some embodiments, R 3 For hydrogen.
[0317] In certain embodiments, R 3 is halogen, substituted or unsubstituted C 1-6 Alkyl, -OR a 、-N(R a )2 or -CN. In certain embodiments, R 3 is halogen, substituted or unsubstituted C 1-6 Alkyl or -OR a In certain embodiments, R 3 -N(R a )2 or -CN. In certain embodiments, R 3 In certain embodiments, R 3 is F. In certain embodiments, R 3 In certain embodiments, R 3 is substituted or unsubstituted C 1-6 Alkyl (e.g., unsubstituted C 1-6 In certain embodiments, R 3 In certain embodiments, R 3 is Et, Pr or Bu. In certain embodiments, R 3 Fluorinated C 1-6 In certain embodiments, R 3 For-OR a In certain embodiments, R 3 In certain embodiments, R 3 -O(substituted or unsubstituted C 1-6 In certain embodiments, R 3 -N(R a )2. In certain embodiments, R 3 In certain embodiments, R 3 NHR a (e.g., -NH(substituted or unsubstituted C 1-6 In certain embodiments, R 3 -N(substituted or unsubstituted C 1-6 In certain embodiments, R 3 It is -CN.
[0318] In certain embodiments, R a Each instance of is independently hydrogen, substituted or unsubstituted C 1-6In certain embodiments, R a Each instance of is hydrogen. In certain embodiments, R a Examples of are not hydrogen. In certain embodiments, R a At least one example of which is a substituted or unsubstituted C 1-6 Alkyl (e.g., unsubstituted C 1-6 In certain embodiments, R a At least one example of is Me. In certain embodiments, R a At least one example of is Et, Pr or Bu. In certain embodiments, R a At least one example of a fluorinated C 1-6 Alkyl (eg, fluorinated methyl, eg, -CF3).
[0319] In certain embodiments, R 2 and R 3 are linked to their intervening atoms to form a substituted or unsubstituted 5-membered monocyclic heterocyclyl or heteroaryl. In certain embodiments, R 2 and R 3 are linked to their intervening atoms to form an unsubstituted 5-membered monocyclic heterocyclyl. In certain embodiments, R 2 and R 3 are connected with their intervening atoms to form a substituted 5-membered monocyclic heteroaryl. In certain embodiments, for In certain embodiments, for In certain embodiments, for (For example, For example, ). In certain embodiments, for In certain embodiments, for In certain embodiments, for (For example, For example, ). In certain embodiments, R 2 and R 3 are connected with their intervening atoms to form a substituted 5-membered monocyclic heteroaryl. In certain embodiments, for
[0320] In certain embodiments, at least one instance of Y is CR 4In certain embodiments, each instance of Y is CR 4 In certain embodiments, at least one instance of Y is N. In certain embodiments, every instance of Y is N.
[0321] In certain embodiments, for In certain embodiments, (For example, )for In certain embodiments, (For example, )for In certain embodiments, (For example, )for In certain embodiments, (For example, )for
[0322] In certain embodiments, R 4 Each instance of is independently hydrogen, halogen, substituted or unsubstituted C 1-6 Alkyl, -OR a 、-N(R a )2 or -CN. In certain embodiments, R 4 At least one example of is hydrogen. In certain embodiments, R 4 Each instance of is hydrogen. In certain embodiments, R 4 At least one instance of is not hydrogen. In certain embodiments, R 4 Examples of are not hydrogen. In certain embodiments, R 4 At least one example is halogen or substituted or unsubstituted C 1-6 In certain embodiments, R 4 At least one example of is halogen. In certain embodiments, R 4 At least one example of is F. In certain embodiments, R 4 At least one example of is Cl. In certain embodiments, R 4 At least one example of substituted or unsubstituted C 1-6 Alkyl (e.g., unsubstituted C 1-6 In certain embodiments, R 4 At least one example of is Me. In certain embodiments, R 4 At least one example of is Et, Pr or Bu. In certain embodiments, R 4 At least one example of a fluorinated C 1-6In certain embodiments, R 4 At least one instance of -OR a In certain embodiments, R 4 At least one example of is -OH. In certain embodiments, R 4 At least one example is -O(substituted or unsubstituted C 1-6 In certain embodiments, R 4 At least one example of -N(R a )2. In certain embodiments, R 4 At least one example of is -NH2. In certain embodiments, R 4 At least one instance of -NHR a (e.g., -NH(substituted or unsubstituted C 1-6 In certain embodiments, R 4 At least one example is -N(substituted or unsubstituted C 1-6 In certain embodiments, R 4 At least one example of is -CN.
[0323] In certain embodiments, is a 6-membered monocyclic aryl or heteroaryl. In certain embodiments, In certain embodiments, for In certain embodiments, for In certain embodiments, for In certain embodiments, for In certain embodiments, for In certain embodiments, for In certain embodiments, is pyridinyl, pyridazinyl, pyrimidinyl or pyrazinyl. In certain embodiments, for (For example, ). In certain embodiments, for (For example, ). In certain embodiments, for (For example, ). In certain embodiments, for (For example, ). In certain embodiments, for (For example, ). In certain embodiments, for (For example, ).
[0324] In certain embodiments, In certain embodiments, for (For example, ). In certain embodiments, for (For example, ). In certain embodiments, for (For example, ). In certain embodiments, for (For example, ).
[0325] In certain embodiments, In certain embodiments, for (For example, ). In certain embodiments, for (For example, ), (For example, ), (For example, ). In certain embodiments, In certain embodiments, for (For example, ). In certain embodiments, for (For example, ). In certain embodiments, In certain embodiments, for In certain embodiments, for (For example, ).
[0326] In certain embodiments, bond b and bond c are para to each other. In certain embodiments, bond b and bond c are meta to each other.
[0327] In certain embodiments, when When is phenyl, pyridyl, pyridazinyl, pyrimidinyl or pyrazinyl, bond b and bond c are para to each other. When it is phenyl, pyridyl, pyridazinyl, pyrimidinyl or pyrazinyl, bond b and bond c are in the meta position relative to each other.
[0328] In certain embodiments, In certain embodiments, for (For example, ). In certain embodiments, for (For example, ), (For example, ), (For example, ).
[0329] In certain embodiments, is a 6-membered monocyclic carbocyclyl or heterocyclyl. In certain embodiments, In certain embodiments, for In certain embodiments, for In certain embodiments, for In certain embodiments, for In certain embodiments, for In certain embodiments, for In certain embodiments, for
[0330] In certain embodiments, In certain embodiments, for In certain embodiments, for In certain embodiments, for In certain embodiments, for
[0331] In some embodiments, In certain embodiments, for In certain embodiments, for In certain embodiments, for In certain embodiments, for
[0332] In some embodiments, In certain embodiments, for In certain embodiments, for In certain embodiments, for In certain embodiments, for
[0333] In certain embodiments, R 5 Each instance of is independently hydrogen, halogen, substituted or unsubstituted C 1-6 Alkyl, -OR a 、-N(R a )2 or -CN. In certain embodiments, R 5 At least one example of is hydrogen. In certain embodiments, R 5 Each instance of is hydrogen. In certain embodiments, R 5 At least one instance of is not hydrogen. In certain embodiments, R 5 Examples of are not hydrogen. In certain embodiments, R 5 At least one example of is halogen. In certain embodiments, R 5 At least one example of is F. In certain embodiments, R 5 At least one example of is Cl. In certain embodiments, R 5 At least one example of substituted or unsubstituted C 1-6 Alkyl (e.g., unsubstituted C 1-6 In certain embodiments, R 5 At least one example of is Me. In certain embodiments, R 5 At least one example of is Et, Pr or Bu. In certain embodiments, R 5 At least one example of a fluorinated C 1-6 In certain embodiments, R 5 At least one instance of -OR aIn certain embodiments, R 5 At least one example of is -OH. In certain embodiments, R 5 At least one example is -O(substituted or unsubstituted C 1-6 In certain embodiments, R 5 At least one example of -N(R a )2. In certain embodiments, R 5 At least one example of is -NH2. In certain embodiments, R 5 At least one instance of -NHR a (e.g., -NH(substituted or unsubstituted C 1-6 In certain embodiments, R 5 At least one example is -N(substituted or unsubstituted C 1-6 In certain embodiments, R 5 At least one example of is -CN. In certain embodiments, R 5 At least one example is halogen, substituted or unsubstituted C 1-6 Alkyl or -OR a .
[0334] In some embodiments, L B -N(R 6 )L 2 In some embodiments, the compound of formula (0) has the following formula: In some embodiments, L 2 In certain embodiments, the compound of formula (0) has the following formula: In some embodiments, L 2 is S(=O)2. In certain embodiments, the compound of formula (0) has the following formula: In some respects, L 2 for In some embodiments, the compound of formula (0) has the formula: In certain embodiments, each R 6 are independently hydrogen. In some embodiments, one R 6 is a methyl group, and one R 6 For hydrogen.
[0335] In certain embodiments, L B -L 2 N(R 6 In some embodiments, the compound of formula (0) has the following formula: In some embodiments, L 2In certain embodiments, the compound of formula (0) has the following formula: In some embodiments, L 2 is S(=O)2. In certain embodiments, the compound of formula (0) has the following formula: In some respects, L 2 for In some embodiments, the compound of formula (0) has the formula: In certain embodiments, each R 6 In some embodiments, one R 6 is a methyl group, and one R 6 In some embodiments, the compound of formula (0) has the following formula:
[0336] In certain embodiments, the compound of formula (0) has formula (0'): In certain embodiments, the compound of formula (0') has the formula
[0337] In certain embodiments, L 2 In certain embodiments, L 2 It is -S(=O)2-.
[0338] In certain embodiments, L 2 for In some embodiments, L 2 for And R 6 In some embodiments, L 2 for And R 6 It is a methyl group.
[0339] In certain embodiments, each R 6 are independently hydrogen, substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 2-6 Alkenyl, substituted or unsubstituted C 2-6 In certain embodiments, each R 6 are independently substituted or unsubstituted C 1-6In certain embodiments, each R 6 is independently hydrogen. In certain embodiments, each R 6 are independently substituted or unsubstituted C 1-6 In certain embodiments, R 6 Each instance of is identical. In some embodiments, R 6 Each instance of is different.
[0340] In certain embodiments, R 6 is hydrogen, substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 2-6 Alkenyl, substituted or unsubstituted C 2-6 In certain embodiments, R 6 is substituted or unsubstituted C 1-6 In certain embodiments, R 6 In certain embodiments, R 6 is substituted or unsubstituted C 1-6 Alkyl (eg, Me).
[0341] In certain embodiments, R 7 is a substituted or unsubstituted 3 to 7 membered monocyclic carbocyclyl. 7 is a substituted or unsubstituted 3 to 7 membered monocyclic heterocyclic group. 7 is substituted or unsubstituted phenyl. In certain embodiments, R 7 is a substituted or unsubstituted 5- to 6-membered monocyclic heteroaryl. 7 is substituted or unsubstituted pyridyl, substituted or unsubstituted pyrimidinyl or substituted or unsubstituted pyridazinyl. In certain embodiments, R 7 is substituted or unsubstituted 3-pyridyl. In certain embodiments, R 7 In certain embodiments, R 7 for In certain embodiments, R 7 for In certain embodiments, R 7 for In certain embodiments, R 7 for In certain embodiments, R 7 for In certain embodiments, R 7 is substituted or unsubstituted 2-pyridyl or 4-pyridyl. In certain embodiments, R 7 is a substituted or unsubstituted 2-pyridyl group. 7 In certain embodiments, R 7 for In certain embodiments, R 7 for In certain embodiments, R 7 for In certain embodiments, R 7 for
[0342] In certain embodiments, R 8 Each instance of is independently -OR a 、-N(R a )2 or -CN. In certain embodiments, R 8 Each instance of is hydrogen. In certain embodiments, R 8 At least one example is halogen or substituted or unsubstituted C 1-6 In certain embodiments, R 8 At least one example of unsubstituted C 1-6 In certain embodiments, R 8 At least one instance of C is substituted with at least one instance of halogen (eg, F). 1-6 alkyl.
[0343] R 9 Each instance of is independently hydrogen, halogen, substituted or unsubstituted C 1-6 Alkyl, OR a 、-N(R a )2 or -CN. In certain embodiments, R 9 At least one example of is hydrogen. In certain embodiments, R 9 Each instance of is hydrogen. In certain embodiments, R 9 In certain embodiments, at least one instance of R is not hydrogen. In certain embodiments, at least one instance of R is not hydrogen. 9 At least one example of is halogen. In certain embodiments, R9 At least one example of is F. In certain embodiments, R 9 At least one example of is Cl. In certain embodiments, R 9 At least one example of substituted or unsubstituted C 1-6 Alkyl (e.g., unsubstituted C 1-6 In certain embodiments, at least one instance of R9 is Me. 9 At least one example of is Et, Pr or Bu. In certain embodiments, R 9 At least one example of a fluorinated C 1-6 In certain embodiments, R 9 At least one instance of -OR a In certain embodiments, R 9 At least one example of is -OH. In certain embodiments, R 9 At least one example is -O(substituted or unsubstituted C 1-6 In certain embodiments, R 9 At least one example of -N(R a )2. In certain embodiments, R 9 At least one example of is -NH2. In certain embodiments, R 9 At least one instance of -NHR a (e.g., -NH(substituted or unsubstituted C 1-6 In certain embodiments, R 9 At least one example is -N(substituted or unsubstituted C 1-6 In certain embodiments, R 9 At least one example of is -CN. In certain embodiments, R 9 At least one example is halogen, substituted or unsubstituted C 1-6 Alkyl or -OR a .
[0344] In some embodiments, s is 1. In certain embodiments, s is 0.
[0345] In certain embodiments, s is 1. In some embodiments, the compound of formula (0) has the following formula: In some embodiments, s is 0. In certain embodiments, the compound of formula (0) has the following formula: In some embodiments, s is 0, and the compound of formula (0) is selected from the group consisting of:
[0346] In certain embodiments, s is 1. In some embodiments, the compound of formula (0') has the following formula: In some embodiments, s is 0. In certain embodiments, the compound of formula (0') has the following formula: In some embodiments, s is 0, and the compound of formula (0') is selected from the group consisting of:
[0347] In certain embodiments, the compound has the formula:
[0348]
[0349] or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, cocrystal, tautomer, stereoisomer, isotope-labeled derivative or prodrug thereof.
[0350] In certain embodiments, the compound has the formula:
[0351]
[0352] or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, cocrystal, tautomer, stereoisomer, isotope-labeled derivative or prodrug thereof.
[0353] In certain embodiments, the compound has the formula:
[0354]
[0355] or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, cocrystal, tautomer, stereoisomer, isotope-labeled derivative or prodrug thereof.
[0356] In certain embodiments, the compound has the formula:
[0357]
[0358] or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, cocrystal, tautomer, stereoisomer, isotope-labeled derivative or prodrug thereof.
[0359] In certain embodiments, the compound has the formula:
[0360]
[0361] or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, cocrystal, tautomer, stereoisomer, isotope-labeled derivative or prodrug thereof.
[0362] In certain embodiments, the compound has the formula:
[0363]
[0364] or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, cocrystal, tautomer, stereoisomer, isotope-labeled derivative or prodrug thereof.
[0365] In certain embodiments, the compound has the formula:
[0366]
[0367] or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, cocrystal, tautomer, stereoisomer, isotope-labeled derivative or prodrug thereof, wherein Z is hydrogen or substituted or unsubstituted C 1-6 alkyl; and
[0368] m is 1, 2, 3, 4, 5 or 6.
[0369] In certain embodiments, the compound has the formula:
[0370]
[0371]
[0372]
[0373]
[0374]
[0375]
[0376]
[0377] or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, cocrystal, tautomer, stereoisomer, isotope-labeled derivative or prodrug thereof.
[0378] In certain embodiments, the compound has the formula:
[0379]
[0380] or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, cocrystal, tautomer, stereoisomer, isotope-labeled derivative or prodrug thereof.
[0381] In certain embodiments, the compound has the formula:
[0382]
[0383] or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, cocrystal, tautomer, stereoisomer, isotope-labeled derivative or prodrug thereof.
[0384] In certain embodiments, the compound has the formula:
[0385]
[0386] or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, cocrystal, tautomer, stereoisomer, isotope-labeled derivative or prodrug thereof.
[0387] In certain embodiments, the compound has the formula:
[0388]
[0389] or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, cocrystal, tautomer, stereoisomer, isotope-labeled derivative or prodrug thereof.
[0390] In certain embodiments, the compound has the formula:
[0391]
[0392] or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, cocrystal, tautomer, stereoisomer, isotope-labeled derivative or prodrug thereof.
[0393] In certain embodiments, the compounds of the present disclosure (compounds described herein) are compounds of formula (0) or (0′), or pharmaceutically acceptable salts, solvates, hydrates, polymorphs, cocrystals, tautomers, stereoisomers, isotopically labeled derivatives, or prodrugs thereof. In certain embodiments, the compounds of the present disclosure are compounds of formula (0) or (0′), or pharmaceutically acceptable salts, tautomers, or stereoisomers thereof. In certain embodiments, the compounds of the present disclosure are compounds of formula (0) or (0′), or pharmaceutically acceptable salts, tautomers, or stereoisomers thereof.
[0394] In certain embodiments, the compounds of the present disclosure (compounds described herein) are compounds of formula (I), or pharmaceutically acceptable salts, solvates, hydrates, polymorphs, cocrystals, tautomers, stereoisomers, isotopically labeled derivatives or prodrugs thereof. In certain embodiments, the compounds of the present disclosure are compounds of formula (I), or pharmaceutically acceptable salts, tautomers or stereoisomers thereof. In certain embodiments, the compounds of the present disclosure are compounds of formula (I), or pharmaceutically acceptable salts, tautomers or stereoisomers thereof.
[0395] The compounds of the present disclosure may have a safe in vitro pharmacological profile. Compared to certain similar known compounds, the compounds of the present disclosure may have a safer (e.g., at least 10%, at least 20%, at least 50%, at least 100%, at least 200%, at least 500%, or at least 1,000% safer) in vitro pharmacological profile.
[0396] The compounds of the present disclosure may have high water solubility. Compared to certain similar known compounds, the compounds of the present disclosure may have higher (e.g., at least 10%, at least 20%, at least 50%, at least 100%, at least 200%, at least 500%, or at least 1,000%) water solubility.
[0397] The compounds of the present disclosure may have high microsomal stability. Compared to certain similar known compounds, the compounds of the present disclosure may have higher (e.g., at least 10%, at least 20%, at least 50%, at least 100%, at least 200%, at least 500%, or at least 1,000%) microsomal stability.
[0398] Exemplary compounds of the present disclosure include compounds in Table A, Table 5, and the following compounds:
[0399]
[0400]
[0401]
[0402]
[0403]
[0404]
[0405]
[0406]
[0407]
[0408]
[0409]
[0410]
[0411]
[0412]
[0413]
[0414]
[0415]
[0416]
[0417]
[0418]
[0419]
[0420]
[0421]
[0422]
[0423]
[0424]
[0425]
[0426]
[0427]
[0428]
[0429]
[0430]
[0431]
[0432]
[0433]
[0434]
[0435]
[0436]
[0437]
[0438]
[0439]
[0440]
[0441]
[0442]
[0443]
[0444]
[0445]
[0446]
[0447]
[0448]
[0449]
[0450]
[0451]
[0452]
[0453]
[0454]
[0455]
[0456]
[0457]
[0458]
[0459]
[0460]
[0461]
[0462]
[0463]
[0464]
[0465]
[0466]
[0467]
[0468]
[0469]
[0470]
[0471]
[0472]
[0473]
[0474]
[0475]
[0476]
[0477]
[0478]
[0479]
[0480]
[0481]
[0482]
[0483]
[0484]
[0485]
[0486]
[0487]
[0488]
[0489]
[0490]
[0491]
[0492]
[0493]
[0494]
[0495]
[0496]
[0497]
[0498]
[0499]
[0500]
[0501]
[0502]
[0503]
[0504]
[0505]
[0506]
[0507]
[0508]
[0509]
[0510]
[0511]
[0512]
[0513]
[0514]
[0515]
[0516]
[0517]
[0518]
[0519]
[0520]
[0521]
[0522]
[0523]
[0524]
[0525]
[0526]
[0527]
[0528]
[0529]
[0530]
[0531]
[0532]
[0533]
[0534]
[0535]
[0536]
[0537]
[0538]
[0539]
[0540]
[0541]
[0542]
[0543]
[0544]
[0545]
[0546]
[0547]
[0548]
[0549]
[0550] Table A
[0551]
[0552]
[0553]
[0554]
[0555]
[0556]
[0557]
[0558]
[0559]
[0560]
[0561]
[0562]
[0563]
[0564]
[0565]
[0566]
[0567]
[0568]
[0569]
[0570]
[0571]
[0572]
[0573]
[0574]
[0575]
[0576]
[0577]
[0578]
[0579]
[0580]
[0581] Compositions and kits
[0582] The present disclosure provides compositions (e.g., pharmaceutical compositions) comprising a compound of the present disclosure and an excipient (e.g., a pharmaceutically acceptable excipient). In certain embodiments, the composition is a pharmaceutical composition. In certain embodiments, the excipient is a pharmaceutically acceptable excipient.
[0583] The compositions described herein can be prepared by any method known in the art. Generally, such preparation methods include associating the disclosed compounds described herein with an excipient, and may include one or more pharmaceutical agents or auxiliary ingredients, and then, if necessary and / or desired, forming and / or packaging the product into desired single or multiple dose units. In certain embodiments, the pharmaceutical agent is a pharmaceutical agent.
[0584] In certain embodiments, the compounds of the present disclosure are in the form of pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, or prodrugs.
[0585] The composition can be prepared, packaged, and / or sold as a single unit dose and / or as a plurality of single unit doses in bulk. A "unit dose" is a discrete amount of a composition containing a predetermined amount of a pharmaceutical agent. The amount of a pharmaceutical agent is generally equal to the dose of the pharmaceutical agent to be administered to a subject and / or a suitable fraction of that dose, such as one-half or one-third of that dose.
[0586] The relative amounts of the compounds of the present disclosure, excipients, pharmaceutical agents, and / or any additional ingredients in the compositions described herein will vary depending on the identity, size, and / or condition of the subject being treated, and will also vary depending on the route of administration of the composition. The composition may contain 0.1% to 100% (w / w) of the pharmaceutical agent.
[0587] Excipients and auxiliary ingredients used to make the provided compositions include inert diluents, dispersants and / or granulating agents, surfactants and / or emulsifiers, disintegrants, binders, preservatives, buffers, lubricants and / or oils. Excipients and auxiliary ingredients such as cocoa butter, polyethylene glycol lipids, phospholipids, suppository waxes, colorants, coating agents, sweeteners, flavorings, and fragrances may also be present in the compositions.
[0588] Exemplary diluents include calcium carbonate, sodium carbonate, calcium phosphate, dicalcium phosphate, calcium sulfate, dibasic calcium phosphate, sodium phosphate, lactose, sucrose, cellulose, microcrystalline cellulose, kaolin, mannitol, sorbitol, inositol, sodium chloride, dry starch, corn starch, powdered sugar, and mixtures thereof.
[0589] Exemplary granulating and / or dispersing agents include potato starch, corn starch, tapioca starch, sodium starch glycolate, clays, alginic acid, guar gum, citrus pulp, agar, bentonite, cellulose and wood products, natural sponges, cation exchange resins, calcium carbonate, silicates, sodium carbonate, cross-linked polyvinyl pyrrolidone (crospovidone), sodium carboxymethyl starch (sodium starch glycolate), carboxymethyl cellulose, cross-linked sodium carboxymethyl cellulose (croscarmellose), methylcellulose, pregelatinized starch (starch 1500), microcrystalline starch, water-insoluble starch, calcium carboxymethyl cellulose, magnesium aluminum silicate (Veegum), sodium lauryl sulfate, quaternary ammonium compounds, and mixtures thereof.
[0590] Exemplary surfactants and / or emulsifiers include natural emulsifiers (e.g., gum arabic, agar, alginic acid, sodium alginate, gum tragacanth, chondrux, xanthan gum, pectin, gelatin, egg yolk, casein, lanolin, cholesterol, waxes, and lecithin), colloidal clays (e.g., bentonite (aluminum silicate) and Veegum (magnesium aluminum silicate)), long chain amino acid derivatives, high molecular weight alcohols (e.g., stearyl alcohol, cetyl alcohol, oleyl alcohol, triacetin monostearate, ethylene glycol distearate, glyceryl monostearate, and propylene glycol monostearate, polyvinyl alcohol), carbomers (e.g., carboxypolymethylene, polyacrylic acid, acrylic acid polymers, and carboxyvinyl polymers), carrageenan, cellulose derivatives (e.g., sodium carboxymethylcellulose, powdered cellulose, hydroxymethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, methylcellulose), sorbitan fatty acid esters (e.g., polyoxyethylene sorbitan monolaurate ( 20), polyoxyethylene sorbitan ( 60), polyoxyethylene sorbitan monooleate ( 80), Sorbitan monopalmitate ( 40), Sorbitan monostearate ( 60), Sorbitan tristearate ( 65), monoolein, sorbitan monooleate [ 80]), polyoxyethylene esters (e.g. polyoxyethylene monostearate ( 45), polyoxyethylene hydrogenated castor oil, polyethoxylated castor oil, polyoxymethylene stearate, and ), sucrose fatty acid esters, polyethylene glycol fatty acid esters (e.g. ), polyoxyethylene ethers (such as polyoxyethylene lauryl ether ( 30)), poly(vinyl-pyrrolidone), diethylene glycol monolaurate, triethanolamine oleate, sodium oleate, potassium oleate, ethyl oleate, oleic acid, ethyl laurate, sodium lauryl sulfate, F-68, poloxamer P-188, cetyltrimethylammonium bromide, cetylpyridinium chloride, benzalkonium chloride, docusate sodium and / or mixtures thereof.
[0591] Exemplary binders include starches (e.g., corn starch and starch paste), gelatin, sugars (e.g., sucrose, glucose, dextrose, dextrin, molasses, lactose, lactitol, mannitol, etc.), natural and synthetic gums (e.g., gum arabic, sodium alginate, carrageenan extract, panwar gum, ghatti gum, mucilage from isapol shells, carboxymethyl cellulose, methyl cellulose, ethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, microcrystalline cellulose, cellulose acetate, poly(vinyl pyrrolidone), magnesium aluminum silicate, and larch arabinogalactan), alginate, polyoxyethylene, polyethylene glycol, inorganic calcium salt, silicic acid, polymethacrylate, wax, water, alcohol and / or mixtures thereof.
[0592] Exemplary preservatives include antioxidants, chelating agents, antimicrobial preservatives, antifungal preservatives, antiprotozoal preservatives, alcohol preservatives, acidic preservatives, and other preservatives. In certain embodiments, the preservative is an antioxidant. In other embodiments, the preservative is a chelating agent.
[0593] Exemplary antioxidants include alpha tocopherol, ascorbic acid, ascorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, monothioglycerol, potassium metabisulfite, propionic acid, propyl gallate, sodium ascorbate, sodium bisulfite, sodium metabisulfite, and sodium sulfite.
[0594] Exemplary chelating agents include ethylenediaminetetraacetic acid (EDTA) and its salts and hydrates (e.g., sodium EDTA, disodium EDTA, trisodium EDTA, calcium disodium EDTA, dipotassium EDTA, etc.), citric acid and its salts and hydrates (e.g., citric acid monohydrate), fumaric acid and its salts and hydrates, malic acid and its salts and hydrates, phosphoric acid and its salts and hydrates, and tartaric acid and its salts and hydrates. Exemplary antimicrobial preservatives include benzalkonium chloride, benzethonium chloride, benzyl alcohol, bronopol, cetrimide, cetylpyridinium chloride, chlorhexidine, chlorobutanol, chlorocresol, chloroxylenol, cresol, ethanol, glycerin, hexetidine, imidurea, phenol, phenoxyethanol, phenylethyl alcohol, phenylmercuric nitrate, propylene glycol, and thimerosal.
[0595] Exemplary antifungal preservatives include butylparaben, methylparaben, ethylparaben, propylparaben, benzoic acid, hydroxybenzoic acid, potassium benzoate, potassium sorbate, sodium benzoate, sodium propionate, and sorbic acid.
[0596] Exemplary alcohol preservatives include ethanol, polyethylene glycol, phenol, phenolic compounds, bisphenol, chlorobutanol, hydroxybenzoates, and phenylethanol.
[0597] Exemplary acidic preservatives include vitamin A, vitamin C, vitamin E, beta-carotene, citric acid, acetic acid, dehydroacetic acid, ascorbic acid, sorbic acid, and phytic acid.
[0598] Other preservatives include tocopherol, tocopheryl acetate, deferoxamine mesylate, cetyltrimonium bromide, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), ethylenediamine, sodium lauryl sulfate (SLS), sodium lauryl ether sulfate (SLES), sodium bisulfite, sodium metabisulfite, potassium sulfite, potassium metabisulfite, Plus, Methylparaben, 115. II. and
[0599] Exemplary buffers include citrate buffer solution, acetate buffer solution, phosphate buffer solution, ammonium chloride, calcium carbonate, calcium chloride, calcium citrate, calcium glucuronate, calcium glucoheptonate, calcium gluconate, D-gluconic acid, calcium glycerophosphate, calcium lactate, propionic acid, calcium levulinate, valeric acid, dibasic calcium phosphate, phosphoric acid, tricalcium phosphate, calcium hydroxide phosphate, potassium acetate, potassium chloride, potassium gluconate, potassium mixtures, dibasic potassium phosphate, monobasic potassium phosphate, potassium phosphate mixtures, sodium acetate, sodium bicarbonate, sodium chloride, sodium citrate, sodium lactate, disodium hydrogen phosphate, monobasic sodium phosphate, sodium phosphate mixtures, tromethamine, magnesium hydroxide, aluminum hydroxide, alginic acid, pyrogen-free water, isotonic saline, Ringer's solution, ethanol, and mixtures thereof.
[0600] Exemplary lubricants include magnesium stearate, calcium stearate, stearic acid, silicon dioxide, talc, malt, glyceryl behenate, hydrogenated vegetable oils, polyethylene glycol, sodium benzoate, sodium acetate, sodium chloride, leucine, magnesium lauryl sulfate, sodium lauryl sulfate, and mixtures thereof.
[0601] Exemplary natural oils include almond, apricot, avocado, babassu, bergamot, black currant seed, borage, juniper, chamomile, canola, caraway, palm wax, castor, cinnamon, cocoa butter, coconut, cod liver, coffee, corn, cottonseed, emu, eucalyptus, evening primrose, fish, flaxseed, citronellol, gourd, grape seed, hazelnut, hyssop, isopropyl myristate, jojoba, macadamia, lavender, lavender, lemon, litsea cubeba, macadamia, mallow, mango seed, meadowfoam seed, mink, nutmeg, olive, citrus, orange roughy, palm, palm kernel, peach kernel, peanut, poppy seed, pumpkin seed, rapeseed, rice bran, rosemary, safflower, sandalwood, camellia, tamarisk, sea buckthorn, sesame, shea butter, silicone, soy, sunflower, tea tree, thistle, tsubaki, vetiver, walnut, and wheat germ oils. Exemplary synthetic oils include butyl stearate, caprylic triglyceride, capric triglyceride, cyclomethicone, diethyl sebacate, dimethicone 360, isopropyl myristate, mineral oil, octyldodecanol, oleyl alcohol, silicone oil, and mixtures thereof.
[0602] In certain embodiments, the composition further comprises a pharmaceutical agent and can be used to deliver the pharmaceutical agent (e.g., to a subject or cell). In certain embodiments, the composition is a pharmaceutical composition that can be used to treat a disease in a subject in need thereof. In certain embodiments, the disease is cancer. In certain embodiments, the cancer is colorectal cancer (e.g., colon cancer or rectal cancer). In certain embodiments, the cancer is gastric cancer. In certain embodiments, the cancer is gastrointestinal stromal tumor (GIST). In certain embodiments, the cancer is ovarian cancer (e.g., ovarian adenocarcinoma). In certain embodiments, the cancer is lung cancer (e.g., small cell lung cancer). In certain embodiments, the cancer is non-small cell lung cancer. In certain embodiments, the cancer is breast cancer. In certain embodiments, the cancer is pancreatic cancer (e.g., pancreatic cancer or pancreatic adenocarcinoma). In certain embodiments, the cancer is prostate cancer (e.g., prostate adenocarcinoma). In certain embodiments, the cancer is testicular cancer. In certain embodiments, the cancer is liver cancer. In certain embodiments, the cancer is endometrial cancer (e.g., uterine cancer). In certain embodiments, the cancer is lymphoma, such as non-Hodgkin's lymphoma (e.g., B-cell non-Hodgkin's lymphoma). In certain embodiments, the cancer is a B cell lymphoma (e.g., Burkitt's B cell lymphoma, large B cell lymphoma). In certain embodiments, the cancer is a T cell lymphoma. In certain embodiments, the cancer is Burkitt's lymphoma (e.g., Burkitt's B cell lymphoma). In certain embodiments, the cancer is a large cell immunoblastic lymphoma. In certain embodiments, the cancer is a leukemia. In certain embodiments, the cancer is acute monocytic leukemia or acute lymphocytic leukemia (e.g., B cell acute lymphoblastic leukemia). In certain embodiments, the cancer is acute lymphoblastic leukemia (e.g., B cell acute lymphoblastic leukemia or T cell acute lymphoblastic leukemia). In certain embodiments, the cancer is multiple myeloma (e.g., B cell myeloma).
[0603] As described herein, the composition can be administered in combination with one or more additional agents. In certain embodiments, the agent is an organic molecule. In certain embodiments, the agent is an inorganic molecule. In certain embodiments, the agent is a targeting agent. In certain embodiments, the agent is an isotope-labeled compound. In certain embodiments, the agent is an agent that can be used for bioprocessing. In certain embodiments, the agent is a pharmaceutical agent (e.g., a therapeutic and / or preventive agent). Pharmaceutical agents include therapeutic agents. Pharmaceutical agents also include preventive agents. Pharmaceutical agents include small organic molecules such as pharmaceutical compounds (e.g., compounds approved by the U.S. Food and Drug Administration for human or veterinary use as provided in the U.S. Code of Federal Regulations (CFR)), peptides, proteins, carbohydrates, monosaccharides, oligosaccharides, polysaccharides, nucleoproteins, mucins, lipoproteins, synthetic polypeptides or proteins, small molecules connected to proteins, glycoproteins, steroids, nucleic acids, DNA, RNA, nucleotides, nucleosides, oligonucleotides, antisense oligonucleotides, polynucleotides, lipids, hormones, vitamins, vaccines, immunizing agents, and cells.
[0604] In certain embodiments, the compounds of the present disclosure described herein are provided in an effective amount in a composition. In certain embodiments, an effective amount is a therapeutically effective amount. In certain embodiments, an effective amount is an amount that effectively treats cancer in a subject in need thereof. In certain embodiments, an effective amount is an amount that effectively inhibits the signaling pathways required for metastasis in a subject or cell.
[0605] In certain embodiments, the cell is in vitro. In certain embodiments, the cell is ex vivo.
[0606] The composition can be formulated into liquid dosage forms for oral and parenteral administration, including pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the medicament, the liquid dosage form may also contain inert diluents commonly used in the art, such as water or other solvents, solubilizers and emulsifiers such as ethanol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (e.g., cottonseed oil, peanut oil, corn oil, germ oil, olive oil, castor oil and sesame oil), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycol and fatty acid esters of sorbitan and mixtures thereof. In addition to inert diluents, oral compositions may also contain adjuvants such as wetting agents, emulsifiers and suspending agents, sweeteners, flavorings and fragrances. In certain embodiments for parenteral administration, the compositions described herein are mixed with a solubilizer such as , alcohols, oils, modified oils, glycols, polysorbates, cyclodextrins, polymers and mixtures thereof.
[0607] Injectable preparations, such as sterile injectable aqueous or oily suspensions can be prepared according to known technology using suitable dispersants or wetting agents and suspending agents. Sterile injectable preparations can be sterile injectable solutions, suspensions or emulsions in parenteral acceptable nontoxic diluents or solvents, for example, as solutions in 1,3-butanediol. Adoptable acceptable vehicles and solvents are water, Ringer's solution (USP) and isotonic sodium chloride solution. In addition, sterile fixed oils are generally used as solvents or suspending media. For this purpose, any gentle fixed oil can be used, including synthetic monoglycerides or diglycerides. In addition, fatty acids such as oleic acid are used to prepare injectable preparations.
[0608] The injectable formulations can be sterilized, for example, by filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions that can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.
[0609] In order to prolong the effects of the compounds of the present invention, it is generally desirable to slow down the absorption of the compound from subcutaneous or intramuscular injection. This can be achieved by using a liquid suspension of a crystalline or amorphous material with poor water solubility. The absorption rate of the compound depends on its dissolution rate, which in turn can depend on crystal size and crystalline form. Alternatively, delayed absorption of a parenteral drug form can be achieved by dissolving or suspending the compound in an oil vehicle.
[0610] Compositions for rectal or vaginal administration are typically suppositories that can be prepared by mixing the compositions described herein with suitable non-irritating excipients or carriers, such as cocoa butter, polyethylene glycol, or a suppository wax, which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the compounds of the present disclosure.
[0611] The composition can be formulated into solid dosage forms for oral administration, including capsules, tablets, pills, powders, and granules. In such solid dosage forms, the compounds of the present disclosure are mixed with at least one pharmaceutically acceptable inert excipient or carrier (such as sodium citrate or dicalcium phosphate) and / or the following: (a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid; (b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose, and acacia; (c) humectants such as glycerol; (d) disintegrants such as agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (e) dissolution retarding agents such as paraffin; (f) absorption accelerators such as quaternary ammonium compounds; (g) wetting agents such as, for example, cetyl alcohol and glyceryl monostearate; (h) adsorbents such as kaolin and bentonite; and (i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may comprise buffering agents.
[0612] Solid compositions of similar types can be used as fillers in soft and hard-filled gelatin capsules using excipients such as lactose or milk sugar and high molecular weight polyethylene glycol. Solid dosage forms of tablets, lozenges, capsules, pills and granules can be prepared using coatings and shells such as enteric coatings and other coatings well known in the field of pharmacology. They can optionally contain opacifiers and can have compositions in which they release the disclosed compounds only or preferentially in a certain part of the intestinal tract, optionally in a delayed manner. Examples of operable encapsulated compositions include polymeric substances and waxes. Solid compositions of similar types can be used as fillers in soft and hard-filled gelatin capsules using excipients such as lactose or milk sugar and high molecular weight polyethylene glycol.
[0613] The compounds of the present invention can be in microencapsulated form with one or more excipients as described above. Solid dosage forms of tablets, lozenges, capsules, pills and granules can be prepared with coatings and shells such as enteric coatings, controlled release coatings and other coatings well known in the field of pharmaceutical formulation. In such solid dosage forms, the compounds of the present invention can be mixed with at least one inert diluent such as sucrose, lactose or starch. Such dosage forms can contain other substances other than inert diluents according to conventional practice, for example, tableting lubricants and other tableting aids, such as magnesium stearate and microcrystalline cellulose. In the case of capsules, tablets and pills, the dosage form can include a buffer. They can optionally include an opacifier and can have a composition in which they release the compounds of the present invention only or preferentially in a certain part of the intestinal tract, optionally in a delayed manner. Examples of usable encapsulating agents include polymeric substances and waxes.
[0614] Dosage forms for topical and / or transdermal administration of the compositions described herein may include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants and / or patches. Typically, the disclosed compounds are mixed under sterile conditions with a pharmaceutically acceptable carrier or excipient and / or any desired preservatives and / or buffers as may be required.
[0615] Suitable devices for delivering intradermal compositions as herein described include short needle devices. Intradermal compositions can be applied by limiting the device of the length of the needle effectively penetrating into the skin. Alternatively or additionally, conventional syringes can be used in the classic Mantoux method of intradermal administration. It is suitable to deliver liquid formulations to the jet injection device of the dermis by a liquid jet injector and / or by puncturing the stratum corneum and producing a jet that arrives at the dermis. It is suitable to use compressed gas to accelerate the ballistic powder / particle delivery device that the polymer present in powder form passes through the outer layer of the skin and arrives at the dermis.
[0616] Preparations suitable for topical administration include liquid and / or semi-liquid preparations such as liniments, lotions, oil-in-water and / or water-in-oil emulsions such as creams, ointments and / or pastes, and / or solutions and / or suspensions. Topically administrable preparations may, for example, contain from about 1% to about 100% (w / w) of a compound of the disclosure, although the concentration of the compound of the disclosure may be as high as the solubility limit of the compound of the disclosure in the solvent. Preparations for topical administration may further comprise one or more additional ingredients as described herein.
[0617] Compositions as described herein can be suitable for preparation, packaging and / or sale in the form of preparations for pulmonary administration via the buccal cavity. Such preparations can include dry particles comprising compounds of the present disclosure. Such compositions are conveniently present in the form of dry powders for administration, and the dry powders are administered using a device comprising a dry powder reservoir that can direct the propellant to flow to disperse the powder and / or using a self-propelling solvent / powder dispersion container such as a device comprising a medicament dissolved and / or suspended in a low-boiling-point propellant in a sealed container. Dry powder compositions can include a solid fine powder diluent such as sugar and conveniently provided in unit dosage form.
[0618] Low-boiling-point propellants typically include liquid propellants having a boiling point below 65°F at atmospheric pressure. Typically, the propellant may comprise 50% to 99.9% (w / w) of the composition, and the disclosed compound may comprise 0.1% to 100% (w / w) of the composition. The propellant may further comprise additional ingredients, such as liquid nonionic and / or solid anionic surfactants and / or solid diluents.
[0619] The compositions described herein formulated for pulmonary delivery can provide the compounds of the present invention in the form of droplets of solutions and / or suspensions. Such formulations can be prepared, packaged, and / or sold as optionally sterile aqueous and / or dilute alcoholic solutions and / or suspensions comprising the compounds of the present invention and can be conveniently administered using any spray and / or atomizing device. Such formulations may further comprise one or more additional ingredients, including flavorings such as sodium saccharin, volatile oils, buffers, surfactants, and / or preservatives such as methyl hydroxybenzoate.
[0620] The formulations described herein that can be used for pulmonary delivery can be used for intranasal delivery of the pharmaceutical compositions described herein. Another formulation suitable for intranasal administration is a coarse powder comprising a compound of the present disclosure. Such formulations are administered by rapid inhalation through the nasal passages from a container containing the powder held close to the nose.
[0621] Formulations for nasal administration may, for example, contain as little as 0.1% (w / w) to as much as 100% (w / w) of a compound of the present disclosure, and may contain one or more additional ingredients as described herein. The pharmaceutical compositions described herein may be prepared, packaged, and / or sold in the form of formulations for buccal administration. Such formulations may, for example, be in the form of tablets and / or lozenges prepared using conventional methods, and may, for example, contain 0.1% to 20% (w / w) of the medicament, the remainder comprising an orally soluble and / or degradable composition and, optionally, one or more additional ingredients as described herein. Alternatively, formulations for buccal administration may comprise a powder and / or an aerosolized and / or atomized solution and / or suspension containing a compound of the present disclosure.
[0622] The compositions described herein can be prepared, packaged, and / or sold in the form of formulations for ophthalmic administration. Such formulations may be present, for example, in the form of eye drops, including, for example, 0.1%-100% (w / w) solutions and / or suspensions of the disclosed compounds in aqueous or oily liquid carriers or excipients. Such drops may also contain a buffer, salts, and / or one or more additional ingredients described herein. Other useful ophthalmically administrable formulations include those containing the disclosed compounds in microcrystalline form and / or in the form of liposomal formulations. Ear drops and / or eye drops are also encompassed within the scope of the present disclosure.
[0623] Although the descriptions of the compositions provided herein relate primarily to compositions suitable for administration to humans, those skilled in the art will understand that such compositions are generally suitable for administration to animals of all kinds. Modifications of compositions suitable for administration to humans to make the compositions suitable for administration to various animals are well known, and the ordinary veterinary pharmacologist can design and / or perform such modifications through ordinary experimentation.
[0624] The compositions provided herein are generally formulated in dosage unit form for ease of administration and uniformity of dosage. However, it will be understood that the total daily dosage of the compositions described herein will be determined by a physician within the scope of sound medical judgment. The specific therapeutically effective dosage level for any particular subject or organism will depend on a variety of factors, including the cancer being treated and the severity of the cancer; the activity of the specific disclosed compound employed; the specific composition employed; the age, weight, general health, sex, and diet of the subject; the time of administration, route of administration, and excretion rate of the specific disclosed compound employed; the duration of treatment; drugs used in combination or concurrently with the specific disclosed compound employed; and similar factors well known in the medical field.
[0625] The compositions provided herein can be administered by any route, including enteral (e.g., oral), parenteral, intravenous, intramuscular, intraarterial, intramedullary, intrathecal, subcutaneous, intraventricular, transdermal, intradermal, rectal, intravaginal, intraperitoneal, topical (e.g., by powders, ointments, creams, and / or drops), mucosal, nasal, buccal, sublingual; by intratracheal instillation, bronchial instillation, and / or inhalation; and / or as oral sprays, nasal sprays, and / or aerosols. Specifically, the intended route is oral administration, intravenous administration (e.g., systemic intravenous injection), topical administration via blood and / or lymphatic supply, and / or direct administration to the affected site. In general, the most suitable route of administration will depend on a variety of factors, including the properties of the disclosed compounds (e.g., their stability in the gastrointestinal environment) and / or the condition of the subject (e.g., whether the subject can tolerate oral administration). In certain embodiments, compositions as described herein are suitable for topical administration to the eyes of the subject.
[0626] In some embodiments, administration of any of the compositions described herein occurs at least one hour prior to treatment with another cancer therapy.
[0627] The composition can be administered in combination with another agent that improves their activity (e.g., efficacy and / or efficacy), improves bioavailability, improves safety, reduces drug resistance, reduces and / or alters metabolism, inhibits excretion, and / or alters distribution in a subject or cell in treating a disease or disorder (e.g., cancer) in a subject in need thereof and / or in inhibiting a signaling pathway in a subject or cell. It will also be understood that the therapy employed may achieve the desired effect for the same condition, and / or it may achieve different effects. In certain embodiments, the compositions described herein (including the compounds of the present disclosure as described herein) and agents exhibit synergistic effects that are not present in compositions comprising one, but not both, of the compounds or agents of the present disclosure.
[0628] The composition can be used simultaneously with one or more other medicaments, before or after one or more other medicaments, which are different from the composition and can be used as, for example, a combination therapy. Each other pharmaceutical agent can be used at a dosage and / or timetable determined for this pharmaceutical agent. Other pharmaceutical agents can also be used in a single dose or separately at different doses, together with each other and / or with the compounds of the present disclosure or the compositions described herein. The specific combination used in the scheme will take into account the compatibility of the compounds of the present disclosure described herein with the other pharmaceutical agents and / or the desired treatment and / or preventive effect to be achieved. In general, it is expected that the other pharmaceutical agents of the combination will be used at a level not exceeding that of their individual use. In some embodiments, the level of the combined use will be lower than those used alone.
[0629] Additional pharmaceutical agents include antiproliferative agents, anticancer agents, cytotoxic agents, antiangiogenic agents, anti-inflammatory agents, immunosuppressants, antibacterial agents, antiviral agents, cardiovascular agents, cholesterol-lowering agents, antidiabetic agents, antiallergic agents, contraceptives, and analgesics. In certain embodiments, the additional pharmaceutical agent is an antiproliferative agent. In certain embodiments, the additional pharmaceutical agent is an anticancer agent. In certain embodiments, the additional pharmaceutical agent is a chemotherapeutic agent. In certain embodiments, the additional pharmaceutical agent is an antiviral agent. In certain embodiments, the additional pharmaceutical agent is a protein kinase binder or inhibitor. In certain embodiments, the additional pharmaceutical agent is selected from the group consisting of: epigenetic or transcriptional regulators (e.g., DNA methyltransferase inhibitors, histone deacetylase inhibitors (HDAC inhibitors), lysine methyltransferase inhibitors), antimitotic drugs (e.g., taxanes and vinca alkaloids), hormone receptor modulators (e.g., estrogen receptor modulators and androgen receptor modulators), cell signaling pathway inhibitors (e.g., tyrosine protein kinase inhibitors), protein stability regulators (e.g., proteasome inhibitors), Hsp90 inhibitors, glucocorticoids, all-trans retinoic acid, and other agents that promote differentiation. In certain embodiments, the compounds or pharmaceutical compositions of the present disclosure described herein can be administered in combination with anti-cancer therapies, including surgery, radiotherapy, transplantation (e.g., stem cell transplantation, bone marrow transplantation), immunotherapy, and chemotherapy. In some embodiments, one or more additional agents, such as one or more additional cancer therapies, are administered to the subject simultaneously, before, or after. In some embodiments, one or more additional cancer therapies include immunotherapy. In general, immunotherapy (also known as biological therapy) is a cancer treatment that strengthens the subject's natural defenses to treat cancer. In certain embodiments, immunotherapy utilizes a compound biologically produced by the subject. In certain embodiments, immunotherapy utilizes a compound not biologically produced by the subject. In certain embodiments, immunotherapy utilizes cells from the subject. In certain embodiments, immunotherapy utilizes cells not from the subject. In certain embodiments, immunotherapy utilizes a compound biologically produced by an organism that is not the subject. In certain embodiments, immunotherapy utilizes cells biologically produced by an organism that is not the subject. In certain embodiments, immunotherapy includes at least one chemical modification of a compound or cell from the subject. In certain embodiments, immunotherapy includes at least one chemical modification of a compound or cell not from the subject.
[0630] In some embodiments, immunotherapy can include one or more of the following steps: preventing or inhibiting the growth of cancer cells; preventing the spread of cancer to other parts of the body; and increasing the ability and activity of the immune system to kill cancer cells. Non-limiting examples of immunotherapy include: monoclonal antibodies, checkpoint inhibitors, nonspecific immunotherapy, oncolytic virus therapy, T cell therapy, and cancer vaccines.
[0631] In certain embodiments, immunotherapy utilizes monoclonal antibodies. In some embodiments, monoclonal antibodies target (bind to) and / or block abnormal proteins on cancer cells.
[0632] In certain embodiments, immunotherapy utilizes checkpoint inhibitors. In certain embodiments, immune checkpoint inhibitors are monoclonal antibodies. Immune checkpoints are regulators of immune activation that maintain immune homeostasis and prevent autoimmunity. In cancer cells, the immune checkpoint mechanism is typically activated to suppress the nascent anti-cancer immune response. In some embodiments, checkpoint inhibitors are inhibitors of PD-1 (programmed cell death protein 1). In some embodiments, checkpoint inhibitors are inhibitors of PD-L1 (programmed death ligand 1). In some embodiments, checkpoint inhibitors are inhibitors of CTLA-4 (cytotoxic T lymphocyte-associated protein 4). Examples of immune checkpoint inhibitors include, but are not limited to, ipilimumab (Yervoy), nivolumab (Opdivo), pembrolizumab (Keytruda), atezolizumab (Tecentriq), avelumab (Bavencio), and durvalumab (Imfinzi).
[0633] In certain embodiments, the immunotherapy is a nonspecific immunotherapy (eg, interferon or interleukin). In certain embodiments, the immunotherapy is an oncolytic virus therapy.
[0634] In certain embodiments, the immunotherapy is T cell therapy. In some embodiments, the T cell therapy is chimeric antigen receptor (CAR) T cell therapy.
[0635] In certain embodiments, the immunotherapy is an anti-cancer vaccine.
[0636] Anticancer agents include biotherapeutic anticancer agents and chemotherapeutic agents. Exemplary biotherapeutic anticancer agents include, but are not limited to, interferons, cytokines (e.g., tumor necrosis factor, interferon alpha, interferon gamma), vaccines, hematopoietic growth factors, monoclonal serum therapy, immunostimulants and / or immunomodulators (e.g., IL-1, 2, 4, 6, or 12), immune cell growth factors (e.g., GM-CSF), and antibodies (e.g., Herceptin (trastuzumab), T-DM1, AVASTIN (bevacizumab), ERBITUX (cetuximab), Vectibix (panitumumab), Rituxan (rituximab), Bexxar (tositumomab)). Exemplary chemotherapeutic agents include, but are not limited to, antiestrogens (e.g., tamoxifen, raloxifene, and megestrol acetate), LHRH agonists (e.g., goserelin and leuprolide), antiandrogens (e.g., flutamide and bicalutamide), photodynamic therapy (e.g., vertoporfin (BPD-MA), phthalocyanine, photosensitizer Pc4, and demethoxy-hypocrellin (2BA-2-DMHA)), nitrogen mustards (e.g., cyclophosphamide, ifosfamide, trofosfamide, chlorambucil, estramustine, and melphalan), nitrosoureas (e.g., Such as carmustine (BCNU) and lomustine (CCNU)), alkyl sulfonates (such as busulfan and treoxazole), triazenes (such as dacarbazine, temozolomide), platinum-containing compounds (such as cisplatin, carboplatin, oxaliplatin), vinca alkaloids (such as vincristine, vinblastine, vindesine and vinorelbine), taxanes (such as paclitaxel or paclitaxel equivalents) docosahexaenoic acid-bound paclitaxel (DHA-paclitaxel, Taxoprexin), polyglutamate-bound paclitaxel (PG-paclitaxel, polyglutamic acid paclitaxel) poliglumex), CT-2103, XYOTAX), tumor-activated prodrugs (TAPs) ANG1005 (Angiopep-2 conjugated to three molecules of paclitaxel), paclitaxel-EC-1 (paclitaxel conjugated to the erbB2 recognition peptide EC-1), and glucose-conjugated paclitaxel, such as 2′-paclitaxel methyl 2-glucopyranosyl succinate;docetaxel, taxol), epipodophyllins (e.g., etoposide, etoposide phosphate, teniposide, topotecan, 9-aminocamptothecin, camptoirinotecan, irinotecan, crestofol, mytomycin C), antimetabolites, DHFR inhibitors (e.g., methotrexate, dichloromethotrexate, trimetrexate, edatrexate), IMP dehydrogenase inhibitors (e.g., mycophenolic acid, tiazofurin, ribavirin, and EICAR), ribonucleotide reductase inhibitors (e.g., hydroxyurea and deferoxamine), uracil analogs (e.g., 5-fluorouracil (5-FU), floxuridine, doxifluridine, ratitrexed, tegafur, capecitabine), cytosine analogs (e.g., cytarabine), C), cytarabine and fludarabine), purine analogs (e.g., mercaptopurine and thioguanine), vitamin D3 analogs (e.g., EB 1089, CB 1093, and KH 1060), prenylation inhibitors (e.g., lovastatin), dopaminergic neurotoxins (e.g., 1-methyl-4-phenylpyridinium salt), cell cycle inhibitors (e.g., staurosporine), actinomycins (e.g., actinomycin D, dactinomycin), bleomycins (e.g., bleomycin A2, bleomycin B2, peplomycin), anthracyclines (e.g., daunorubicin, doxorubicin, pegylated liposomal doxorubicin, idarubicin, epirubicin, pirarubicin, levorubicin, mitoxantrone), MDR inhibitors (e.g., verapamil), Ca; 2+ ATPase inhibitors (e.g., thapsigargin), imatinib, thalidomide, lenalidomide, tyrosine kinase inhibitors (e.g., axitinib (AG013736), bosutinib (SKI-606), cediranib (RECENTIN TM , AZD2171), dasatinib ( BMS-354825), erlotinib Gefitinib Imatinib ( CGP57148B, STI-571), lapatinib CEP-701, Neratinib (HKI-272), Nilotinib Semaxinib (SU5416), sunitinib ( SU11248), toceranib ( )、Vandetanib( ZD6474), vatalanib (PTK787, PTK / ZK), trastuzumab Bevacizumab Rituximab Cetuximab Panitumumab Ranibizumab Nilotinib Sorafenib Everolimus Alemtuzumab Gemtuzumab ozogamicin temsirolimus ENMD-2076, PCI-32765, AC220, dovitinib lactate (TKI258, CHIR-258), BIBW 2992 (TOVOK TM ), SGX523, PF-04217903, PF-02341066, PF-299804, BMS-777607, ABT-869, MP470, BIBF 1120 AP24534, JNJ-26483327, MGCD265, DCC-2036, BMS-690154, CEP-11981, tivozanib (AV-951), OSI-930, MM-121, XL-184, XL-647 and / or XL228), proteasome inhibitors (e.g., bortezomib (Velcade)), mTOR inhibitors (e.g., rapamycin, temsirolimus (CCI-779), everolimus (RAD-001), ridaforolimus), AP23573 (Ariad), AZD8055 (AstraZeneca), BEZ235 (Novartis), BGT226 (Norvartis), XL765 (Sanofi
[0015] The following are examples of the drugs listed in Table 1: Aventis), PF-4691502 (Pfizer), GDC0980 (Genetech), SF1126 (Semafoe), and OSI-027 (OSI), oblimersen, gemcitabine, carminomycin, leucovorin, pemetrexed, cyclophosphamide, dacarbazine, procarbizine, prednisolone, dexamethasone, campathecin, plicamycin, asparaginase, aminopterin, methylfolate, methylmitomycin, melphalan, isovinblastine, vinblastine cyclooxygenase, chlorambucil, trabectedin, procarbazine, discodermolide, carminomycin, aminopterin, and altretamine.
[0637] In some embodiments, the composition is substantially soluble in water (e.g., hydrophilic). In some embodiments, the composition is substantially insoluble in water (e.g., hydrophobic). In some embodiments, the composition is substantially insoluble in water and requires greater than about 10,000 parts of water to dissolve 1 part of a compound of the present disclosure.
[0638] In some embodiments, the percentage of the composition comprising the compounds of the present disclosure is from about 1 to about 100% (e.g., about 1%, about 2%, about 3%, about 4%, about 5%, about 10%, about 15%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, or about 100%). In some embodiments, the percentage of the composition comprising the compounds of the present disclosure is less than about 50%, for example, less than about 40%, less than about 35%, less than about 30%, less than about 25%, less than about 20%, less than about 15%, or less than about 10%. In some embodiments, the percentage of the composition comprising the compounds of the present disclosure is from about 5% to about 50%, from about 5% to about 40%, from about 5% to about 30%, from about 5% to about 25%, or from about 5% to about 20%. In some embodiments, the percentage of the composition comprising the compounds of the present disclosure is from about 5% to 90%. In some embodiments, the percentage of the composition comprising a compound of the present disclosure is from about 5% to about 75%. In some embodiments, the percentage of the composition comprising a compound of the present disclosure is from about 5% to about 50%. In some embodiments, the percentage of the composition comprising a compound of the present disclosure is from about 10% to about 25%.
[0639] In some embodiments, the total amount of Compounds of the Disclosure present in the composition is greater than about 1% (e.g., about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 12%, about 15%, about 20%, about 25%, about 30%, or more) of the total size or weight of the composition. In some embodiments, the total amount of Compounds of the Disclosure present in the composition is greater than about 10% (e.g., about 12%, about 15%, about 20%, about 25%, about 30%, or more) of the total size or weight of the composition.
[0640] Without wishing to be bound by theory, the compositions disclosed herein may enhance the efficacy of the disclosed compounds by increasing one or more of their localization and / or release (e.g., preferential release) to target cells (e.g., cancer or fibrotic cells; cells associated with a hypoxic environment), or increasing the half-life of the disclosed compounds, thereby resulting in significantly higher amounts of released disclosed compounds at the target site (e.g., tumor or liver (e.g., cirrhotic cells). Thus, the compositions disclosed herein may be more therapeutically effective than the free compounds (e.g., due to enhanced drug absorption in the target tissue) and / or allow for lower therapeutic doses of the disclosed compounds, e.g., without substantially compromising the resulting drug concentration at the target tissue. In some embodiments, the compositions disclosed herein may reduce side effects associated with systemic administration of the free form of the compounds.
[0641] In some embodiments, the compounds of the present disclosure are incorporated into compositions at a dose that is less than the dose or amount of the compound in free form to have a desired effect (e.g., a desired therapeutic effect). In certain embodiments, the compositions increase the amount of the compounds of the present disclosure delivered to tissues or cells in need thereof and reduce the amount of the compounds of the present disclosure exposed to non-target tissues or cells compared to the free compound.
[0642] In another aspect, kits are provided that include a compound of the disclosure; or a pharmaceutical composition described herein; and instructions for using the compound of the disclosure or pharmaceutical composition.
[0643] In certain embodiments, the instructions for use in the kit may further include information required by regulatory agencies such as the U.S. Food and Drug Administration (FDA). In certain embodiments, the information included in the kit is prescription information. In certain embodiments, the kit and instructions are used to deliver the disclosed compounds. In certain embodiments, the kit and instructions are used to deliver compositions. In certain embodiments, the kit and instructions are used to treat cancer in subjects in need thereof. In certain embodiments, the kit and instructions are used to inhibit signal transduction pathways in subjects or cells.
[0644] Treatment and prevention methods and uses
[0645] Some aspects of the present invention relate to methods, uses, compositions and kits for administering to a subject in need thereof. In some embodiments, the subject is a subject suffering from, suspected of suffering from, or having a risk of developing a disease or disorder (e.g., cancer). As used herein, "subject," "individual," and "patient" can be used interchangeably. In some embodiments, the subject is a mammalian subject, including but not limited to dogs, cats, horses, cows, pigs, sheep, goats, chickens, rodents, or primates. In some embodiments, the subject is a human subject, such as a patient. The human subject can be a pediatric or adult subject.
[0646] As used herein, "treating" includes ameliorating, curing, preventing worsening, slowing the rate of progression, preventing a disorder from reoccurring (i.e., preventing recurrence), or preventing or slowing the rate of metastasis. An effective amount of a composition refers to the amount of the composition that results in a therapeutic effect. For example, in a method or use for treating cancer in a subject, an effective amount of a chemotherapeutic agent is any amount that provides an anti-cancer effect, such as reducing or preventing cancer cell proliferation or being cytotoxic to cancer cells.
[0647] The methods and uses disclosed herein involve administering an effective amount of any compound of the present disclosure or a composition described herein to a subject suffering from a proliferative disease. In some embodiments, the proliferative disease is cancer. In some embodiments, the proliferative disease is a benign tumor.
[0648] The methods and uses disclosed herein involve administering an effective amount of any compound of the present disclosure or a composition as described herein to a subject suffering from cancer or at risk of developing cancer. In some embodiments, the cancer is characterized by the presence of cancer stem cells. In some embodiments, the cancer comprises, involves, or is associated with stem cells. In some embodiments, the subject has been or is receiving cancer therapy (e.g., chemotherapy, immunotherapy, surgery, radiation). Whether a subject is considered to be "at risk" for a disease or disorder such as cancer can be determined by a skilled practitioner.
[0649] In certain embodiments, the cancer is colorectal cancer. Colorectal cancer is cancer that begins in the colon or rectum. Depending on where the cancer develops, these cancers may also be referred to as colon cancer or rectal cancer. Colon and rectal cancers are often grouped together due to several common features. Most colorectal cancers begin as growths on the lining of the colon or rectum. The Colorectal Cancer (CRC) Typing Consortium unified six independent molecular classification systems into a single consensus system with four distinct groups, called consensus molecular subtypes (CMS), based on gene expression data. The CMSs were identified and associated with epigenomic, transcriptomic, microenvironmental, genetic, prognostic, and clinical characteristics. The CMS1 subtype is immunogenic and hypermutable. CMS2 tumors have activated the WNT-β-catenin pathway and are generally associated with higher overall survival. CMS3 is characterized by a metabolic cancer phenotype. CMS4 cancers are associated with the lowest survival and have a strong mesenchymal gene signature. Molecular subtypes CMS2 and CMS4 exhibit the highest levels of embryonic signaling. 11
[0650] In certain embodiments, the cancer is gastric cancer. Gastric cancer is a cancer that begins in the stomach. Gastric cancer tends to develop slowly over many years. Before true cancer occurs, precancerous changes usually occur in the lining (mucosa) of the stomach. These early changes rarely cause symptoms and are therefore often undetected. The types of gastric cancer include adenocarcinoma, lymphoma, gastrointestinal stromal tumor (GIST), carcinoid tumor, squamous cell carcinoma, small cell carcinoma and leiomyosarcoma. The Cancer Genome Atlas (TCGA) project recently discovered four molecular subtypes of gastric cancer: Epstein-Barr virus (EBV), microsatellite instability (MSI), genomic stability (GS) and chromosomal instability (CIN). GS (genomic stability) and CIN (chromosomal instability) molecular subtypes show the highest levels of embryonic signaling, as measured by a comprehensive analysis of gene expression patterns in gastric cancer subtypes. 12,13
[0651] In certain embodiments, other therapy has been applied to the subject.In certain embodiments, further apply (co-administered) other therapy (for example, before, while and / or after applying compound as described herein or composition).Other therapy is different from compound as described herein or composition.In certain embodiments, compared with co-administered (for example, before, while and / or after) with compound as described herein or composition in method or purposes described herein, independent other therapy is invalid or effectiveness is lower.
[0652] The exact amount of a compound of the disclosure required to achieve an effective amount will vary from subject to subject depending on, for example, the species, age, and general condition of the subject, the severity of side effects or symptoms, the identity of the specific compound of the disclosure, the mode of administration, and the like.
[0653] An effective amount can be included in a single dose (e.g., a single oral dose) or multiple doses (e.g., multiple oral doses). In certain embodiments, when multiple doses are administered to a subject or applied to a tissue or cell, any two doses in the multiple doses contain different or substantially the same amount of an agent as described herein.
[0654] In certain embodiments, when multiple doses are administered to a subject or applied to a tissue or cell, the frequency of multiple doses administered to a subject or applied to a tissue or cell is three doses a day, two doses a day, one dose a day, one dose every other day, one dose every three days, one dose a week, one dose every two weeks, one dose every three weeks, or one dose every four weeks or longer. In certain embodiments, when multiple doses are administered to a subject or applied to a tissue or cell, the duration between the first dose of multiple doses and the last dose is one day, two days, four days, one week, two weeks, three weeks, one month, two months, three months, four months, six months, nine months, one year, two years, three years, four years, five years, seven years, ten years, fifteen years, twenty years or the life span of a subject, a tissue or cell. In certain embodiments, the duration between the first dose of multiple doses and the last dose is three months, six months or one year. In certain embodiments, the duration between the first dose of multiple doses and the last dose is the life span of a subject, a tissue or cell.
[0655] Any of the compositions described herein can be administered in a therapeutically effective amount. In some embodiments, the methods and uses involve administering a composition comprising any of the compounds described herein to achieve a desired amount (e.g., a therapeutically effective amount) of the compound at a specific site in a subject. In some embodiments, the methods and uses involve administering a composition comprising any of the compounds described herein to achieve a desired amount (e.g., a therapeutically effective amount) of the compound at a tumor site in a subject.
[0656] Dosage may be adjusted appropriately to achieve desired local levels of the compound.
[0657] "Dose" and "dosage" are used interchangeably herein. In some embodiments, the amount of the compound administered to the subject is about 0.1 μg to 1 μg, 0.001 mg to 0.01 mg, 0.01 mg to 0.1 mg, 0.1 mg to 1 mg, 1 mg to 3 mg, 3 mg to 10 mg, 10 mg to 30 mg, 30 mg to 100 mg, 100 mg to 300 mg, 300 mg to 1,000 mg, or 1 g to 10 g (inclusive) of a compound of the disclosure as described herein. In certain embodiments, the doses described herein independently include 1 mg to 3 mg (inclusive) of a compound of the disclosure as described herein. In certain embodiments, the doses described herein independently include 3 mg to 10 mg (inclusive) of a compound of the disclosure as described herein. In certain embodiments, the doses described herein independently include 10 mg to 30 mg (inclusive) of a compound of the disclosure as described herein. In certain embodiments, the dosages described herein independently comprise 30 mg to 100 mg (inclusive) of a compound of the disclosure described herein.
[0658] In some embodiments, an initial dose of any of the compositions described herein is administered to a subject, followed by one or more additional doses of any of the compositions described herein. In some embodiments, the initial dose may comprise a different amount of any of the compounds described herein than one or more additional doses. In some embodiments, the initial dose is a higher dose (e.g., comprises more of any of the compounds described herein) than one or more additional doses.
[0659] The dosage ranges described herein provide guidance for administering the provided compositions to adults. For example, the amount administered to a child or adolescent can be determined by a medical practitioner or person skilled in the art and can be lower than or the same as that administered to an adult. In certain embodiments, the dosages described herein are for an adult weighing 70 kg.
[0660] For example, the efficacy of treating cancer can be measured by determining the growth, replication, proliferation, metastasis and / or gene expression profile of one or more cancer cells.Thus, an effective amount is an amount that a clinician considers to be toxicologically tolerable but effective.
[0661] Without being bound by a particular theory, it is believed that the compounds disclosed herein induce differentiation of embryonic cells and / or cells showing embryonic cell characteristics. In some embodiments, methods disclosed herein and uses relate to administering an effective amount of any compositions described herein to a subject in need of regenerative medicine or regenerative therapy. In some embodiments, the subject needs to recover or improve one or more biological functions of dysfunctional or damaged cells, tissues and / or organs. In some embodiments, the subject needs tissue engineering and organ regeneration. In some embodiments, the compositions described herein regenerate or differentiate cells, tissues and / or organs that may be damaged. In some embodiments, the subject has experienced brain damage (for example, damage or damage to brain tissue or cells) and / or damage to the central nervous system (for example, damage or damage to the tissue or cells of the central nervous system) and needs to repair the tissue or cell. In some embodiments, the subject has experienced cardiac damage (for example, damage or damage to cardiac tissue or cells), and needs to repair the tissue or cell.
[0662] In some embodiments, administration of any of the compositions described herein is by oral administration, intravenous administration (e.g., systemic intravenous injection), parenteral administration, subcutaneous administration, intramuscular administration, mucosal administration, transdermal administration, intradermal administration, intravaginal administration, intraperitoneal administration, topical administration, nasal administration, buccal administration, sublingual administration; administration via the intratracheal area supplied by the blood and / or lymph, and / or direct administration to the affected area.
[0663] The present disclosure provides a method for treating cancer, comprising administering to a subject a therapeutically effective amount of a compound of formula (0):
[0664]
[0665] or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, cocrystal, tautomer, stereoisomer, isotopically labeled derivative or prodrug thereof, wherein:
[0666] L A -N(R 2 )(L 1 R 1 ) or -C(=O)NR 1 R 2 ;
[0667] L 1 is a single bond or -C(=O)-;
[0668] When L 1 When it is a single bond, R 1 is hydrogen, substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 2-6Alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted 3- to 13-membered monocyclic or bicyclic carbocyclyl, substituted or unsubstituted 3- to 13-membered monocyclic or bicyclic heterocyclyl, or substituted or unsubstituted 5- to 11-membered monocyclic or bicyclic heteroaryl;
[0669] When L 1 When it is -C(=O)-, R 1 is substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 2-6 Alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted 3- to 13-membered monocyclic or bicyclic carbocyclyl, substituted or unsubstituted 3- to 13-membered monocyclic or bicyclic heterocyclyl, substituted or unsubstituted 6- to 11-membered monocyclic or bicyclic aryl, or substituted or unsubstituted 5- to 11-membered monocyclic or bicyclic heteroaryl;
[0670] R 2 is hydrogen, substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 2-6 Alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted 3- to 13-membered monocyclic or bicyclic carbocyclyl, substituted or unsubstituted 3- to 13-membered monocyclic or bicyclic heterocyclyl, substituted or unsubstituted 5- to 11-membered monocyclic or bicyclic heteroaryl, or a nitrogen protecting group;
[0671] R 3 is hydrogen, halogen, substituted or unsubstituted C 1-6 Alkyl, -OR a 、-N(R a )2 or -CN;
[0672] R a Each instance of is independently hydrogen, substituted or unsubstituted C 1-6 Alkyl, oxygen protecting group when attached to oxygen atom or nitrogen protecting group when attached to nitrogen atom;
[0673] or R 2 and R 3 are linked to their intervening atoms to form a substituted or unsubstituted 5-membered or 6-membered monocyclic heterocyclic or heteroaryl group;
[0674] q is 0 or 1;
[0675] Each instance of Y is independently N or CR 4 ;
[0676] R 4 Each instance of is independently hydrogen, halogen, substituted or unsubstituted C 1-6 Alkyl, -OR a、-N(R a )2 or -CN;
[0677] is phenyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, imidazolyl, oxazolyl, thiazolyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, azetidinyl, -C≡C- or
[0678] when When it is phenyl, pyridyl, pyridazinyl, pyrimidinyl or pyrazinyl, bond b and bond c are in meta or para position relative to each other;
[0679] R 5 Each instance of is independently hydrogen, halogen, substituted or unsubstituted C 1-6 Alkyl, -OR a 、-N(R a )2 or -CN;
[0680] Where valence permits, n is 0, 1, 2, 3 or 4, wherein when n is 1, 2, 3 or 4, there is no R 5 When connected to nitrogen atoms;
[0681] L B -N(R 6 )L 2 -or-L 2 N(R 6 )-;
[0682] L 2 -C(=O)-, or -S(=O)2-;
[0683] Each R 6 are independently hydrogen, substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 2-6 Alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted 3- to 13-membered monocyclic or bicyclic carbocyclyl, substituted or unsubstituted 3- to 13-membered monocyclic or bicyclic heterocyclyl, substituted or unsubstituted 6- to 11-membered monocyclic or bicyclic aryl, substituted or unsubstituted 5- to 11-membered monocyclic or bicyclic heteroaryl, or a nitrogen protecting group;
[0684] s is 0 or 1;
[0685] R 7 is a substituted or unsubstituted 3- to 7-membered monocyclic carbocyclyl, a substituted or unsubstituted 3- to 7-membered monocyclic heterocyclyl, a substituted or unsubstituted phenyl, or a substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl; and
[0686] R 8Each instance of is independently hydrogen, halogen, substituted or unsubstituted C 1-6 Alkyl, -OR a 、-N(R a )2 or -CN.
[0687] In certain aspects, the present disclosure further provides methods for treating cancer, comprising administering to a subject a therapeutically effective amount of a compound of formula (0'):
[0688]
[0689] or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, cocrystal, tautomer, stereoisomer, isotopically labeled derivative or prodrug thereof, wherein:
[0690] L 1 is a single bond or -C(=O)-;
[0691] When L 1 When it is a single bond, R 1 is hydrogen, substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 2-6 Alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted 3- to 13-membered monocyclic or bicyclic carbocyclyl, substituted or unsubstituted 3- to 13-membered monocyclic or bicyclic heterocyclyl, or substituted or unsubstituted 5- to 11-membered monocyclic or bicyclic heteroaryl;
[0692] When L 1 When it is -C(=O)-, R 1 is substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 2-6 Alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted 3- to 13-membered monocyclic or bicyclic carbocyclyl, substituted or unsubstituted 3- to 13-membered monocyclic or bicyclic heterocyclyl, substituted or unsubstituted 6- to 11-membered monocyclic or bicyclic aryl, or substituted or unsubstituted 5- to 11-membered monocyclic or bicyclic heteroaryl;
[0693] R 2 is hydrogen, substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 2-6 Alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted 3- to 13-membered monocyclic or bicyclic carbocyclyl, substituted or unsubstituted 3- to 13-membered monocyclic or bicyclic heterocyclyl, substituted or unsubstituted 5- to 11-membered monocyclic or bicyclic heteroaryl, or a nitrogen protecting group;
[0694] R 3is hydrogen, halogen, substituted or unsubstituted C 1-6 Alkyl, -OR a 、-N(R a )2 or -CN;
[0695] R a Each instance of is independently hydrogen, substituted or unsubstituted C 1-6 Alkyl, oxygen protecting group when attached to oxygen atom or nitrogen protecting group when attached to nitrogen atom;
[0696] or R 2 and R 3 are linked to their intervening atoms to form a substituted or unsubstituted 5-membered or 6-membered monocyclic heterocyclic or heteroaryl group;
[0697] q is 0 or 1;
[0698] Each instance of Y is independently N or CR 4 ;
[0699] R 4 Each instance of is independently hydrogen, halogen, substituted or unsubstituted C 1-6 Alkyl, -OR a 、-N(R a )2 or -CN;
[0700] is phenyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, imidazolyl, oxazolyl, thiazolyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, azetidinyl, -C≡C- or
[0701] when When it is phenyl, pyridyl, pyridazinyl, pyrimidinyl or pyrazinyl, bond b and bond c are in meta or para position relative to each other;
[0702] R 5 Each instance of is independently hydrogen, halogen, substituted or unsubstituted C 1-6 Alkyl, -OR a 、-N(R a )2 or -CN;
[0703] Where valence permits, n is 0, 1, 2, 3 or 4, wherein when n is 1, 2, 3 or 4, there is no R 5 When connected to nitrogen atoms;
[0704] L 2 -C(=O)-, or -S(=O)2-;
[0705] Each R 6 are independently hydrogen, substituted or unsubstituted C1-6 Alkyl, substituted or unsubstituted C 2-6 Alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted 3- to 13-membered monocyclic or bicyclic carbocyclyl, substituted or unsubstituted 3- to 13-membered monocyclic or bicyclic heterocyclyl, substituted or unsubstituted 6- to 11-membered monocyclic or bicyclic aryl, substituted or unsubstituted 5- to 11-membered monocyclic or bicyclic heteroaryl, or a nitrogen protecting group;
[0706] s is 0 or 1;
[0707] R 7 is a substituted or unsubstituted 3- to 7-membered monocyclic carbocyclyl, a substituted or unsubstituted 3- to 7-membered monocyclic heterocyclyl, a substituted or unsubstituted phenyl, or a substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl; and
[0708] R 8 Each instance of is independently hydrogen, halogen, substituted or unsubstituted C 1-6 Alkyl, -OR a 、-N(R a )2 or -CN.
[0709] The present disclosure also provides a method for treating cancer, comprising administering to a subject a therapeutically effective amount of a compound of formula (I):
[0710]
[0711] or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, cocrystal, tautomer, stereoisomer, isotopically labeled derivative or prodrug thereof, wherein:
[0712] L 1 is a single bond or -C(=O)-;
[0713] When L 1 When it is a single bond, R 1 is hydrogen, substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 2-6 Alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted 3- to 13-membered monocyclic or bicyclic carbocyclyl, substituted or unsubstituted 3- to 13-membered monocyclic or bicyclic heterocyclyl, or substituted or unsubstituted 5- to 11-membered monocyclic or bicyclic heteroaryl;
[0714] When L 1 When it is -C(=O)-, R 1 is substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 2-6 Alkenyl, substituted or unsubstituted C 2-6alkynyl, substituted or unsubstituted 3- to 13-membered monocyclic or bicyclic carbocyclyl, substituted or unsubstituted 3- to 13-membered monocyclic or bicyclic heterocyclyl, substituted or unsubstituted 6- to 11-membered monocyclic or bicyclic aryl, or substituted or unsubstituted 5- to 11-membered monocyclic or bicyclic heteroaryl;
[0715] R 2 is hydrogen, substituted or unsubstituted C 1-6 Alkyl or nitrogen protecting group;
[0716] R 3 is hydrogen, halogen, substituted or unsubstituted C 1-6 Alkyl, -OR a 、-N(R a )2 or -CN;
[0717] R a Each instance of is independently hydrogen, substituted or unsubstituted C 1-6 Alkyl, oxygen protecting group when attached to oxygen atom or nitrogen protecting group when attached to nitrogen atom;
[0718] or R 2 and R 3 are linked to their intervening atoms to form a substituted or unsubstituted 5-membered or 6-membered monocyclic heterocyclic or heteroaryl group;
[0719] Each instance of Y is independently N or CR 4 ;
[0720] R 4 Each instance of is independently hydrogen, halogen, substituted or unsubstituted C 1-6 Alkyl, -OR a 、-N(R a )2 or -CN;
[0721] is phenyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, imidazolyl, oxazolyl, azetidinyl, -C≡C- or
[0722] Bond b and bond c are in meta or para position relative to each other;
[0723] R 5 Each instance of is independently hydrogen, halogen, substituted or unsubstituted C 1-6 Alkyl, -OR a 、-N(R a )2 or -CN;
[0724] Where valence permits, n is 0, 1, 2, 3 or 4, wherein when n is 1, 2, 3 or 4, there is no R 5 When connected to nitrogen atoms;
[0725] L 2 is -C(=O)- or -S(=O)2-;
[0726] R 6 is hydrogen, substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 2-6 Alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted 3- to 13-membered monocyclic or bicyclic carbocyclyl, substituted or unsubstituted 3- to 13-membered monocyclic or bicyclic heterocyclyl, substituted or unsubstituted 6- to 11-membered monocyclic or bicyclic aryl, substituted or unsubstituted 5- to 11-membered monocyclic or bicyclic heteroaryl, or a nitrogen protecting group;
[0727] R 7 is a substituted or unsubstituted 3- to 7-membered monocyclic carbocyclyl, a substituted or unsubstituted 3- to 7-membered monocyclic heterocyclyl, a substituted or unsubstituted phenyl, or a substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl; and
[0728] R 8 Each instance of is independently hydrogen, halogen, substituted or unsubstituted C 1-6 Alkyl, -OR a 、-N(R a )2 or -CN.
[0729] In certain embodiments of the methods of treatment and prevention:
[0730] L 1 is a single bond or -C(=O)-;
[0731] When L 1 When it is a single bond, R 1 is hydrogen, substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 2-6 Alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted 3- to 13-membered monocyclic or bicyclic carbocyclyl, substituted or unsubstituted 3- to 13-membered monocyclic or bicyclic heterocyclyl, or substituted or unsubstituted 5- to 11-membered monocyclic or bicyclic heteroaryl;
[0732] When L 1 When it is -C(=O)-, R 1 is substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 2-6 Alkenyl, substituted or unsubstituted C 2-6alkynyl, substituted or unsubstituted 3- to 13-membered monocyclic or bicyclic carbocyclyl, substituted or unsubstituted 3- to 13-membered monocyclic or bicyclic heterocyclyl, substituted or unsubstituted 6- to 11-membered monocyclic or bicyclic aryl, or substituted or unsubstituted 5- to 11-membered monocyclic or bicyclic heteroaryl;
[0733] R 2 is hydrogen, substituted or unsubstituted C 1-6 Alkyl or nitrogen protecting group;
[0734] R 3 is hydrogen, halogen, substituted or unsubstituted C 1-6 Alkyl, -OR a 、-N(R a )2 or -CN;
[0735] R a Each instance of is independently hydrogen, substituted or unsubstituted C 1-6 Alkyl, oxygen protecting group when attached to oxygen atom or nitrogen protecting group when attached to nitrogen atom;
[0736] or R 2 and R 3 are linked to their intervening atoms to form a substituted or unsubstituted 5-membered or 6-membered monocyclic heterocyclic or heteroaryl group;
[0737] Each instance of Y is independently N or CR 4 ;
[0738] R 4 Each instance of is independently hydrogen, halogen, substituted or unsubstituted C 1-6 Alkyl, -OR a 、-N(R a )2 or -CN;
[0739] is phenyl, pyridyl, pyridazinyl, pyrimidinyl or pyrazinyl;
[0740] Bond b and bond c are in meta or para position relative to each other;
[0741] R 5 Each instance of is independently hydrogen, halogen, substituted or unsubstituted C 1-6 Alkyl, -OR a 、-N(R a )2 or -CN;
[0742] Where valence permits, n is 0, 1, 2, 3 or 4, wherein when n is 1, 2, 3 or 4, there is no R 5 When connected to nitrogen atoms;
[0743] L 2is -C(=O)- or -S(=O)2-;
[0744] R 6 is hydrogen, substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 2-6 Alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted 3- to 13-membered monocyclic or bicyclic carbocyclyl, substituted or unsubstituted 3- to 13-membered monocyclic or bicyclic heterocyclyl, substituted or unsubstituted 6- to 11-membered monocyclic or bicyclic aryl, substituted or unsubstituted 5- to 11-membered monocyclic or bicyclic heteroaryl, or a nitrogen protecting group;
[0745] R 7 is a substituted or unsubstituted 3- to 7-membered monocyclic carbocyclyl, a substituted or unsubstituted 3- to 7-membered monocyclic heterocyclyl, a substituted or unsubstituted phenyl, or a substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl; and
[0746] R 8 Each instance of is independently hydrogen, halogen, substituted or unsubstituted C 1-6 Alkyl, -OR a 、-N(R a )2 or -CN.
[0747] In certain aspects, the present disclosure provides a method of treating cancer, comprising administering to a subject a therapeutically effective amount of a compound of formula (I):
[0748]
[0749] or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, cocrystal, tautomer, stereoisomer, isotopically labeled derivative or prodrug thereof, wherein:
[0750] L 1 is a single bond or -C(=O)-;
[0751] When L 1 When it is a single bond, R 1 is hydrogen, substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 2-6 Alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted 3- to 13-membered monocyclic or bicyclic carbocyclyl, substituted or unsubstituted 3- to 13-membered monocyclic or bicyclic heterocyclyl, or substituted or unsubstituted 5- to 11-membered monocyclic or bicyclic heteroaryl;
[0752] When L 1 When it is -C(=O)-, R 1 is substituted or unsubstituted C 1-6Alkyl, substituted or unsubstituted C 2-6 Alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted 3- to 13-membered monocyclic or bicyclic carbocyclyl, substituted or unsubstituted 3- to 13-membered monocyclic or bicyclic heterocyclyl, substituted or unsubstituted 6- to 11-membered monocyclic or bicyclic aryl, or substituted or unsubstituted 5- to 11-membered monocyclic or bicyclic heteroaryl;
[0753] R 2 is hydrogen, substituted or unsubstituted C 1-6 Alkyl or nitrogen protecting group;
[0754] R 3 is hydrogen, halogen, substituted or unsubstituted C 1-6 Alkyl, -OR a 、-N(R a )2 or -CN;
[0755] R a Each instance of is independently hydrogen, substituted or unsubstituted C 1-6 Alkyl, oxygen protecting group when attached to oxygen atom or nitrogen protecting group when attached to nitrogen atom;
[0756] or R 2 and R 3 are linked to their intervening atoms to form a substituted or unsubstituted 5-membered or 6-membered monocyclic heterocyclic or heteroaryl group;
[0757] Each instance of Y is independently N or CR 4 ;
[0758] R 4 Each instance of is independently hydrogen, halogen, substituted or unsubstituted C 1-6 Alkyl, -OR a 、-N(R a )2 or -CN;
[0759] is phenyl, pyridyl, pyridazinyl, pyrimidinyl or pyrazinyl;
[0760] Bond b and bond c are in meta or para position relative to each other;
[0761] R 5 Each instance of is independently hydrogen, halogen, substituted or unsubstituted C 1-6 Alkyl, -OR a 、-N(R a )2 or -CN;
[0762] Where valence permits, n is 0, 1, 2, 3 or 4, wherein when n is 1, 2, 3 or 4, there is no R 5 When connected to nitrogen atoms;
[0763] L 2 is -C(=O)- or -S(=O)2-;
[0764] R 6 is hydrogen, substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 2-6 Alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted 3- to 13-membered monocyclic or bicyclic carbocyclyl, substituted or unsubstituted 3- to 13-membered monocyclic or bicyclic heterocyclyl, substituted or unsubstituted 6- to 11-membered monocyclic or bicyclic aryl, substituted or unsubstituted 5- to 11-membered monocyclic or bicyclic heteroaryl, or a nitrogen protecting group;
[0765] R 7 is a substituted or unsubstituted 3- to 7-membered monocyclic carbocyclyl, a substituted or unsubstituted 3- to 7-membered monocyclic heterocyclyl, a substituted or unsubstituted phenyl, or a substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl; and
[0766] R 8 Each instance of is independently hydrogen, halogen, substituted or unsubstituted C 1-6 Alkyl, -OR a 、-N(R a )2 or -CN.
[0767] In certain embodiments of the treatment and prevention methods and uses section, L 1 、R 1 、R 2 、R 3 、R a 、R 4 , Y, Key b and key c, R 5 、n、L 2 、R 6 、R 7 and R 8 As described in the Compounds section.
[0768] In certain embodiments of the treatment and prevention methods and uses section, when L 1 When it is a single bond, R 1 In certain embodiments of the treatment and prevention methods and uses section, when L 1 When it is -C(=O)-, R 1 C 1-6 In certain embodiments of the treatment and prevention methods and uses section, when L 1 When it is -C(=O)-, R 1 For unsubstituted C 1-6 Alkyl (eg, Me or Et).
[0769] In certain embodiments of the treatment and prevention methods and uses section, R 3 For hydrogen.
[0770] In certain embodiments of the treatment and prevention methods and uses section, R 2 and R 3 and their intervening atoms to form a substituted or unsubstituted 6-membered monocyclic heterocyclyl or heteroaryl. In certain embodiments of the treatment and prevention methods and uses section, R 2 and R 3 and their intervening atoms are connected to form an unsubstituted 6-membered monocyclic heterocyclyl. In certain embodiments of the treatment and prevention methods and uses section, for
[0771] In certain embodiments of the treatment and prevention methods and uses section, the compound of formula (I) has the formula or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, cocrystal, tautomer, stereoisomer, isotope-labeled derivative or prodrug thereof.
[0772] In certain embodiments of the treatment and prevention methods and uses section, the compound of formula (I) has the formula or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, cocrystal, tautomer, stereoisomer, isotope-labeled derivative or prodrug thereof.
[0773] Another method
[0774] The present disclosure also provides methods for contacting cells with an effective amount of a compound of the present disclosure. The present disclosure also provides uses for contacting cells with an effective amount of a compound of the present disclosure.
[0775] In some embodiments, any compound described herein is contacted with a cell in vivo, for example, in an organism. In some embodiments, any compound described herein is contacted with a cell in vitro, for example, in cell culture. In some embodiments, any compound described herein is contacted with a cell ex vivo, which means that the cell is removed from the organism before contact. It will be apparent to those skilled in the art that the term cell can be used to refer to a single cell as well as a cell population. In some embodiments, a cell population is contacted with any compound described herein to regenerate or differentiate one or more cells in a cell population. In some embodiments, a cell population is contacted with any compound described herein for individualized medication, for example, for diagnostic and / or therapeutic purposes.
[0776] Generally, any cell known in the art can be used for the methods and uses described herein. In some embodiments, the cell is a cell of a cell line. In some embodiments, the cell is obtained from an organism, such as a subject. In some embodiments, the cell is a cancer cell (e.g., a cancer stem cell). In some embodiments, the cell is a stem cell. In some embodiments, the cell is an embryonic stem cell. In some embodiments, the cell is an induced pluripotent stem cell. In some embodiments, the cell is a neural cell, such as a neural stem cell. In some embodiments, the cell is an adult stem cell, such as a gastric stem cell or an intestinal stem cell.
[0777] In some embodiments, the methods and uses also include inhibiting cell growth. In other embodiments, the methods and uses include killing cells. In some embodiments, the cells are stem cells. In some embodiments, the cells are selected from the group consisting of cancer stem cells, embryonic stem cells, induced pluripotent stem cells, neural stem cells, or adult stem cells. In certain embodiments, the cells are cancer stem cells. In certain embodiments, the cells are embryonic stem cells. In certain embodiments, the present disclosure provides methods and uses for inhibiting cell growth and / or killing cells using an effective amount of a compound of the present disclosure. In certain aspects, inhibiting cell growth and / or killing cells can be used to treat proliferative diseases including cancer.
[0778] In some embodiments, described method and purposes also comprise the level of one or more embryo characteristics of measurement or assessment cell.In some embodiments, after making cell contact with any compositions as herein described, the level of one or more embryo characteristics of assessment cell.In some embodiments, the level of one or more embryo characteristics after cell is contacted with any compositions as herein described and in reference sample or the level of one or more embryo characteristics before cell is contacted with compositions is compared.In some embodiments, making the contact of cell with any compositions as herein described reduce one or more embryo characteristics of cell.In some respects, described method and purposes can be used for determining whether cell is sensitive to the treatment with compositions as herein described.In some embodiments, if after making cell contact with any compositions as herein described, reduced the level of one or more embryo characteristics, then determine that this cell is sensitive to the treatment with said compositions.In some embodiments, if after making cell contact with any compositions as herein described, reduced the level of one or more embryo characteristics, then determine that said composition is the material standed for the disease relevant to cell or obstacle.
[0779] In some embodiments, the methods and purposes described herein can be used for regenerative medicine. In some embodiments, cell is contacted with any compositions as described herein to promote differentiation and / or loss of one or more embryonic characteristics of cell. In some embodiments, cell is contacted with any compositions as described herein to promote the regenerative ability of cell. In some embodiments, the regenerative ability of cell is enhanced by contacting any compositions as described herein. In some embodiments, cell is contacted with any compositions as described herein to enhance the regenerative ability of cell. In some embodiments, cell is regenerated by contacting any compositions as described herein with a cell group, such as a tissue or an organ. In some embodiments, the regenerated cell group (such as a tissue or an organ) can be applied to or implanted in a subject. In some embodiments, the subject is the same subject from which cell is obtained. In some embodiments, the subject is the different subjects (such as autologous transplantation) from which cell is obtained. In some embodiments, the subject is the different subjects from which cell is obtained, but belongs to the same species (such as, allogeneic transplantation). In some embodiments, the subject is the different subjects from which cell is obtained, and belongs to different species (such as xenotransplantation).
[0780] Example
[0781] In order to more fully understand the present disclosure, the following examples are listed.The synthetic and biological examples described in this application are provided to illustrate the compounds, pharmaceutical compositions, methods and uses provided herein and are not to be construed in any way as limiting the scope thereof.
[0782] Example 1. Kinetic cell viability of AGS cells
[0783] Approximately 50,000 AGS cells were seeded into each well of a 96-well plate in culture medium containing NanoLuc luciferase and the MT cell viability substrate provided in PROMEGA's RealTime Glo MT cell viability assay kit. Four hours after plating, cells were treated with DMSO alone (no drug treatment) or decreasing concentrations of the disclosed compounds to achieve final concentrations of 20, 10, 5, and 2.5 μM. Luminescence units (RLU) were measured every 16-20 hours using a SynergyHTX plate reader with a 30 millisecond integration (see Figure 1 ).
[0784] Example 2. Human microarray studies
[0785] AGS human gastric adenocarcinoma cells were treated with compound I-1 or DMSO alone (as a negative control) for two days. Two days later, RNA was isolated from cells treated with compound I-1 and DMSO in duplicate and microarray analysis was performed using AFFYMETRIX CLARIOM S microarrays. The data are expressed as a fold change relative to the cells treated with compound I-1, with negative values indicating genes that are higher in cells treated with compound I-1 than in cells treated with DMSO, and positive values indicating genes that are higher in cells treated with DMSO than in cells treated with compound I-1. The values of the replicate samples were averaged. Data for genes whose expression was changed more than 3 times in response to compound I-1 were included.
[0786] Table 1 shows a list of genes that were upregulated after treatment of the AGS human gastric cancer cell line with compound 1-1 (shown below). Negative numbers indicate fold upregulation after drug treatment. Positive numbers indicate fold downregulation after drug treatment. Overall, these data represent the reactivation of tumor suppressor genes, as well as a decrease in the expression of tumor-promoting genes. For example, DUSP10, NR1D1, and Per1 all showed tumor suppressor activity in preventing uncontrolled cell proliferation, and the expression of these three genes was greatly increased by treatment with compound 1-1. In addition, Chac1, PCK2, and SLC7A11 all showed tumor-promoting activity and were associated with more dangerous and lethal forms of cancer, and these three genes were the three most strongly suppressed genes detected in this analysis.
[0787] There are other instances in the data that support this model, but the overall model is that compound 1-1 increases the expression of tumor suppressor genes and decreases the expression of tumor-promoting genes.
[0788]
[0789] Table 1.
[0790]
[0791]
[0792] Table 2 shows the list of genes downregulated after treatment of AGS human gastric cancer cell line with compound 1-1.
[0793] Table 2.
[0794]
[0795]
[0796]
[0797]
[0798] Example 3. Kinetic cell viability of AGS cells
[0799] Compound 1-1 was tested for its ability to inhibit the growth of 12 additional cell lines derived from a variety of different types of human cancer. In addition to potent inhibition of gastric adenocarcinoma and gastrointestinal stromal cell growth (gastric adenocarcinoma data shown in Example 1, gastrointestinal stromal tumor data shown in Table 3), compound 1-1 also had the most potent effect on non-Hodgkin's lymphoma, small cell lung cancer, pancreatic cancer, gastrointestinal stromal, and ovarian adenocarcinoma cells. Exemplary results are shown in Table 3. Results are presented as IC 50 The IC50 value is the lowest concentration of compound 1-1 that results in 50% inhibition of cancer cell growth.
[0800] Table 3.
[0801] cell lines Cancer type <![CDATA[IC 50 (μM)]]> IGROV-1 Ovarian adenocarcinoma 4.54 NCI-H69 Small cell lung cancer 1.50 RL Non-Hodgkin lymphoma 0.13 MCF-7 Breast cancer 6.00 Colo205 Duke's D colorectal adenocarcinoma >10 DLD-1 Duke's C colorectal adenocarcinoma >10 MiaPaca-2 pancreatic cancer 3.38 PC-3 Prostate cancer 5.52 A549 Lung adenocarcinoma >10 CFPAC-1 pancreatic cancer 8.24 UACC-62 Melanoma >10 A498 Kidney cancer >10 GIST T1 Gastrointestinal stromal tumors 0.98
[0802] General Methods Used in Examples 4 to 10 and 11
[0803] Unless otherwise provided, Examples 4 to 10 and 11 were performed according to the general methods described in this subsection.
[0804] RT-qPCR
[0805] Place approximately 2.5 x 10 5 AGS cells were treated with DMSO alone (no drug treatment) or 10 μM of compound I-1 in DMSO for 4 days. The cells were lysed and RNA was extracted using Zymo's Quick RNA-Microprep according to the manufacturer's instructions. 100 ng of RNA was reverse transcribed using MuLV reverse transcriptase (New England Biolabs, USA). qPCR was performed in a Stratagene Mx 3005P using 2 μl cDNA and Luna Universal qPCR Master Mix from NEB.
[0806] Hepatotoxicity assay
[0807] On the day after perfusion, fresh primary CD-1 mouse hepatocytes were obtained from XenoTech in 96-well plates. After 24 hours of recovery at 37°C using OptiCulture Hepatocyte Medium, the medium containing only DMSO (no drug treatment) or 10 μM compound I-1 was replaced every day for 4 days. Cell viability was measured using PROMEGA's CellTiter Glo 2.0 kit according to the manufacturer's instructions. Luminescence was measured using a SynergyHTX plate reader with a 1-second integration.
[0808] Kinetic cell viability
[0809] Approximately 50,000 AGS cells were seeded into a 96-well plate in a culture medium containing NanoLuc luciferase and the MT cell viability substrate provided in the RealTime Glo MT cell viability assay kit from PROMEGA. Four hours after seeding, cells were treated with DMSO alone (no drug treatment) or reduced concentrations of compound I-1 to reach final concentrations of 20, 10, 5, and 2.5 μM. Luminescence units (RLU) were measured every 16-20 hours using a SynergyHTX plate reader with a 30 millisecond integration.
[0810] Absorption, distribution, metabolism, and excretion (ADME) profiling
[0811] Plasma stability. Plasma stability was determined by the QuintaraBio stability assay using samples provided in DMSO solution. Briefly, the compound was incubated in duplicate at 37°C in the presence of mouse plasma at a final concentration of 1 μM. At four different time points, 300 μL of a quenching solution (50% acetonitrile, 50% methanol, and 0.05% formic acid, warmed at 37°C) containing an internal standard was added to each well. The plate was sealed, vortexed, and centrifuged at 4000 rpm for 15 minutes at 4°C. The supernatant was transferred to a fresh plate for LC / MS / MS analysis. All samples were analyzed on LC / MS / MS using an ABSciex API 4000 instrument connected to a Shimadzu LC-20AD LC pump system. The extent of metabolism was calculated as the disappearance of the test compound compared to a 0-minute control reaction incubation. The initial rate of compound concentration was calculated and used to determine t 1 / 2 value.
[0812] Microsomal stability. Microsomal stability was determined using the sample assay provided in the DMSO solution by the QuintaraBio stability assay. In brief, the assay was performed in 96-well microtiter plates at 37°C. A reaction mixture (25 μL) containing a final concentration of 1 μM test compound, 0.5 mg / mL liver microsomal protein, and 1 mM NADPH and / or 1 mM uridine 5′-diphospho-α-D-glucuronic acid (UDPGA) (containing propyl methylglycin) was incubated in 100 mM potassium phosphate pH 7.4 buffer containing 3 mM MgCl . At each time point (0.25, 0.5, 1, 2, 4, 6, 8, and 24 minutes), 150 μL of quenching solution (100% acetonitrile and 0.1% formic acid) containing an internal standard was transferred to each well. The plate was sealed and centrifuged at 4°C for 15 minutes at 4000 rpm. The supernatant was transferred to a fresh plate for LC / MS / MS analysis. All samples were analyzed on an AB Sciex API 4000 instrument connected to a Shimadzu LC-20AD LC pump system. The extent of metabolism was calculated as the disappearance of the test compound compared to a 0-minute incubation. The initial rate was calculated for the compound concentration and used to determine t 1 / 2 The intrinsic clearance CLint is then calculated as (0.693)(1 / t 1 / 2 (min)) (g liver / kg body weight) (mL incubation / mg microsomal protein) (45 mg microsomal protein / g liver weight).
[0813] Kinetic solubility. Solubility was determined by the QuintaraBio solubility assay using samples provided in DMSO solution. Briefly, 10 mM compound I-1 was diluted with an appropriate amount of buffer (PBS, pH 7.4) and mixed by shaking for 1.5 hours, followed by vacuum filtration. The samples were subsequently analyzed by reversed-phase HPLC with UV detection. Quantification was accomplished by reference to a three-point standard curve constructed by serial dilutions of the drug dissolved in 100% DMSO.
[0814] Pharmacokinetic profile
[0815] The pharmacokinetic profile of Compound I-1 was determined in male CD1 mice (n=3) after oral gavage at 100 mg / kg using a freshly prepared formulation. Approximately 0.025 mL of blood was collected from the dorsal plantar vein at 15 minutes, 30 minutes, and 1, 2, 4, 6, 8, and 24 hours after dosing. Plasma concentrations of the drug were analyzed by LC / MS / MS.
[0816] Maximum tolerated dose study
[0817] The maximum tolerated dose distribution of Compound I-1 was determined in female BALB / c nude mice after oral gavage of vehicle control (n=3) or Compound I-1 (n=9) using freshly prepared formulations. Animals were dosed with 50 mg / kg (n=3), 25 mg / kg (n=3), or 12 mg / kg (n=3) for 5 consecutive days and then underwent clinical observation for another 5 consecutive days.
[0818] Example 4.
[0819] AGS gastric cancer cells were treated with DMSO alone (no drug treatment) or compound I-1 at 10 μM for 4 days. RNA was isolated and oct4 RNA levels were measured by RT-qPCR. Exemplary results are shown in Figure 2 middle.
[0820] Example 5.
[0821] AGS gastric cancer cells were treated with DMSO alone (no drug treatment) or 10 μM Compound I-1 for 4 days. RNA was isolated and nanog RNA levels were measured by RT-qPCR. Exemplary results are shown in Figure 3 middle.
[0822] Example 6.
[0823] Normal healthy mouse liver cells were treated with DMSO alone (no drug treatment) or 10 μM Compound I-1 for 4 days. Cell health was measured using CELLTITER GLO reagent, which provides luminescence readings as a measure of total ATP concentration. Exemplary results are shown in Figure 4 middle.
[0824] Example 7.
[0825] AGS gastric cancer cells were treated with DMSO alone (no drug treatment) or various concentrations of compound I-1 (including 2.5M, 5M, 10M, and 20M) for 4 days. Cell health and replication were measured using the REALTIME-GLO MT cell viability assay, which provides luminescence readings as a measure of cell number and health. Exemplary results are shown in Figure 5 middle.
[0826] Example 8.
[0827] Selected chemical properties of Compound 1-1 were measured. Solubility was measured in aqueous solution at pH 1.2 or 7.4. Mouse liver microsomal stability was measured as half-life (t 1 / 2 , in minutes), while plasma stability is listed as the percentage of Compound 1-1 remaining in mouse plasma after 4 hours. Exemplary results are shown in Figure 6 middle.
[0828] Example 9.
[0829] After a single PO (oral) injection of 100 mg / kg into mice, the concentration of Compound 1-1 in plasma was measured over a 24-hour period. Figure 7 Medium. Half-life is approximately 6 hours.
[0830] Example 10.
[0831] Nude BALB / c mice were treated with vehicle control or 50 mg / kg Compound I-1, 25 mg / kg Compound I-1, or 12.5 mg / kg Compound I-1 once daily (orally) for 5 days, with 3 mice treated with vehicle control and 3 mice treated with Compound I-1. The mice were monitored for 10 days and their body weight was measured to assess their overall health. Exemplary results are shown in Figure 8 In.
[0832] Example 11. Kinetic cell viability of AGS cells
[0833] Compound 1-1 was tested for its ability to inhibit the growth of 11 additional cell lines derived from a variety of different types of human cancer. Exemplary results are shown in Table 4. Results are presented as IC 50 The IC50 value is the lowest concentration of compound 1-1 that results in 50% inhibition of cancer cell growth.
[0834] Table 4.
[0835]
[0836] Example 12. Preparation of exemplary compounds
[0837] Compounds I-152, I-156, I-157, I-160, I-168, I-171, I-174, I-175, I-176, I-178, I-179, I-180 and I-181 were purchased through commercial suppliers.
[0838] The following LC-MS methods (analytics) were used to prepare compounds I-215, I-224, I-225, I-227, I-228, I-230, I-231, I-232, I-241, I- 246, I-248, I-252, I-257, I-258, I-260, I-263, I-264, I-271, I-272, I-284, I-285 and I-296.
[0839] Method 1 (LC-MS) 2min_low_3_97_BEH: LC / MS system: Acquity UPLC coupled with SQD mass spectrometer; Column: Acquity UPLC BEH C18 (50 mm x 2.1 mm ID, 1.7 μm packing diameter); Mobile phase A: 0.1% formic acid in water, Mobile phase B: 0.1% formic acid in acetonitrile; Gradient: 0.0 min 97% A, 3% B, flow rate 0.9 ml / min; 1.5 min 3% A, 97% B, flow rate 0.9 ml / min; 1.9 min 3% A, 97% B, flow rate 0.9 ml / min; 2.0 min 97% A, 3% B, flow rate 0.05 ml / min; column temperature: 40°C; UV detection: 210 nm to 350 nm; MS conditions: ionization mode: alternating scanning positive and negative electrospray (ES+ / ES-); scanning range: 100 to 1000 AMU.
[0840] Method 2 (LC-MS): 2min_high_3_97_BEH: LC / MS system: Acquity UPLC coupled with SQD mass spectrometer; column: Acquity UPLC BEH C18 (50 mm x 2.1 mm ID, 1.7 μm packing diameter); mobile phase A: 10 mM aqueous ammonium bicarbonate (adjusted to pH 10 with aqueous ammonia), mobile phase B: acetonitrile gradient: 0.0 min 97% A, 3% B, flow rate 0.9 ml / min; 1.5 min 3% A, 97% B, flow rate 0.9 ml / min; 1.9 min 3% A, 97% B, flow rate 0.9 ml / min; 2.0 min 97% A, 3% B, flow rate 0.05 ml / min; column temperature: 40°C; UV detection: 210 nm to 350 nm; MS conditions: ionization mode: alternating scanning positive and negative electrospray (ES+ / ES-); scanning range: 100 to 1500 AMU.
[0841] Method 5 (LC-MS): 12min_low_3_97_BEH: LC / MS system: Acquity UPLC coupled with SQD mass spectrometer; column: Acquity UPLC BEH C18 (50 mm x 2.1 mm ID, 1.7 μm packing diameter); mobile phase A: 0.1% formic acid in water, mobile phase B: 0.1% formic acid in acetonitrile; gradient: 0.0 min 97% A, 3% B, flow rate 0.9 ml / min; 1.5 min 97% A, 3% B, flow rate 0.9 ml / min; 11.5 min 3% A, 97% B, flow rate 0.9 ml / min; 12.0 min 97% A, 3% B, flow rate 0.05 ml / min; column temperature: 40°C; UV detection: 210 nm to 350 nm; MS conditions: ionization mode: alternating scanning positive and negative electrospray (ES+ / ES-); scanning range: 100 to 1500 AMU.
[0842] Method 6 (LC-MS): 12min_high_3_97_BEH: LC / MS system: Acquity UPLC coupled with SQD mass spectrometer; column: Acquity UPLC BEH C18 (50 mm x 2.1 mm ID, 1.7 μm packing diameter); mobile phase A: 10 mM aqueous ammonium bicarbonate (adjusted to pH 10 with aqueous ammonia), mobile phase B: acetonitrile; gradient: 0.0 min 97% A, 3% B, flow rate 0.9 ml / min; 1.5 min 97% A, 3% B, flow rate 0.9 ml / min; 11.5 min 3% A, 97% B, flow rate 0.9 ml / min; 12.0 min 97% A, 3% B, flow rate 0.05 ml / min; column temperature: 40°C; UV detection: 210 nm to 350 nm; MS conditions: ionization mode: alternating scanning positive and negative electrospray (ES+ / ES-); scanning range: 100 to 1500 AMU.
[0843] Synthesis of 4-(1-acetylindolin-5-yl)-N-(pyridin-3-ylmethyl)benzamide (Compound I-42)
[0844] Preparation of tert-butyl 5-bromoindoline-1-carboxylate
[0845]
[0846] Procedure A: To a mixture of 5-bromoindoline (10.0 g, 50.8 mmol) in DCM (80 mL) was added a solution of di-tert-butyl dicarbonate (11.2 g, 51.3 mmol) in DCM (20 mL). The reaction mixture was stirred at room temperature for 2 h and concentrated in vacuo to afford tert-butyl 5-bromoindoline-1-carboxylate (18.0 g, quantitative yield) as a yellow oil. LC-MS (ESI): m / z (M) + =297.12 / 299.33.
[0847] Preparation of tert-butyl 5-(4-(methoxycarbonyl)phenyl)indoline-1-carboxylate
[0848]
[0849] Procedure B: To a mixture of tert-butyl 5-bromoindoline-1-carboxylate (18.0 g, 50.8 mmol) in dioxane / H2O (135 mL) was added (4-(methoxycarbonyl)phenyl)boronic acid (13.2 g, 76.2 mmol), Pd(dppf)Cl2 (4.2 g, 5.1 mmol) and Cs2CO3 (49.4 g, 152 mmol). The reaction mixture was stirred at 80°C for 20 h, then diluted with DCM and washed with brine. The organic layer was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (PE / EA 4:1, v / v) to give tert-butyl 5-(4-(methoxycarbonyl)phenyl)indoline-1-carboxylate (11.2 g, 62%) as a yellow solid. LC-MS (ESI): m / z (M-56) + =298.14.
[0850] Preparation of 4-(1-(tert-butoxycarbonyl)indolin-5-yl)benzoic acid
[0851]
[0852] Step C: To a mixture of tert-butyl 5-(4-(methoxycarbonyl)phenyl)indoline-1-carboxylate (5.0 g, 14.2 mmol) in MeOH / THF 1:1 (60 mL) was added LiOH (1 N, 30 ml). The reaction mixture was stirred at 70°C for 3 hours. It was then concentrated in vacuo and acidified with aqueous HCl (1 N). After filtration, the solid was dried to give 4-(1-(tert-butoxycarbonyl)indolin-5-yl)benzoic acid (5.6 g, quantitative yield) as a white solid. LC-MS (ESI): m / z (M-56) + =284.09.
[0853] Preparation of tert-butyl 5-(4-((pyridin-3-ylmethyl)carbamoyl)phenyl)indoline-1-carboxylate
[0854]
[0855] Process D To a mixture of 4-(1-(tert-butoxycarbonyl)indolin-5-yl)benzoic acid (3.0 g, 8.8 mmol) in DMF were added pyridin-3-ylmethylamine (1.1 g, 10.6 mmol), HATU (5.0 g, 13.2 mmol) and DIPEA (3.4 g, 26.4 mmol). The reaction mixture was stirred at room temperature for 20 hours. It was then diluted with DCM and washed with water and brine. The organic layer was dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (DCM / MeOH 9:1, v / v) to give tert-butyl 5-(4-((pyridin-3-ylmethyl)carbamoyl)phenyl)indolin-1-carboxylate (3.2 g, 85%) as a solid. LC-MS (ESI): m / z (M+1) + =430.28.
[0856] Preparation of 4-(indolin-5-yl)-N-(pyridin-3-ylmethyl)benzamide
[0857]
[0858]
[0266] Procedure E: To a mixture of tert-butyl 5-(4-((pyridin-3-ylmethyl)carbamoyl)phenyl)indoline-1-carboxylate (2.0 g, 4.7 mmol) in DCM (5 mL) was added HCl in dioxane (4 N, 20 mL). The reaction mixture was stirred at room temperature for 18 h and then concentrated under reduced pressure to give a red solid (2.4 g). The residue (100 mg) was purified by preparative HPLC (C18, 40-100% MeCN in H2O with 0.1% formic acid) to give 4-(indolin-5-yl)-N-(pyridin-3-ylmethyl)benzamide (27 mg, 35%) as a white solid.
[0859] Preparation of 4-(1-acetylindolin-5-yl)-N-(pyridin-3-ylmethyl)benzamide (Compound I-42)
[0860]
[0861] Procedure D was followed, starting with 4-(indolin-5-yl)-N-(pyridin-3-ylmethyl)benzamide (200 mg, 0.5 mmol) and HOAc (36 mg, 0.6 mmol). In this case, the reagents were added at 0°C and the reaction mixture was allowed to warm to room temperature. (1-acetylindolin-5-yl)-N-(pyridin-3-ylmethyl)benzamide (47 mg, 25%) was isolated as a white solid. LC-MS (ESI): m / z (M+H) + =372.21. 1 H NMR (400MHz, DMSO-d6) δ9.12 (t, J=5.9Hz, 1H), 8.57 (d, J=1.8Hz, 1H), 8.46 (dd, J=4.7, 1.5Hz, 1H), 8.15-8.06 (m, J=8.4Hz, 1H), 7.98-7.92 (m, J=8.4Hz, 2H), 7.78-7.71 (m, J= 9.0, 5.1Hz, 3H), 7.63 (s, 1H), 7.57-7.52 (m, J=8.4Hz, 1H), 7.39-7.34 (m, J=7.8, 4.8Hz , 1H), 4.51 (d, J=5.9Hz, 2H), 4.14 (t, J=8.5Hz, 2H), 3.21 (t, J=8.5Hz, 2H), 2.18 (s, 3H).
[0862] Synthesis of 4-(1-propionylindolin-5-yl)-N-(pyridin-3-ylmethyl)benzamide (Compound I-43)
[0863] 3.4.1 Preparation of 4-(1-propionylindolin-5-yl)-N-(pyridin-3-ylmethyl)benzamide (Compound I-43)
[0864]
[0865] Following General Procedure D, starting from 4-(indolin-5-yl)-N-(pyridin-3-ylmethyl)benzamide (1.5 g, 5.0 mmol) and propionic acid (340 mg, 6.0 mmol), 4-(1-propionylindolin-5-yl)-N-(pyridin-3-ylmethyl)benzamide (690 mg, 36%) was isolated as a white solid. LC-MS (ESI): m / z (M+H) + =386.23. 1H NMR (400MHz, DMSO-d6) δ9.17-9.09 (m, J=5.9Hz, 1H), 8.57 (d, J=1.7Hz, 1H), 8.47 (d d, J=4.7, 1.5Hz, 1H), 8.22-8.11(m, 1H), 7.99-7.92(m, 2H), 7.80-7.71(m, 5.2Hz, 3 H), 7.63 (s, 1H), 7.58-7.53 (m, 1H), 7.40-7.31 (m, 1H), 4.52 (d, J=5.8Hz, 2H), 4.12 (t, J=8.5Hz, 2H), 3.21 (t, J=8.4Hz, 2H), 2.50-2.44 (m, 2H), 1.08 (t, J=7.3Hz, 3H).
[0866] Synthesis of 4′-propionamido-N-(pyridin-3-ylmethyl)-[1,1′-biphenyl]-4-carboxamide (Compound I-44)
[0867]
[0868] To a solution of methyl 4-iodobenzoate (3.0 g, 11.5 mmol), 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (3.03 g, 13.8 mmol) and KCO (3.2 g, 23.0 mmol) in dioxane / H0 (25 / 5 mL) was added Pd(PPh) (1.33 g, 1.15 mmol) in one portion. The mixture was stirred at 100° C. for 10 hours. It was then extracted with EA, and the combined organic layers were washed with brine, dried over NaSO, concentrated, and purified by flash chromatography to give methyl 4′-amino-[1,1′-biphenyl]-4-carboxylate (2.5 g, quantitative yield) as a white solid. LC-MS (ESI): m / z (M+H) + =220.19.
[0869] Methyl 4'-propionamido-[1,1'-biphenyl]-4-carboxylate (2.1 g, 70%) was isolated as a white solid starting from methyl 4'-amino-[1,1'-biphenyl]-4-carboxylate (2.4 g, 10.6 mmol) and propionic acid (1.18 g, 15.9 mmol) according to General Procedure D. LC-MS (ESI): m / z (M+H) = 284.14.
[0870] To a solution of methyl 4′-propionamido-[1,1′-biphenyl]-4-carboxylate (200 mg, 0.7 mmol) in MeOH / THF (2 / 2 mL) was added NaOH (3.5 mL, 3.5 mmol). The mixture was stirred at room temperature for 12 hours. Acidified with 4N HCl and extracted with EA. The combined organic layers were washed with brine, dried over Na2SO4, concentrated, and purified by flash chromatography to give 4′-propionamido-[1,1′-biphenyl]-4-carboxylic acid (150 mg, 79%) as a white solid. LC-MS (ESI): m / z (M+H) = 270.09.
[0871] Compound I-44 was prepared according to General Procedure D starting from 4′-propionamido-[1,1′-biphenyl]-4-carboxylic acid (150 mg, 0.56 mmol) and pyridin-3-ylmethylamine (91 mg, 0.84 mmol). Purification by preparative HPLC gave 4′-propionamido-N-(pyridin-3-ylmethyl)-[1,1′-biphenyl]-4-carboxamide (32 mg, 16%) as a white solid. LC-MS (ESI): m / z (M+H) + =360.25. 1 H NMR (400MHz, DMSO-d6) δ10.00 (s, 1H), 9.13 (t, J=5.9Hz, 1H), 8.57 (d, J=1.5Hz, 1H), 8.47 (dd, J=4.7, 1.4Hz, 1H), 7.96 (d, J=8.4Hz, 2H), 7.81-7.65 (m, 7H), 7.40-7.33 (m, 1H), 4.52 (d, J=5.8Hz, 2H), 2.35 (q, J=7.5Hz, 2H), 1.10 (t, J=7.5Hz, 3H).
[0872] Synthesis of 4′-(N-methylpropionamido)-N-(pyridin-3-ylmethyl)-[1,1′-biphenyl]-4-carboxamide (Compound I-45)
[0873]
[0874] To a solution of methyl 4′-propionamido-[1,1′-biphenyl]-4-carboxylate (500 mg, 1.77 mmol) and CsCO (1.36 g, 3.54 mmol) in MeCN (10 mL) was added MeI (0.22 mL, 3.54 mmol) in one portion. The mixture was stirred at 80° C. for 10 hours. It was then extracted with EA, and the combined organic layers were washed with brine, dried over NaSO, concentrated, and purified by flash chromatography to give methyl 4′-(N-methylpropionamido)-[1,1′-biphenyl]-4-carboxylate (475 mg, 90%) as a white solid. LC-MS (ESI): m / z (M+H) + =298.14.
[0875] To a solution of methyl 4′-(N-methylpropionamido)-[1,1′-biphenyl]-4-carboxylate (200 mg, 0.68 mmol) in MeOH / THF (2 / 2 mL) was added NaOH (3.4 mL, 3.4 mmol) in one portion. The mixture was stirred at room temperature for 12 hours. It was then acidified with 4N HCl and extracted with EA. The combined organic layers were washed with brine, dried over Na2SO4, concentrated and purified by flash chromatography to give 4′-(N-methylpropionamido)-[1,1′-biphenyl]-4-carboxylic acid (140 mg, 73%) as a white solid. LC-MS (ESI): m / z (M+H) + =284.14.
[0876] Following General Procedure D, starting from 4′-(N-methylpropionamido)-[1,1′-biphenyl]-4-carboxylic acid (140 mg, 0.50 mmol) and pyridin-3-ylmethanamine (82 mg, 0.75), 4′-(N-methylpropionamido)-N-(pyridin-3-ylmethyl)-[1,1′-biphenyl]-4-carboxamide (30 mg, 16%) was isolated as a white solid. LC-MS (ESI): m / z (M+H) + =374.30. 1 H NMR (400MHz, DMSO-d6) δ9.17 (t, 1H), 8.58 (s, 1H), 8.47 (d, J = 3.7Hz, 1H), 8.00 (d, J = 8.3Hz, 2H), 7.90-7.66 (m, 5H), 7. 44 (d, J=8.3Hz, 2H), 7.40-7.31 (m, 1H), 4.53 (d, J=5.8Hz, 2H), 3.20 (s, 3H), 2.32-1.89 (m, 2H), 0.95 (t, J=7.3Hz, 3H).
[0877] Synthesis of 4-(1-acetyl-1,2,3,4-tetrahydroquinolin-6-yl)-N-(pyridin-3-ylmethyl)benzamide (Compound I-46)
[0878]
[0879] To a solution of 1,2,3,4-tetrahydroquinoline (2.0 g, 15.0 mmol) in DMF (20 mL) was added NBS (2.67 g, 15.0 mmol) in one portion. The mixture was stirred at 0°C for 1 hour. It was then extracted with EA, and the combined organic layers were washed with brine, dried over Na2SO4, concentrated, and purified by flash chromatography to give 6-bromo-1,2,3,4-tetrahydroquinoline (3.1 g, 97%) as a yellow oil. LC-MS (ESI): m / z (M+H) = 212.08 / 214.08.
[0880] To a solution of 6-bromo-1,2,3,4-tetrahydroquinoline (13.1 g, 14.6 mmol) and DIPEA (6.5 mL, 36.5 mmol) in DCM (30 mL) was added AcCl (1.72 g, 21.9 mmol) in one portion at 0°C. The reaction mixture was stirred at room temperature for 4 hours and then quenched with water. It was extracted with EA, and the combined organic layers were washed with brine, dried over Na2SO4, and concentrated to give 1-(6-bromo-3,4-dihydroquinolin-1(2H)-yl)ethan-1-one (3.33 g, 90%) as a light yellow oil. LC-MS (ESI): m / z (M+H) + =254.06 / 256.06.
[0881] To a solution of 1-(6-bromo-3,4-dihydroquinolin-1(2H)-yl)ethan-1-one (1.0 g, 4.0 mmol), (4-(methoxycarbonyl)phenyl)boronic acid (1.08 g, 6.0 mmol) and NaCO (850 mg, 8.0 mmol) in dioxane / HO (10 / 2 mL) was added Pd(PPh) (466 mg, 0.4 mmol). The mixture was stirred at 100° C. for 10 h. It was then extracted with EA and the combined organic layers were washed with brine, dried over NaSO, concentrated, and purified by flash chromatography to give methyl 4-(1-acetyl-1,2,3,4-tetrahydroquinolin-6-yl)benzoate (1.25 g, 100%) as a white solid. LC-MS (ESI): m / z (M+H) + =310.13.
[0882] Procedure F: To a solution of methyl 4-(1-acetyl-1,2,3,4-tetrahydroquinolin-6-yl)benzoate (500 mg, 1.62 mmol) in MeOH (10 mL) was added NaOH (2.1 mL, 8.1 mmol). The mixture was stirred at 50° C. for 12 h, acidified with HCl (4 N), and then extracted with EA. The combined organic layers were washed with brine, dried over Na2SO4, concentrated, and purified by flash chromatography to give 4-(1-acetyl-1,2,3,4-tetrahydroquinolin-6-yl)benzoic acid (445 mg, 93%) as a white solid. LC-MS (ESI): m / z (M+H) + =296.15.
[0883] Following General Procedure D, starting from 4-(1-acetyl-1,2,3,4-tetrahydroquinolin-6-yl)benzoic acid (150 mg, 0.51 mmol) and pyridin-3-ylmethanamine (66 mg, 0.61 mmol), 4-(1-acetyl-1,2,3,4-tetrahydroquinolin-6-yl)-N-(pyridin-3-ylmethyl)benzamide (53 mg, 27%) was isolated as a white solid. LC-MS (ESI): m / z (M+H) + =386.25. 1 H NMR (400MHz, DMSO-d6) δ9.17 (t, J=5.9Hz, 1H), 8.51 (d, J=5.5Hz, 2H), 8.00 (d, J=8.3Hz, 2H), 7.80 (d, J=8.3Hz, 2H), 7.66-7.48 (m , 3H), 7.32 (d, J=5.5Hz, 2H), 4.52 (d, J=5.8Hz, 2H), 3.71 (t, J=6.3Hz, 2H), 2.80 (t, J=6.5Hz, 2H), 2.21 (s, 3H), 1.94-1.87 (m, 2H).
[0884] Synthesis of 4-(1-(2-hydroxyacetyl)indolin-5-yl)-N-(pyridin-3-ylmethyl)benzamide (Compound I-47)
[0885] Preparation of 4-(1-(2-(benzyloxy)acetyl)indolin-5-yl)-N-(pyridin-3-ylmethyl)benzamide
[0886]
[0887] Following General Procedure D, starting from 4-(indolin-5-yl)-N-(pyridin-3-ylmethyl)benzamide (150 mg, 0.45 mmol) and 2-(benzyloxy)acetic acid (60 mg, 0.54 mmol), 4-(1-(2-(benzyloxy)acetyl)indolin-5-yl)-N-(pyridin-3-ylmethyl)benzamide (140 mg, 65%) was obtained as a white solid. LC-MS (ESI): m / z (M-56) + =478.32.
[0888] Preparation of 4-(1-(2-hydroxyacetyl)indolin-5-yl)-N-(pyridin-3-ylmethyl)benzamide (Compound I-47)
[0889]
[0890] To a solution of 4-(1-(2-(benzyloxy)acetyl)indolin-5-yl)-N-(pyridin-3-ylmethyl)benzamide (100 mg, 0.209 mmol) in DCM (5 mL) was added BBr (262 mg, 1.05 mmol). The reaction mixture was stirred at 0 ° C for 2 h under N2. After quenching with aqueous NaHCO3, the mixture was extracted with DCM and washed with brine. The organic layer was dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by preparative HPLC (C18, 40-100% MeCN in H2O with 0.1% formic acid) to give 4-(1-(2-hydroxyacetyl)indolin-5-yl)-N-(pyridin-3-ylmethyl)benzamide (15 mg, 18%) as a white solid. LC-MS (ESI): m / z (M+H) + =388.61. 1 H NMR (400MHz, DMSO-d6) δ9.14 (t, J=5.9Hz, 1H), 8.57 (d, J=1.6Hz, 1H), 8.47 (dd, J =4.7, 1.4Hz, 1H), 8.15 (d, J = 8.3Hz, 1H), 7.96 (d, J = 8.4Hz, 2H), 7.82-7.70 (m, 3H ), 7.65 (s, 2H), 7.59 (d, J = 8.4Hz, 1H), 7.37 (dd, J = 7.7, 4.8Hz, 1H), 4.94 (s, 1H), 4.52 (d, J=5.8Hz, 2H), 4.21 (s, 2H), 4.06 (t, J=8.5Hz, 2H), 3.22 (t, J=8.3Hz, 2H).
[0891] Synthesis of 4-(1-propionylindolin-5-yl)-N-(pyridin-3-ylmethyl)benzenesulfonamide (Compound I-48)
[0892] Preparation of 1-(5-bromoindolin-1-yl)propan-1-one
[0893]
[0894] Following General Procedure D, starting from 5-bromoindoline (3.0 g, 15.2 mmol) and propionic acid (1.37 g, 18.3 mmol), the reagents were added at 0°C and the reaction mixture was allowed to warm to room temperature. 1-(5-bromoindolin-1-yl)propan-1-one (3.0 g, 78%) was isolated as a white solid. LC-MS (ESI): m / z (M) + =253.01,255.52.
[0895] Preparation of 1-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indolin-1-yl)propan-1-one
[0896]
[0897] Procedure G: To a mixture of 1-(5-bromoindolin-1-yl)propan-1-one (1.5 g, 5.9 mmol) in dioxane (15 mL) were added B2Pin2 (1.65 g, 6.5 mmol), Pd(dppf)Cl2 (240 mg, 0.3 mmol) and KOAc (1.7 g, 17.7 mmol). The reaction mixture was stirred at 80°C for 20 hours. It was then diluted with DCM and washed with water and brine. The organic layer was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (PE / EA 4:1, v / v) to give 1-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indolin-1-yl)propan-1-one (800 mg, 45%) as a yellow solid. LC-MS (ESI): m / z (M-56) + =254.20.
[0898] Preparation of 4-bromo-N-(pyridin-3-ylmethyl)benzenesulfonamide
[0899]
[0900] To a mixture of 4-bromo-N-(pyridin-3-ylmethyl)benzenesulfonamide (200 mg, 0.783 mmol) in THF (5 mL) was added pyridin-3-ylmethylamine (92.9 mg, 0.861 mmol) and DIPEA (303.1 mg, 2.349 mmol). The reaction mixture was stirred at room temperature for 2 hours. It was quenched with water, washed with brine, and extracted with EA. The organic layer was dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by silica gel flash column chromatography (PE / EA 4:1, v / v) to give 4-bromo-N-(pyridin-3-ylmethyl)benzenesulfonamide (140 mg, 55%) as a yellow solid. LC-MS (ESI): m / z (M) + =326.02,328.33.
[0901] Preparation of 4-(1-propionylindolin-5-yl)-N-(pyridin-3-ylmethyl)benzenesulfonamide (Compound I-48)
[0902]
[0903] Procedure B was followed starting from 4-bromo-N-(pyridin-3-ylmethyl)benzenesulfonamide (100 mg, 0.31 mmol) and 1-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indolin-1-yl)propan-1-one. In this case, the reaction mixture was stirred in a microwave at 80° C. for 1 h. Purification by preparative HPLC (C18, 40-100% MeCN in H 2 O with 0.1% formic acid) gave 4-(1-propionylindolin-5-yl)-N-(pyridin-3-ylmethyl)benzenesulfonamide (18 mg, 13%) as a white solid. LC-MS (ESI): m / z (M+1) + =422.23.
[0904] 1 H NMR (400MHz, DMSO-d6) δ8.47-8.40 (m, 2H), 8.31-8.25 (m, J=15.9Hz, 1H), 8.21-8 .13 (m, J=8.3Hz, 1H), 7.83 (s, 4H), 7.68-7.61 (m, J=11.3, 3.2Hz, 2H), 7.59-7.54 (m, J=8.4Hz, 1H), 7.32-7.27 (m, J=7.8, 4.8Hz, 1H), 4.15 (t, J=8.5Hz, 2H), 4.07( d, J=3.5Hz, 2H), 3.23 (t, J=8.4Hz, 3H), 2.50-2.46 (m, 2H), 1.09 (t, J=7.3Hz, 3H).
[0905] Synthesis of 4-(1-propionylindolin-5-yl)-N-(pyridin-4-ylmethyl)benzamide (Compound I-49)
[0906] Preparation of methyl 4-(indolin-5-yl)benzoate
[0907]
[0908] According to step E, methyl 4-(indolin-5-yl)benzoate (1.5 g, 95%) was obtained as a solid. LC-MS (ESI): m / z (M-56) + =254.14.
[0909] Preparation of methyl 4-(1-propionylindolin-5-yl)benzoate
[0910]
[0911] Following General Procedure D, starting with methyl 4-(indolin-5-yl)benzoate (4.8 g, 19.0 mmol) and propionic acid (1.7 g, 22.7 mmol), the reagents were added at 0°C and the reaction mixture was allowed to warm to room temperature. Methyl 4-(1-propionylindolin-5-yl)benzoate (4.4 g, 75%) was isolated as a solid. LC-MS (ESI): m / z (M+1) + =310.14.
[0912] Preparation of 4-(1-propionylindolin-5-yl)benzoic acid
[0913]
[0914] According to step C, 4-(1-propionylindolin-5-yl)benzoic acid (Intermediate B) (1.3 g, 76%) was obtained as a white solid from methyl 4-(1-propionylindolin-5-yl)benzoate (1.8 g, 5.8 mmol). LC-MS (ESI): m / z (M+1) + =296.09.
[0915] Preparation of 4-(1-propionylindolin-5-yl)-N-(pyridin-4-ylmethyl)benzamide (Compound I-49)
[0916]
[0917] Following General Procedure D, starting from 4-(1-propionylindolin-5-yl)benzoic acid (100 mg, 0.34 mmol) and pyridin-4-ylmethanamine (44 mg, 0.41 mmol), 4-(1-propionylindolin-5-yl)-N-(pyridin-4-ylmethyl)benzamide (70 mg, 53%) was isolated as a white solid. LC-MS (ESI): m / z (M+H) + =386.22. 1 H NMR (400MHz, DMSO-d6) δ9.16 (t, J=6.0Hz, 1H), 8.55-8.45 (m, J=4.5, 1.6Hz, 2H) , 8.16 (d, J=8.4Hz, 1H), 8.02-7.93 (m, J=8.5Hz, 2H), 7.81-7.73 (m, J=8.5Hz, 2H ), 7.64 (s, 1H), 7.60-7.54 (m, J=8.4Hz, 1H), 7.32 (d, J=5.9Hz, 2H), 4.52 (d, J=5 .9Hz, 2H), 4.13 (t, J=8.5Hz, 2H), 3.21 (t, J=8.4Hz, 2H), 1.08 (t, J=7.3Hz, 3H).
[0918] Synthesis of 4-(1-propionylindolin-5-yl)-N-(pyrimidin-5-ylmethyl)benzamide (Compound I-51)
[0919]
[0920] To a solution of pyrimidine-5-carboxaldehyde (500 mg, 4.6 mmol) in MeOH (10 mL) was added NaBH4 (262 mg, 6.9 mmol) in one portion at 0°C. The mixture was stirred at room temperature for 4 hours. It was then washed with brine and extracted with EA. The combined organic layers were washed with brine, dried over Na2SO4, and concentrated to give pyrimidin-5-ylmethanol (456 mg, 89%) as a white solid. LC-MS (ESI): m / z (M+H) = 111.13.
[0921] To a solution of pyrimidin-5-ylmethanol (410 mg, 3.7 mmol) in THF (10 mL) was added SOCl (1.33 g, 11.1 mmol) in one portion at 0°C. The mixture was stirred at room temperature for 4 hours. It was then quenched with NaCO, the mixture was extracted with EA, and the combined organic layers were washed with brine, dried over NaSO, and concentrated to give 5-(chloromethyl)pyrimidine (456 mg, 95%) as a white solid. LC-MS (ESI): m / z (M+H) = 129.02 / 131.07.
[0922] To a solution of 5-(chloromethyl)pyrimidine (200 mg, 1.56 mmol) in THF was added NH3·H2O (4 mL). The mixture was stirred at room temperature for 30 minutes. The reaction mixture was then concentrated and purified by flash chromatography to give (pyrimidin-5-ylmethylamine) (130 mg, 38%) as a white solid. LC-MS (ESI): m / z (M+H) = 110.13.
[0923] 4-(1-Propanylindolin-5-yl)-N-(pyrimidin-5-ylmethyl)benzamide (38 mg, 12%) was isolated as a white solid starting from 4-(1-propionylindolin-5-yl)benzoic acid (238 mg, 0.8 mmol) and pyrimidin-5-ylmethanamine (130 mg, 1.2 mmol) according to General Procedure D. LC-MS (ESI): m / z (M+H) = 387.24. 1 H NMR (400MHz, DMSO-d6) δ9.21-9.06 (m, 2H), 8.80 (s, 2H), 8.16 (d, J = 6.2Hz, 1H), 7.95 (d, J = 6.6Hz, 2H), 7.76 (d, J = 6.4Hz, 2H), 7.67-7.52(m, 2H), 4.61-4.48(m, 2H), 4.19-4.06(m, 2H), 3.28-3.14(m, 2H), 2.50-2.39(m, 2H), 1.13-1.02(m, 3H).
[0924] Synthesis of 4-(1-propionylindolin-5-yl)-N-(pyridazin-4-ylmethyl)benzamide (Compound I-52)
[0925]
[0926] Following General Procedure D, starting from 4-(1-propionylindolin-5-yl)benzoic acid (106 mg, 0.36 mmol) and pyridazin-4-ylmethanamine (50 mg, 0.33 mmol), 4-(1-propionylindolin-5-yl)-N-(pyridazin-4-ylmethyl)benzamide (59 mg, 42%) was isolated as a white solid. LC-MS (ESI): m / z (M+H) + =387.22. 1H NMR (400MHz, DMSO-d6) δ9.29-9.24 (m, 1H), 9.22 (s, 1H), 9.16 (dd, J=5.3, 1.0Hz, 1H), 8.20-8.13 (m, 1H), 8.01-7.96 (m, 2H), 7.80-7.75 (m, 2H), 7.64 (s, 1H), 7.60-7.54 (m, 2H), 4.55 (d, J=5.8Hz, 2H), 4.13 (t, J=8.5Hz, 2H), 3.21 (t, J=8.3Hz, 2H), 2.50-2.44 (m, 2H), 1.08 (t, J=7.3Hz, 3H).
[0927] Synthesis of 4-(1-propionylindolin-5-yl)-N-(1-(pyridin-3-yl)ethyl)benzamide (Compound I-57)
[0928]
[0929] Following General Procedure D, starting from 4-(1-propionylindolin-5-yl)benzoic acid (100 mg, 0.34 mmol) and 1-(pyridin-3-yl)ethan-1-amine (38 mg, 0.31 mmol), 4-(1-propionylindolin-5-yl)-N-(1-(pyridin-3-yl)ethyl)benzamide (50 mg, 40%) was isolated as a white solid. LC-MS (ESI): m / z (M+H) + =400.20. 1 H NMR (400MHz, DMSO-d6) δ8.90 (d, J=7.8Hz, 1H), 8.62 (d, J=2.0Hz, 1H), 8.45 (dd, J=4.7, 1.5Hz , 1H), 8.16 (d, J=8.4Hz, 1H), 7.95 (d, J=8.4Hz, 2H), 7.83-7.78 (m, 1H), 7.75 (d, J=8.4Hz, 2H) , 7.62 (s, 1H), 7.55 (d, J=8.4Hz, 1H), 7.39-7.34 (m, 1H), 5.26-5.18 (m, 1H), 4.13 (t, J=8.5Hz , 2H), 3.21 (t, J=8.3Hz, 2H), 2.50-2.44 (m, 2H), 1.53 (d, J=7.1Hz, 3H), 1.08 (t, J=7.3Hz, 3H).
[0930] Synthesis of 4-(1-propionylindolin-5-yl)-N-(2-(pyridin-3-yl)propan-2-yl)benzamide (Compound I-58)
[0931]
[0932] Following General Procedure D, starting from 4-(1-propionylindolin-5-yl)benzoic acid (80 mg, 0.271 mmol) and 2-(pyridin-3-yl)propan-2-amine (40 mg, 0.29 g), 4-(1-propionylindolin-5-yl)-N-(2-(pyridin-3-yl)propan-2-yl)benzamide (63 mg, 56%) was isolated as a white solid. LC-MS (ESI): m / z (M+H) + =414.32. 1 H NMR (400MHz, DMSO-d6) δ8.62 (d, J=2.2Hz, 1H), 8.56 (s, 1H), 8.39 (dd, J=4.7, 1.4Hz, 1H), 8.16 (d, J=8.3Hz, 1H), 7.91 (d, J=8.4Hz, 2H), 7.77-7.71 (m, 3H), 7 .62 (s, 1H), 7.55 (d, J = 8.3Hz, 1H), 7.33-7.29 (m, 1H), 4.13 (t, J = 8.5Hz, 2H), 3.21 (t, J=8.5Hz, 2H), 2.50-2.46 (m, 2H), 1.71 (s, 6H), 1.08 (t, J=7.3Hz, 3H).
[0933] Synthesis of N-((6-methylpyridin-3-yl)methyl)-4-(1-propionylindolin-5-yl)benzamide (Compound I-59)
[0934] Preparation of (6-methylpyridin-3-yl)methylamine
[0935]
[0936] Procedure H: To a mixture of 6-methylnicotinonitrile (300 mg, 2.54 mmol) in MeOH / NH3 (7N, 10 mL) was added Raney nickel (50 mg). The reaction mixture was stirred at room temperature under H2 for 3 h. It was then filtered and the filtrate was concentrated in vacuo to afford 6-methylpyridin-3-yl)methanamine (280 mg, 90%) as a yellow oil. LC-MS (ESI): m / z (M+1) + =123.30.
[0937] Preparation of N-((6-methylpyridin-3-yl)methyl)-4-(1-propionylindolin-5-yl)benzamide (Compound I-59)
[0938]
[0939] Following General Procedure D, starting from 4-(1-propionylindolin-5-yl)benzoic acid (100 mg, 0.34 mmol) and (6-methylpyridin-3-yl)methanamine (50 mg, 0.41 mmol), N-((6-methylpyridin-3-yl)methyl)-4-(1-propionylindolin-5-yl)benzamide (50 mg, 36%) was isolated as a white solid. LC-MS (ESI): m / z (M+H) + =400.32. 1 H NMR (400MHz, DMSO-d6) δ9.08 (t, J=5.8Hz, 1H), 8.42 (d, J=1.9Hz, 1H), 8.15 (d, J=8 .4Hz, 1H), 7.94 (d, J=8.4Hz, 2H), 7.75 (d, J=8.4Hz, 2H), 7.65-7.59 (m, 2H), 7.56 ( d, J=8.4Hz, 1H), 7.21 (d, J=8.0Hz, 1H), 4.46 (d, J=5.8Hz, 2H), 4.13 (t, J=8.4Hz, 2 H), 3.21 (t, J=8.4Hz, 2H), 2.50-2.47 (m, 2H), 2.44 (s, 3H), 1.07 (t, J=7.3Hz, 3H).
[0940] Synthesis of N-((2,6-dimethylpyridin-3-yl)methyl)-4-(1-propionylindolin-5-yl)benzamide (Compound I-60)
[0941] Preparation of 2,6-dimethylnicotinonitrile
[0942]
[0943] Procedure I: To a mixture of 3-bromo-2,6-dimethylpyridine (500 mg, 2.69 mmol) in DMF (5 mL) was added CuCN (480 mg, 5.38 mmol). The reaction mixture was stirred at 150° C. for 12 hours. It was then diluted with DCM and washed with aqueous NH 4 Cl (85%) / NH 3 .H 2 O (15%), water, and brine. The organic layer was dried over anhydrous Na 2 SO 4 , filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (DCM / MeOH 10:1, v / v) to give 2,6-dimethylnicotinonitrile (210 mg, 59%) as a yellow solid. LC-MS (ESI): m / z (M+1) + =133.17.
[0944] Preparation of (2,6-dimethylpyridin-3-yl)methylamine
[0945]
[0946] According to procedure H, (2,6-dimethylpyridin-3-yl)methanamine (60 mg, 58%) was obtained from 2,6-dimethylnicotinonitrile (100 mg, 0.176 mmol) as a yellow oil. LC-MS (ESI): m / z (M+1) + =137.20.
[0947] Preparation of N-((2,6-dimethylpyridin-3-yl)methyl)-4-(1-propionylindolin-5-yl)benzamide (Compound I-60)
[0948]
[0949] Following General Procedure D, starting from 4-(1-propionylindolin-5-yl)benzoic acid (100 mg, 0.34 mmol) and (2,6-dimethylpyridin-3-yl)methanamine (50 mg, 0.41 mmol), N-((2,6-dimethylpyridin-3-yl)methyl)-4-(1-propionylindolin-5-yl)benzamide (41 mg, 29%) was isolated as a white solid. LC-MS (ESI): m / z (M+H) + =414.32. 1 H NMR (400MHz, DMSO-d6) δ8.96 (t, J=5.5Hz, 1H), 8.18-8.14 (m, 1H), 7.96 (d, J=8. 3Hz, 2H), 7.75 (d, J=8.3Hz, 2H), 7.62 (s, 1H), 7.55 (d, J=8.3Hz, 1H), 7.49 (d, J= 7.8Hz, 1H), 7.04 (d, J=7.7Hz, 1H), 4.44 (d, J=5.5Hz, 2H), 4.13 (t, J=8.4Hz, 2H) , 3.21 (t, J=8.4Hz, 2H), 2.50-2.45 (m, 5H), 2.39 (s, 3H), 1.08 (t, J=7.2Hz, 3H).
[0950] Synthesis of N-((2-methylpyridin-3-yl)methyl)-4-(1-propionylindolin-5-yl)benzamide (Compound I-61)
[0951] Preparation of 2-methylnicotinonitrile
[0952]
[0953] According to step I, 2-methylnicotinonitrile (110 mg, 32%) was obtained from 3-bromo-2-methylpyridine (500 mg, 2.9 mmol) as a yellow solid. LC-MS (ESI): m / z (M+1)+ =119.20.
[0954] Preparation of (2-methylpyridin-3-yl)methylamine
[0955]
[0956] According to Procedure H: (2-methylpyridin-3-yl)methanamine (80 mg, 77%) was obtained from 2-methylnicotinonitrile (100 mg, 0.85 mmol) as a yellow solid. LC-MS (ESI): m / z (M+1) + =123.71.
[0957] Preparation of N-((2-methylpyridin-3-yl)methyl)-4-(1-propionylindolin-5-yl)benzamide (Compound I-61)
[0958]
[0959] Following General Procedure D, starting from 4-(1-propionylindolin-5-yl)benzoic acid (145 mg, 0.49 mmol) and (2-methylpyridin-3-yl)methanamine (60 mg, 0.49 mmol), N-((2-methylpyridin-3-yl)methyl)-4-(1-propionylindolin-5-yl)benzamide (41 mg, 29%) was obtained as a white solid. LC-MS (ESI): m / z (M+H) + =400.31. 1 HNMR (400MHz, DMSO-d6) δ9.02 (t, J=5.6Hz, 1H), 8.33 (d, J=3.9Hz, 1H), 8.16 (d, J=8.4Hz, 1H), 7.97 (d, J=8.3Hz, 2H), 7.75 (d, J=8.3Hz, 2H), 7.65-7.52 (m , 3H), 7.20 (dd, J=7.5, 4.9Hz, 1H), 4.49 (d, J=5.5Hz, 2H), 4.13 (t, J=8.4Hz, 2H), 3.21 (t, J=8.3Hz, 3H), 2.53 (s, 3H), 2.48 (t, 2H), 1.08 (t, J=7.2Hz, 3H).
[0960] Synthesis of N-methyl-4-(1-propionylindolin-5-yl)-N-(pyridin-3-ylmethyl)benzamide (Compound I-62)
[0961] Preparation of N-(pyridin-3-ylmethyl)formamide
[0962]
[0963] A mixture of pyridin-3-ylmethylamine (1.0 g, 9.2 mmol) in ethyl formate (10 mL) was stirred at 60° C. for 4 h. It was then concentrated under reduced pressure to give N-(pyridin-3-ylmethyl)formamide (1.0 g, 79%) as a colorless oil. LC-MS (ESI): m / z (M+1) + =137.06.
[0964] Preparation of N-methyl-1-(pyridin-3-yl)methanamine
[0965]
[0966] To a solution of N-(pyridin-3-ylmethyl)formamide (500 mg, 3.6 mmol) in THF (20 mL) was added a solution of BH3·MeS in THF (10 N, 3 mL). The reaction mixture was stirred at 60 ° C for 4 hours. It was then diluted with DCM and washed with NH4Cl aqueous solution and brine. The organic layer was concentrated under reduced pressure, and the residue was purified by preparative HPLC (C18, 40-100% MeCN in H2O with 0.1% formic acid) to give N-methyl-1-(pyridin-3-yl)methanamine (600 mg, quantitative yield) as a yellow oil. LC-MS (ESI): m / z (M+H) + =151.31.
[0967] Preparation of N-methyl-4-(1-propionylindolin-5-yl)-N-(pyridin-3-ylmethyl)benzamide (Compound 1-62)
[0968]
[0969] Following General Procedure D, starting from 4-(1-propionylindolin-5-yl)benzoic acid (100 mg, 0.34 mmol) and N-methyl-1-(pyridin-3-yl)methanamine (62 mg, 0.41 mmol), N-methyl-4-(1-propionylindolin-5-yl)-N-(pyridin-3-ylmethyl)benzamide (36 mg, 26%) was obtained as a yellow solid. LC-MS (ESI): m / z (M+H) + =400.31. 1H NMR (400MHz, DMSO-d6) δ 8.90-8.68 (m, 2H), 8.44-8.25 (m, 1H), 8.18-8.13 (m, 1H), 7.92-7.81 (m, 1H), 7.72 (d, J=7.2Hz, 2H), 7.66-7 .47 (m, 4H), 4.89-4.71 (m, 2H), 4.13 (t, J=8.2Hz, 2H), 3.21 (t, J=8.2Hz, 2H), 2.99 (s, 3H), 2.49-2.45 (m, 2H), 1.08 (t, J=7.2Hz, 3H).
[0970] Synthesis of N-(piperidin-3-ylmethyl)-4-(1-propionylindolin-5-yl)benzamide (Compound I-63)
[0971] Preparation of piperidin-3-ylmethylamine
[0972]
[0973] To a solution of 4-piperidine-3-carboxamide (500 mg, 3.9 mmol) in THF (20 mL) was added LiAlH4 (300 mg, 7.8 mmol) at 0°C. The reaction mixture was then stirred at 70°C for 12 h. Water (0.3 mL) was added, followed by NaOH (10%, 0.3 mL). The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure to give piperidin-3-ylmethylamine (200 mg, 44%) as a colorless oil. LC-MS (ESI): m / z (M+H) + =115.20.
[0974] Preparation of N-(piperidin-3-ylmethyl)-4-(1-propionylindolin-5-yl)benzamide (Compound I-63)
[0975]
[0976] Following General Procedure D, starting from 4-(1-propionylindolin-5-yl)benzoic acid (100 mg, 0.34 mmol) and piperidin-3-ylmethylamine (43 mg, 0.38 mmol), N-(piperidin-3-ylmethyl)-4-(1-propionylindolin-5-yl)benzamide (31 mg, 23%) was isolated as a white solid. LC-MS (ESI): m / z (M+H) + =392.33. 1H NMR (400MHz, DMSO-d6) δ8.15 (d, J=8.3Hz, 1H), 7.90 (d, J=8.4Hz, 2H), 7.72 (d, J=8.4Hz, 2H), 7.62(s, 1H), 7.55(d, J=8.3Hz, 1H), 4.13(t, J=8.5Hz, 2H), 3.21( t, J=8.4Hz, 2H), 3.12 (t, J=6.3Hz, 2H), 2.96-2.90 (m, 1H), 2.86-2.80 (m, 1H), 2 .48-2.40 (m, 3H), 2.24-2.16 (m, 1H), 1.79-1.26 (m, 6H), 1.08 (t, J=7.3Hz, 3H).
[0977] Synthesis of 4-(1-propionylindolin-5-yl)-N-((1,2,3,6-tetrahydropyridin-4-yl)methyl)benzamide (Compound I-69)
[0978] Preparation of tert-butyl (pyridin-4-ylmethyl)carbamate
[0979]
[0980] To a mixture of pyridin-4-ylmethylamine (1.0 g, 9.3 mmol) in THF (30 mL) was added a solution of di-tert-butyl dicarbonate (2.1 g, 9.4 mmol) in DCM (20 mL). The reaction mixture was stirred at room temperature for 10 hours. It was then concentrated in vacuo to give tert-butyl (pyridin-4-ylmethyl)carbamate as a colorless oil (crude product 1.9 g, quantitative yield). LC-MS (ESI): m / z (M+1) + =209.33.
[0981] Preparation of 1-benzyl-4-(((tert-butoxycarbonyl)amino)methyl)pyridin-1-ium bromide
[0982]
[0983] To a mixture of tert-butyl (pyridin-4-ylmethyl)carbamate (1.9 g, 9.3 mmol) in acetone (40 mL) was added BnBr solution (2.4 g, 14.1 mmol). The reaction mixture was stirred at room temperature for 15 hours. It was then diluted with DCM and washed with brine. The organic layer was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give 1-benzyl-4-(((tert-butoxycarbonyl)amino)methyl)pyridin-1-ium bromide (crude product 2.5 g, quantitative yield) as a blue oil. LC-MS (ESI): m / z (M+1) + =299.24.
[0984] Preparation of tert-butyl ((1-benzyl-1,2,3,6-tetrahydropyridin-4-yl)methyl)carbamate
[0985]
[0986] To a mixture of benzyl-4-(((tert-butoxycarbonyl)amino)methyl)pyridin-1-ium bromide (crude product 2.5 g, 9.3 mmol) in MeOH (15 mL) was added NaBH4 (1.0 g, 21.9 mmol) at 0°C. The reaction mixture was stirred at 0°C for 3 hours. It was then diluted with EA and washed with brine. The organic layer was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel flash column chromatography (DCM / MeOH 3:1, v / v) to give tert-butyl ((1-benzyl-1,2,3,6-tetrahydropyridin-4-yl)methyl)carbamate (1.7 g, 60%) as a yellow oil. LC-MS (ESI): m / z (M-56) + =304.29.
[0987] Preparation of (1-benzyl-1,2,3,6-tetrahydropyridin-4-yl)methylamine
[0988]
[0989] To a mixture of tert-butyl ((1-benzyl-1,2,3,6-tetrahydropyridin-4-yl)methyl)carbamate (200 mg, 0.66 mmol) in DCM (10 mL) was added TFA (5 mL), and the reaction mixture was stirred at room temperature for 0.5 hours. The reaction mixture was concentrated in vacuo to give (1-benzyl-1,2,3,6-tetrahydropyridin-4-yl)methanamine as a purple solid (crude product 250 mg, quantitative yield). LC-MS (ESI): m / z (M+1) + =204.50.
[0990] Preparation of N-((1-benzyl-1,2,3,6-tetrahydropyridin-4-yl)methyl)-4-(1-propionylindolin-5-yl)benzamide
[0991]
[0992] Following General Procedure D, starting from 4-(1-propionylindolin-5-yl)benzoic acid (233 mg, 0.79 mmol) and (1-benzyl-1,2,3,6-tetrahydropyridin-4-yl)methanamine (crude product 250 mg, 0.66 mmol), N-((1-benzyl-1,2,3,6-tetrahydropyridin-4-yl)methyl)-4-(1-propionylindolin-5-yl)benzamide (230 mg, 72%) was obtained as a solid. LC-MS (ESI): m / z (M+1) + =480.30.
[0993] Preparation of Monoformate 4-(1-propionylindolin-5-yl)-N-((1,2,3,6-tetrahydropyridin-4-yl)methyl)benzamide (Monoformate of Compound I-69)
[0994]
[0995] To a solution of N-((1-benzyl-1,2,3,6-tetrahydropyridin-4-yl)methyl)-4-(1-propionylindolin-5-yl)benzamide (100 mg, 0.21 mmol) in DCM (3 mL) was added 1-chloroethyl chloroformate (44 mg, 0.31 mmol). The reaction mixture was stirred at room temperature for 12 h and then filtered. The filtrate was concentrated under reduced pressure and the residue was purified by preparative HPLC (C18, 40-100% MeCN in H2O with 0.1% formic acid) to give 4-(1-propionylindolin-5-yl)-N-((1,2,3,6-tetrahydropyridin-4-yl)methyl)benzamide (11 mg, 13%) as a white solid. LC-MS (ESI): m / z (M+H) + =390.22. 1 H NMR (400MHz, DMSO-d6) δ8.74 (t, J=5.8Hz, 1H), 8.39 (s, 1H), 8.16 (d, J=8.4Hz, 1H), 7.95 (d, J=8.4Hz, 2H), 7.74 (d, J=8.4Hz, 2H), 7.62 (s, 1H), 7.55 (d, J=8.4Hz, 1H), 5.55 (s, 1H ), 4.39 (s, 2H), 4.12 (t, J=8.5Hz, 2H), 3.86 (d, J=4.4Hz, 3H), 3.41 (s, 2H), 3.21 (t, J=8. 3Hz, 2H), 3.02 (t, J=5.5Hz, 2H), 2.50-2.44 (m, 1H), 2.14 (s, 2H), 1.08 (t, J=7.3Hz, 3H).
[0996] Synthesis of N-(piperidin-4-ylmethyl)-4-(1-propionylindolin-5-yl)benzamide (Compound I-70)
[0997] Preparation of tert-butyl 4-((4-(1-propionylindolin-5-yl)benzamido)methyl)piperidine-1-carboxylate
[0998]
[0999] Following General Procedure D, starting from 4-(1-propionylindolin-5-yl)benzoic acid (120 mg, 0.41 mmol) and tert-butyl 4-(aminomethyl)piperidine-1-carboxylate (105 mg, 0.49 mmol), tert-butyl 4-((4-(1-propionylindolin-5-yl)benzamido)methyl)piperidine-1-carboxylate (200 mg, 99%) was obtained as a white solid. LC-MS (ESI): m / z (M+1) + =436.36.
[1000] Preparation of N-(piperidin-4-ylmethyl)-4-(1-propionylindolin-5-yl)benzamide (Compound I-70)
[1001]
[1002] Following Procedure E, starting from tert-butyl 4-((4-(1-propionylindolin-5-yl)benzamido)methyl)piperidine-1-carboxylate (200 mg, 0.40 mmol), purification by preparative HPLC (C18, 40-100% MeCN in H2O with 0.1% formic acid) afforded N-(piperidin-4-ylmethyl)-4-(1-propionylindolin-5-yl)benzamide (76 mg, 48%) as a white solid. LC-MS (ESI): m / z (M+H) + =392.31. 1 H NMR (400MHz, DMSO-d6) δ8.56 (t, J=5.8Hz, 1H), 8.15 (d, J=8.4Hz, 1H), 7.91 (d, J=8.4Hz, 2H), 7.73 (d, J=8.4Hz, 2H), 7.62 (s, 1H), 7.55 (d, J=8.4Hz, 1H ), 4.13 (t, J = 8.5Hz, 3H), 3.24-3.13 (m, 6H), 2.69 (t, J = 11.4Hz, 2H), 2.49- 2.4...
Claims
1. A compound of the formula: or a pharmaceutically acceptable salt thereof, wherein: yes R 1 It is ethyl; R a Each instance of is independently hydrogen, substituted or unsubstituted C 1-6 Alkyl, an oxygen protecting group when attached to an oxygen atom, or a nitrogen protecting group when attached to a nitrogen atom; q is 0; Each instance of Y is CR 4 ; R 4 Each instance of is independently hydrogen, halogen, substituted or unsubstituted C 1-6 Alkyl, -OR a 、-N(R a )2 or -CN; is phenyl, pyridyl, pyridazinyl, pyrimidinyl or pyrazinyl; when When it is phenyl, pyridyl, pyridazinyl, pyrimidinyl or pyrazinyl, bond b and bond c are in meta or para position relative to each other; R 5 Each instance of is independently hydrogen, halogen, substituted or unsubstituted C 1-6 Alkyl, -OR a 、-N(R a )2 or -CN; Where valence permits, n is 0, 1, 2, 3 or 4, wherein when n is 1, 2, 3 or 4, there is no R 5 The connection with nitrogen atom; R 6 are independently hydrogen or substituted or unsubstituted C 1-6 alkyl; s is 1; R 7 is a substituted or unsubstituted 3- to 7-membered monocyclic heterocyclyl, a substituted or unsubstituted phenyl, a substituted or unsubstituted pyridyl, a substituted or unsubstituted pyrimidinyl, a substituted or unsubstituted pyridazinyl, a substituted or unsubstituted triazinyl, an unsubstituted pyrazolyl, a substituted or unsubstituted imidazolyl, a substituted or unsubstituted oxazolyl, a substituted or unsubstituted thiazolyl, or an unsubstituted furanyl; and R 8 is hydrogen; Wherein "substituted" refers to substitution by carbon atom substituents and / or nitrogen atom substituents, wherein the carbon atom substituents are selected from halogen, unsubstituted C 1-6 Alkyl, -OR aa 、-SR aa 、-N(R bb )2, -CN, -SCN, -NO2, -C(=O)R aa 、-CO2R aa 、-C(=O)N(R bb )2, -OC(=O)R aa 、-OCO2R aa 、-OC(=O)N(R bb )2.-NR bb C(=O)R aa 、-NR bb CO2R aa , and -NR bb C(=O)N(R bb )2; and The nitrogen atom substituents are selected from unsubstituted C 1-6 Alkyl, -C(=O)R aa 、-CO2R aa 、-C(=O)N(R bb )2, and a nitrogen protecting group; Where R aa is hydrogen, unsubstituted C 1-6 alkyl, an oxygen protecting group attached to an oxygen atom, or a sulfur protecting group attached to a sulfur atom; and each R bb are independently hydrogen, unsubstituted C 1-6 Alkyl or nitrogen protecting group.
2. The compound of claim 1, wherein the compound has formula (IA): or a pharmaceutically acceptable salt thereof.
3. The compound of claim 2, wherein the compound has the formula: or a pharmaceutically acceptable salt thereof, Where R 9 Each instance of is independently hydrogen, halogen, substituted or unsubstituted C 1-6 Alkyl, -OR a 、-N(R a )2 or -CN.
4. The compound of claim 3, wherein the compound has the formula: or a pharmaceutically acceptable salt thereof.
5. The compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein R 4 Each instance of is hydrogen.
6. The compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein R 4 At least one example is halogen or substituted or unsubstituted C 1-6 alkyl.
7. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein It is phenyl.
8. The compound of claim 7, or a pharmaceutically acceptable salt thereof, wherein for 9. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein is pyridyl, pyridazinyl, pyrimidinyl or pyrazinyl.
10. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein bond b and bond c are para to each other.
11. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein bond b and bond c are meta to each other.
12. The compound of any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein R 5 Each instance of is hydrogen.
13. The compound of any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein R 5 At least one example is halogen, substituted or unsubstituted C 1-6 Alkyl or -OR a .
14. The compound of any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein R 6 For hydrogen.
15. The compound of any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein R 6 is substituted or unsubstituted C 1-6 alkyl.
16. The compound according to claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein R 7 It is a substituted or unsubstituted 3- to 7-membered monocyclic heterocyclic group.
17. The compound of any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein R 7 is substituted or unsubstituted pyridyl, substituted or unsubstituted pyrimidinyl, substituted or unsubstituted pyridazinyl, substituted or unsubstituted triazinyl, unsubstituted pyrazolyl, substituted or unsubstituted imidazolyl, substituted or unsubstituted oxazolyl, substituted or unsubstituted thiazolyl, or unsubstituted furanyl.
18. The compound according to claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein R 7 is substituted or unsubstituted pyridyl, substituted or unsubstituted pyrimidinyl, or substituted or unsubstituted pyridazinyl.
19. The compound of any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein R 7 is a substituted or unsubstituted 3-pyridyl group.
20. The compound of any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein R 7 It is an unsubstituted 3-pyridyl group.
21. The compound of claim 19, or a pharmaceutically acceptable salt thereof, wherein R 7 for Where R 9 is hydrogen, halogen, substituted or unsubstituted C 1-6 Alkyl, -OR a 、-N(R a )2 or -CN.
22. A compound as described in any one of claims 3, 4 or 21, or a pharmaceutically acceptable salt thereof, wherein R 9 Each instance of is hydrogen.
23. A compound as described in any one of claims 3, 4 or 21, or a pharmaceutically acceptable salt thereof, wherein R 9 At least one example is halogen, substituted or unsubstituted C 1-6 Alkyl or -OR a .
24. The compound of claim 1, wherein the compound has the formula: or a pharmaceutically acceptable salt thereof.
25. The compound of claim 1, wherein the compound has the formula: or a pharmaceutically acceptable salt thereof.
26. The compound of claim 1, wherein the compound has the formula: or a pharmaceutically acceptable salt thereof.
27. The compound of claim 1, wherein the compound has the formula: or a pharmaceutically acceptable salt thereof.
28. The compound of claim 1, wherein the compound has the formula: or a pharmaceutically acceptable salt thereof.
29. The compound of claim 1, wherein the compound has the formula: or a pharmaceutically acceptable salt thereof.
30. A compound of the formula: or a pharmaceutically acceptable salt thereof.
31. Use of the compound according to any one of claims 1 to 30 or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating cancer.
32. The use of claim 31, wherein the cancer comprises cancer stem cells.
33. The use of claim 31, wherein the cancer is gastric cancer, gastrointestinal stromal tumor, ovarian cancer, lung cancer, breast cancer, pancreatic cancer or prostate cancer.
34. The use according to claim 33, wherein the gastric cancer is gastric cancer GS subtype or gastric cancer CIN subtype.
35. The use of claim 31, wherein the cancer is colorectal cancer.
36. The use according to claim 35, wherein the colorectal cancer is colorectal cancer CMS2 subtype or colorectal cancer CMS4 subtype.
37. The use of claim 31, wherein the cancer is testicular cancer.
38. The use of claim 31, wherein the cancer is liver cancer.
39. The use of claim 31, wherein the cancer is endometrial cancer.
40. The use of claim 39, wherein the endometrial cancer is uterine cancer.
41. The use of claim 31, wherein the cancer is lymphoma.
42. The use of claim 41, wherein the lymphoma is non-Hodgkin's lymphoma.
43. The use of claim 41, wherein the lymphoma is B-cell lymphoma, Burkitt's lymphoma, or immunoblastic large cell lymphoma.
44. The use of claim 43, wherein the B cell lymphoma is a large B cell lymphoma.
45. The use of claim 43, wherein the Burkitt's lymphoma is Burkitt's B-cell lymphoma.
46. The use of claim 31, wherein the cancer is leukemia.
47. The use of claim 46, wherein the leukemia is acute monocytic leukemia or acute lymphoblastic leukemia.
48. The use of claim 47, wherein the acute lymphoblastic leukemia is B-cell acute lymphoblastic leukemia.
49. The use of claim 46, wherein the leukemia is chronic myeloid leukemia (CML) or chronic lymphocytic leukemia.
50. The use of claim 46, wherein the leukemia is acute lymphoblastic leukemia.
51. The method of claim 50, wherein the acute lymphoblastic leukemia is B-cell acute lymphoblastic leukemia or T-cell acute lymphoblastic leukemia.
52. The use of claim 31, wherein the cancer is multiple myeloma.
53. The use of claim 52, wherein the multiple myeloma is a B-cell myeloma.
54. The use of claim 31, wherein the medicament is for a subject who has received or is receiving one or more additional cancer treatments.
55. The use of claim 31, wherein the medicament is for use in a subject in need of regenerative medicine.
56. A pharmaceutical composition comprising: A compound according to any one of claims 1 to 30, or a pharmaceutically acceptable salt thereof; and optionally a pharmaceutically acceptable excipient.
57. The pharmaceutical composition of claim 56, further comprising an additional pharmaceutical agent.
58. The pharmaceutical composition of claim 57, wherein the additional pharmaceutical agent is a chemotherapeutic agent.
59. Use of the pharmaceutical composition according to any one of claims 56 to 58 in the preparation of a medicament for treating cancer.
60. A kit comprising: A compound as defined in any one of claims 1 to 30, or a pharmaceutically acceptable salt thereof; Or a pharmaceutical composition as described in any one of claims 56-58; as well as Instructions for use of the compound, its pharmaceutically acceptable salt or pharmaceutical composition.
